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Abstract 
 Lomaiviticin A (1) and B (2) are natural products with remarkably complex C2-symmetric 
structures and potent antiproliferative properties. Achieving total syntheses of 1 and 2 has been a 
long-standing project in the Shair group and part one of this thesis describes our first successful 
synthesis of the C4-epi-lomaiviticin A and B core structures. A key stereoselective oxidative enolate 
dimerization of an oxanorbornanone system was employed to establish the highly hindered C2–C2' 
bond. Crucial to our completion of the lomaiviticin core structures was the discovery of subtle yet 
far-reaching stereoelectronic effects imparted by the C4/C4'-stereocenters. 
The Lycopodium alkaloids are a family of complex polycyclic alkaloid natural products that 
have long served as popular targets for developing synthetic chemistry. More recently, select 
members have been reported to exhibit neurological effects. Part two of this thesis presents the 
development of a biomimetic, unified strategy for the synthesis of 7-membered ring-containing 
Lycopodium alkaloids and its successful application toward the first total syntheses of the proposed 
structure of (–)-himeradine A (38), (–)-lycopecurine (39), and (–)-dehydrolycopecurine (199), and 
the syntheses of (+)-lyconadin A (31) and (–)-lyconadin B (32). A biosynthetically inspired one-pot 
cascade reaction sequence was developed to construct the strained polycyclic core structure shared 
amongst these alkaloids. Additionally, the syntheses of 38, 39, and 199 featured a biomimetic 
intramolecular Mannich reaction to furnish the tetracyclic ring system. The successful application of 
our unifying strategy toward the synthesis of a diverse set of alkaloids lends support to our 
biosynthetic hypothesis that 7-membered ring-containing Lycopodium alkaloids arise from a 
	    iv 
common precursor. Our synthetic approach can potentially provide access to all such natural 
products. 
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Chapter 1 
Introduction to Lomaiviticin A and B 
  
  2 
Introduction  
 The lomaiviticins comprise a family of type-II polyketide natural products with remarkable 
C2-symmetric structures (1 and 2, Figure 1.1). The lomaiviticins were first isolated by He and 
coworkers in 2001 1  from a strain of actinomycetes originally classified as Micromonospora 
lomaivitiensis (reclassified as Salinispora pacifica),2 and exhibit an array of biological activity. 
Lomaiviticin A (1) is potently cytotoxic toward 24 human cancer cell lines with IC50 values ranging 
from 0.007 to 72 nM. Furthermore, both 1 and lomaiviticin B (2) are antibiotics against Gram-
positive bacteria, including Staphylococcus aureus and Enterococcus faecium. 
 
 
Figure 1.1. Lomaiviticin A (1) and B (2). 
 Elucidating the biological mechanism of action of the lomaiviticins (1 and 2) has been an 
area of active research. In the original isolation report, He and coworkers discovered that lomaiviticin 
A (1) cleaves double-stranded DNA (dsDNA) in vitro under reductive conditions; the details of these 
experiments have not been published. The biological activity of the lomaiviticins is postulated to 
arise from the diazobenzofluorene system, in analogy to the kinamycins2 (Figure 1.2), which are 
                                                                                                                                                 
1 He, H.; Ding, W.; Bernan, V. S.; Richardson, A. D.; Ireland, C. M.; Greenstein, M.; Ellestad, G. A.; Carter, G. 
T. J. Am. Chem. Soc. 2001, 123, 5362–5363. 
 
2 (a) Woo, C. M.; Beizer, N. E.; Janso, J. E.; Herzon, S. B. J. Am. Chem. Soc. 2012, 134, 15285–15288. (b) 
Herzon, S. B.; Woo, C. M. Nat. Prod. Rep. 2012, 29, 87–118. 
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closely related monomeric natural products. The kinamycins also display anticancer properties; (–)-
kinamycin C is cytotoxic against the NCI-60 cell line panel3 with an average GI50 = 340 nM. 
 
 
Figure 1.2. Kinamycins A–J. 
Melander and coworkers have demonstrated that the kinamycins cleave dsDNA in the 
presence of a reducing cofactor, such as glutathione (GSH),4 at relevant intracellular concentrations. 
Two possible mechanisms for kinamycin-mediated dsDNA cleavage are proposed (Figure 1.3). First, 
an initial 2e– reduction of kinamycin leads to the corresponding hydroquinone, such as 3 or 4. In the 
first proposed mechanism, subsequent expulsion of nitrogen may then afford the reactive ortho-
quinone methide 5, which can alkylate DNA and induce subsequent DNA cleavage. Alternatively, an 
exogenous nucleophile could add to the terminal nitrogen of the electrophilic diazo group of 3, 
forming adduct 6, which could then undergo C–N bond homolysis to form sp2-radical 7, leading to 
DNA damage. The lack of sequence specificity in the observed dsDNA cleavage products supports 
the latter radical-based mechanism.  
                                                                                                                                                 
3 (a) Shoemaker, R. H. Nat. Rev. Cancer 2006, 6, 813–823. (b) Data at http://dtp.nci.nih.gov/. 
 
4 (a) Ballard, T. E.; Melander, C. Tetrahedron Lett. 2008, 49, 3157–3161. (b) Heinecke, C. L.; Melander, C. 
Tetrahedron Lett. 2010, 51, 1455–1458. 
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Figure 1.3. Proposed biological mechanism of action for the kinamycins. 
More recently,5 Herzon and coworkers have demonstrated that lomaiviticin A (1) induces 
dsDNA breaks in the presence of dithiothreitol (DTT) in a plasmid cleavage assay. Labelling studies 
seemed to suggest that DNA cleavage occurred via a radical pathway, supporting the formation of 
carbon-centered radical species 7. The anti-proliferative properties of the lomaiviticins are believed to 
be due to an analogous biological mechanism of action involving the diazobenzofluorene system 
(Figure 1.4). Vinyl radical species 9 could lead to DNA damage and the formation of ortho-quinone 
methide 10. Next, expulsion of the aminosugar residues at C4/C4' would generate the corresponding 
vinylogous ortho-quinone methide intermediate, whereupon DNA could act as a nucleophile and add 
to the C4/C4'-positions to afford alkylated species 11. However, despite structural similarities with 
the kinamycins, the lomaiviticins exhibit enhanced cytotoxicity, which can likely be attributed to 
other structural elements. This includes the C2-symmetric structure and the sugar residues, which may 
potentially serve as recognition elements for bringing the lomaiviticins to their biological target. In 
order to elucidate the biological mechanism of action, a synthesis of the lomaiviticins is necessary 
due to the low abundance of natural sources. 
                                                                                                                                                 
5 (a) Colis, L. C.; Woo, C. M.; Hegan, D. C.; Li, Z.; Glazer, P. M.; Herzon, S. B. Nature Chem. 2014, 6, 504–
510. (b) Mulcahy, S. P.; Woo, C. M.; Ding, W.; Ellestad, G. A.; Herzon, S. B. Chem. Sci. 2012, 3, 1070–1074. 
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Figure 1.4. Proposed biological mechanism of action for the lomaiviticins. 
The biosynthesis of the kinamycins has been extensively studied6 and the kinamycin carbon 
skeleton has been demonstrated to be entirely polyketide-derived (10 equivalents of acetylcoenzyme 
A). Due to structural similarities with the kinamycins, the biosynthesis of the lomaiviticins is 
proposed to occur via a similar pathway, with key additional steps including two phenolic oxidations 
(Figure 1.5). An oxidation of the A-ring phenol in the kinamycins to the corresponding hydroquinone 
is required. Furthermore, a phenolic oxidative coupling is likely involved in the key dimerization 
                                                                                                                                                 
6 (a) Gould, S. J. Chem. Rev. 1997, 97, 2499–2510. (b) Sato, Y.; Gould, S. J. Tetrahedron Lett. 1985, 26, 4023–
4026. (c) Seaton, P. J.; Gould, S. J. J. Am. Chem. Soc. 1987, 109, 5282–5284. (d) Seaton, P. J.; Gould, S. J. J. 
Antibiot. 1989, 42, 189–197. (e) Gould, S. J.; Melville, C. R. Bioorg. Med. Chem. Lett. 1995, 5, 51–54. (f) 
Gould, S. J.; Melville, C. R.; Cone, M. C.; Chen, J.; Carney, J. R. J. Org. Chem. 1997, 62, 320–324.  
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reaction.7 Subsequently, the lomaiviticin biosynthetic pathway could then follow the biosynthesis of 
the kinamycins, concluding with glycosylations of the C4/C4'- and C3/C3'-hydroxyl groups. 
 
 
Figure 1.5. Proposed phenolic oxidative dimerization during the biosynthesis of the lomaiviticins.8 
  
                                                                                                                                                 
7 (a) Huettel, W.; Mueller, M. ChemBioChem 2007, 8, 521–529. (b) Zhao, B.; Guengerich, F. P.; Bellamine A.; 
Lamb, D. C.; Izumikawa, M.; Lei, L.; Podust, L. M.; Sundaramoorthy, M.; Kalaitzis, J. A.; Reddy, L. M.; 
Kelly, S. L.; Moore, B. S.; Stec, D.; Voehler, M.; Falck, J. R.; Shimada, T.; Waterman, M. R. J. Biol. Chem. 
2005, 280, 11599–11607. (c) Dewick, P. R. Medicinal Natural Products; 2nd ed.; John Wiley & Sons, LTC: 
West Sussex, 1995. 
 
8 Prekinamycin 12 is an intermediate identified in the biosynthetic pathway of the kinamycins. 
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First Total Synthesis and Selected Synthetic Studies of the Lomaiviticin Aglycon 
 The lomaiviticin family of natural products have long attracted synthetic interest due to their 
remarkable C2-symmetric structures and complex architecture. The structural complexity of 1 and 2 
poses several synthetic challenges (Figure 1.1). The highly oxidized carbon skeleton includes up to 
four 2-deoxyglycosides, and the central C2–C2' bond links two densely functionalized halves to 
generate up to eight contiguous stereocenters. Each monomeric half possesses an unusual 
diazofluorene system, a naphthazarin, and a β-alkoxyenone subunit.  
 Arguably, the stereoselective construction of the key C2–C2' bond presents the most 
formidable obstacle in achieving a synthesis of the lomaiviticins (Figure 1.6). Constructing the C2–
C2' bond via a dimerization strategy is complicated by two critical challenges: (1) a high potential for 
β-elimination of the C3-alkoxy group by a C1–C2 enolate and (2) difficulty in achieving 
stereoselective formation of the C2/C2'-stereocenters. 
 
 
Figure 1.6. Potential problems for an oxidative dimerization strategy. 
Altogether, these features render the lomaiviticins challenging synthetic targets. Indeed, 
despite efforts by various groups,9 only one synthesis of the aglycon 35 has been accomplished to 
                                                                                                                                                 
9 (a) Nicolaou, K. C.; Denton, R. M.; Lenzen, A.; Edmonds, D. J.; Li, A.; Milburn, R. R.; Harrison, S. T. 
Angew. Chem. Int. Ed. 2006, 45, 2076–2081. (b) Nicolaou, K. C.; Nold, A. L.; Li, H. Angew. Chem. Int. Ed. 
2009, 48, 5860–5863. (c) Zhang, W.; Baranczak, A.; Sulikowski, G. A. Org. Lett. 2008, 10, 1939–1941. (d) 
Feldman, K. S.; Selfridge, B. R. Org. Lett. 2012, 14, 5484–5487. 
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date10 and a total synthesis of the natural product has yet to be achieved. Selected synthetic studies 
toward the lomaiviticin aglycon, including the first synthesis, will be discussed. 
The first approach to the core structures of lomaiviticin A (1) and B (2) utilizing a bridged 
tricyclic scaffold to control the stereochemistry of the model system by Nicolaou and coworkers will 
be discussed (Scheme 1.1).9a It was envisioned that core structures 16 or 17 could arise from tricycle 
18, where X would serve as a tethering group to provide a conformationally locked system that could 
subsequently be converted to the corresponding 1,4-dicarbonyl function (17). Due to the locked 
framework in 1,4-dicarbonyl 19, organometallic double addition to the carbonyl groups should occur 
stereoselectively. 19 could arise from bis(cyclohexenone) 20. 
 
 
Scheme 1.1 Nicolaou’s retrosynthetic analysis of the lomaiviticin core structure featuring a bridged 
tricyclic scaffold to control the stereoselective synthesis of the model system (16). 
 
 The synthesis commenced with the conjugate addition of dimethyl malonate to bisenone 20, 
affording the double Michael-addition product 21 as a single diastereomer (Scheme 1.2). Exposure of 
21 to ethyl cerium reagent generated in situ provided adduct 23 via proposed intermediate lactone 22. 
23 was converted to ketone 24 in 7 steps in 68% overall yield. Double α-oxygenation of 24 upon 
treatment with KHMDS and P(OEt)3 yielded C2-symmetric ketone 25 as a single diastereomer. 
Reduction of the ketone in 25 with LiAlH4 afforded triol 26. Finally, hydrogenolysis of the BOM 
ethers furnished pentaol 27. 
                                                                                                                                                 
10 (a) Herzon, S. B.; Lu, L.; Woo, C. M.; Gholap, S. L. J. Am. Chem. Soc. 2011, 133, 7260–7263. (b) Woo, C. 
M.; Gholap, S. L.; Lu, L.; Kaneko, M.; Li, Z.; Ravikumar, P. C.; Herzon, S. B. J. Am. Chem. Soc. 2012, 134, 
17262–17273. 
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Scheme 1.2. Synthesis of tricycle 27. 
Exposure of triol 26 to Pb(OAc)4 resulted in the formation of tetracyclic acetal 28, which 
underwent reduction upon treatment with LiBH4 and subsequent oxidative cleavage with Pb(OAc)4 to 
afford hemiketal 29 as a 3:1 mixture of diastereomers (Scheme 1.3). Oxidation of the major 
diastereomer with TPAP and NMO then yielded the model core system of lomaiviticin A (30). 
 
 
Scheme 1.3. Synthesis of the model core system 30 of lomaiviticin A (1). 
The synthesis of the lomaiviticin B core model system (Scheme 1.4) was accomplished from 
intermediate 27 by initial exposure of 27 to Pb(OAc)4 to furnish formate 33 via: (1) cleavage of the 
cis-1,2-diol to afford keto-aldehyde 31 and (2) oxidative cleavage of intermediate hemiacetal 32. 
Finally, cleavage of the formate ester in 33 in the presence of methanolic ammonia provided the 
desired lomaiviticin B core 34. In conclusion, Nicolaou and coworkers achieved the first 
stereoselective synthesis of the lomaiviticin A and B core systems using a bridged tricyclic scaffold 
strategy. 
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Scheme 1.4. Synthesis of the model core system 34 of lomaiviticin B (2). 
 In 2011, Herzon and coworkers accomplished the first synthesis of the lomaiviticin aglycon 
(35, Scheme 1.5).10 Remarkably, an efficient enantioselective synthesis was realized in 13 steps from 
commercial starting material. Despite potential challenges associated with a synthetic strategy relying 
on late-stage dimerization of a monomer resembling kinamycin, including β-elimination of the C3-
hydroxy or alkoxy group and uncertainty regarding the stereochemical outcome, a late-stage 
oxidative coupling was pursued. 
 
 
Scheme 1.5. Herzon’s retrosynthesis of the lomaiviticin aglycon 35 featuring a late-stage oxidative 
dimerization to establish the key C2−C2' bond. 
 
 A 1:1 diastereomeric mixture of mesitylaldehyde acetals 37 was synthesized in five steps 
from 3-ethylphenol (Scheme 1.6). 1,4-Conjugate addition of trimethylsilylmethylmagnesium chloride 
to enone 37 in the presence of CuI, followed by enolate trapping with TMSCl and subsequent 
Saegusa oxidation, afforded enone 38. 38 and naphthoquinone 39 were efficiently coupled together 
upon treatment with TASF(Et) to furnish tricycle 40. Heck cyclization mediated by Pd(OAc)2 in the 
presence of polymer-supported (PS) PPh3 provided cyclized product 41. Diazo transfer with TfN3 
then afforded diazofluorenes 42 and 43, which were readily separable at this stage. Finally, formation 
of silyl enol ether 44 from ketone 43 occurred readily, yielding the dimerization substrate. 
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 An extensive screen of oxidants was next conducted to effect the oxidative dimerization of 
either 43 or 44 (Scheme 1.7). It was eventually discovered that Mn(hfacac)3 was capable of 
accomplishing the oxidative coupling of silyl enol ether 44, albeit in low yield (26% desired 
diastereomer) and diastereoselectivity (~2:1 dr). 
 
 
Scheme 1.6. Synthesis of diazofluorene dimerization substrate 44. 
Finally, deprotection of 45 occurred upon exposure to TFA and TBHP to afford the desired 
lomaiviticin B aglycon 47 after purification. Prior to silica gel preparative thin-layer chromatography, 
the initial product isolated from the deprotection reaction exists in the form of the open-chain ketone 
isomer lomaiviticin A (see 35) aglycon, which could also be readily converted to 47 upon standing in 
MeOH. In conclusion, Herzon and coworkes have accomplished the first synthesis of the lomaiviticin 
aglycon by utilizing a late-stage oxidative silyl enol ether dimerization strategy. 
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Scheme 1.7. Completed synthesis of the lomaiviticin aglycon 47. 
To summarize this chapter, a brief introduction and background for the lomaiviticin family of 
natural products was presented. Two selected key syntheses, Nicolaou’s synthesis of the model core 
systems of lomaiviticin A and B and Herzon’s enantioselective synthesis of the lomaiviticin aglycon, 
were discussed. 
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Introduction 
 Achieving a synthesis of lomaiviticin A (1) and B (2) has been a long-standing project in the 
Shair group.11 We were first attracted to the lomaiviticins not only because of their interesting 
biological activity, but also because of their fascinating and complex architecture. The structural 
composition and relative stereochemistry of the aglycon and carbohydrate residues were elucidated 
by extensive 1H, 13C, COSY, TOCSY, HMQC, HMBC, and ROESY NMR experiments, as well as 
IR and FTICR mass spectrometry. At the outset of the project, the absolute stereochemistry of the 
aglycon and the carbohydrate residues was ambiguous; however, this was subsequently determined 
by Herzon and coworkers in 2012.2 
 Selected routes pursued by the Shair group toward the synthesis of the lomaiviticin aglycon 
47 will be discussed in detail.11 We envisioned constructing the central C2−C2' bond in 1 and 2 via a 
late-stage oxidative enolate dimerization reaction12 in order to minimize double processing (e.g., 
Scheme 1.5). A variety of oxidants13 reported in the literature are capable of performing such an 
oxidative enolate dimerization to afford the corresponding 1,4-diketone product. Examples of such 
oxidants include CuCl2, Cu(OTf)2, Cu(2-ethylhexanoate)2, FeCl3, Fe(acac)3, ferrocenium salts, I2, 
hypervalent iodine, and TiCl4. 
                                                                                                                                                 
11 (a) More than 10 different generations of routes have been pursued. Only the most relevant routes will be 
discussed. (b) Krygowski, E. S. Ph.D. Thesis, Harvard University, 2008. (c) Lee, H. G. Ph.D. Thesis, Harvard 
University, 2012. 
 
12 (a) Ivanoff, D.; Spassof, A. Bull. Soc. Chim. Fr. 1935, 2, 76−78. (b) Ito, Y.; Konoike, T.; Saegusa, T. J. Am. 
Chem. Soc. 1975, 97, 2912−2914. 
 
13 (a) For review, see: Guo, F.; Clift, M. D.; Thomson, R. J. Eur. J. Org. Chem. 2012, 4881−4896. (b) 
Kobayashi, Y.; Taguchi, T.; Tokuno, E. Tetrahedron Lett. 1977, 42, 3741−3742. (c) Baran, P. S.; Richter, J. M. 
J. Am. Chem. Soc. 2004, 126, 7450−7451. (d) Frazier, R. H.; Harlow, R. L. J. Org. Chem. 1980, 45, 
5408−5411. (e) Baran, P. S.; Guerrero, C. A.; Ambhaikar, N. B.; Hafensteiner, B. D. Angew. Chem. Int. Ed. 
2005, 44, 606−609. (f) Nguyen, P. Q.; Schaefer, H. J. Org. Lett. 2001, 3, 2993−2995. (g) Zhdankin, V. V.; 
Tykwinski, R.; Capple, R.; Berglund, B.; Kozʹ′min, A. S.; Zefirov, S. Tetrahedron Lett. 1988, 29, 3717−3720. 
(h) Ojima, I.; Brandstadter, S. M.; Donovan, R. J. Chem. Lett. 1992, 21, 1591−1594. 
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 While the exact mechanism for oxidative enolate dimerization is not completely understood, 
it is generally accepted that single electron transfers are involved. Three plausible mechanisms are 
shown in Scheme 2.1. In the first mechanism (Eq. 1), two equivalents of enoxy radical 50, generated 
by single electron oxidation of the enolate 49, can combine together to form 1,4-diketone 51. In the 
second mechanism14 (Eq. 2), the electrophilic enoxy radical 50 undergoes nucleophilic attack by one 
enolate equivalent 49, forming ketyl radical anion 52. A subsequent single electron oxidation of 52 
then affords 51. Thirdly (Eq. 3), another possibility is the involvement of a metal chelated 
intermediate (53). Depending on the oxidant and conditions utilized, these mechanisms may be 
differentially operative in individual contexts. 
 
 
Scheme 2.1. Possible mechanisms for oxidative enolate dimerizations. 
While there was precedence supporting our proposed oxidative enolate dimerization15 
reaction, several critical challenges existed. Not only does the central C2−C2' bond link two densely 
functionalized and sterically hindered halves, but two key concerns needed to be addressed: (1) 
controlling the stereoselective formation of the C2−C2' bond and (2) preventing β-elimination of the 
C3- and C3'-alkoxy groups. 
                                                                                                                                                 
14 Schmittel, M.; Haeuseler, A. J. Organomet. Chem. 2002, 661, 169−179. 
 
15 At the outset of this project, a strategy utilizing an oxidative enolate dimerization for constructing the key 
C2−C2' bond in the lomaiviticins had not been reported in the literature. 
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A solution to both of these problems was discovered in the form of the oxanorbornanone16 
system, or specifically, an oxygen bridge between C3 and C6 (Figure 2.1). Stereoselective formation 
of the C2- and C2'-stereocenters is controlled by dimerization of the endocyclic enolate 54 from the 
less hindered convex exo face of the oxanorbornanone.17 Furthermore, in oxanorbornanone system 
54, β-elimination is prevented due to the nearly orthogonal orientation of the endocyclic C1−C2 
enolate π-system with the antibonding σ*-orbital of the bridging C−O bond.18 An exocyclic enolate 
(C5−C4a, see 55), however, would have greater conformational flexibility and can thus achieve 
requisite orbital overlap for β-elimination.19 We planned to exploit this stereoelectronic dichotomy of 
the oxanorbornanone system to achieve stereoselective oxidative endocyclic enolate dimerization 
without β-elimination, and at a subsequent stage, conduct regioselective fragmentation of the oxygen 
bridge via an exocyclic enolate. 
 
 
                                                                                                                                                 
16 Vogel, P.; Cossy, J.; Plumet, J.; Arjona, O. Tetrahedron 1999, 55, 13521–13642. 
 
17 (a) Mosimann, H.; Vogel, P.; Pinkerton, A. A.; Kirschbaum, K. J. Org. Chem. 1997, 62, 3002–3007. (b) 
Marchionni, C.; Vogel, P.; Roversi, P. Tetrahedron Lett. 1996, 37, 4149–4152. (c) Arjona, O.; Menchaca, R.; 
Plumet, J. Org. Lett. 2001, 3, 107–109. 
 
18 (a) Tojo, S.; Isobe, M. Synthesis 2005, 1237–1244. (b) Jackson, S. R.; Johnson, M. G.; Mikami, M.; 
Shiokawa, S.; Carreira, E. M. Angew. Chem. Int. Ed. 2001, 40, 2694–2697. 
 
19 (a) McMorris, T. C.; Staake, M. D.; Kelner, M. J. J. Org. Chem. 2004, 69, 619–623. (b) Jung, M. E.; Min, S. 
J. Tetrahedron 2007, 63, 3682–3701. 
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Figure 2.1. Reactivity of endocyclic vs. exocyclic oxanorbornanone enolates. 
Due to the fascinating structural complexity of lomaiviticin A (1) and B (2) and their 
interesting biological activity, we embarked on a total synthesis of these two natural products. 
Specifically, we wished to address whether an oxidative oxanorbornanone enolate dimerization 
reaction to construct the key C2−C2' bond could be accomplished stereoselectively and without β-
elimination of the C3-alkoxy group. At the outset of our project, a synthesis of the lomaiviticin 
aglycon had not yet been published. 
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Previous Approaches in the Shair Group 
A simple model system was devised by Dr. Evan S. Krygowski and Dr. Kerry Murphy-
Benenato in order to test the feasibility of an oxidative dimerization of an oxanorbornanone enolate 
or silyl enol ether (Scheme 2.2).20 Gratifyingly, they discovered that treatment of silyl enol ether 57 
with Ag2O in DMSO at 100 °C afforded the desired dimerization product as a 7:1 mixture of C2-
symmetric 58 and meso 59 diastereomers.21 Both products arise from exclusive exo-exo dimerization 
of 57 and no β-elimination products were observed. 
 
Scheme 2.2. Stereoselective dimerization of an oxanorbornanone model system. 
 
A second model system was synthesized in order to study the β-elimination of the oxygen 
bridge via an exocyclic enolate (Scheme 2.3). Surprisingly, exposure of oxanorbornanone 60 to 
K2CO3 in MeOH at 0 °C not only resulted in β-elimination of the oxygen bridge, but also 
displacement of the phenylsulfone group with methoxide (vide infra).22 
 
Scheme 2.3. Successful β-elimination of the oxygen bridge and displacement of the phenylsulfone. 
                                                                                                                                                 
20 Krygowski, E. S.; Murphy-Benenato, K.; Shair, M. D. Angew. Chem. Int. Ed. 2008, 47, 1680–1684. 
 
21 A diastereomeric mixture of products was obtained because 57 was not a single enantiomer. 
 
22 We originally hypothesized that 61 resulted from initial β-elimination of the phenylsulfone group, followed 
by 1,4-conjugate addition of methoxide and generation of the corresponding exocyclic enolate. β-Elimination 
of the oxygen bridge from this enolate intermediate would then furnish 61. This mechanism was subsequently 
revised. 
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In summary, we demonstrated that (1) an oxanorbornanone system can be dimerized 
stereoselectively and (2) subsequent β-elimination of the oxygen bridge via an exocyclic enolate can 
be achieved with displacement of the phenylsulfone group by a suitable nucleophile. With the 
success of these two model systems in hand, we embarked on a synthesis of the lomaiviticin aglycon. 
Initial efforts were focused on synthesizing the central CD/C'D'-ring system, which we believed 
would allow us to study our key strategy in detail and could potentially be elaborated to the full 
carbon skeleton. However, our ultimate goal was to perform a late-stage oxidative enolate 
dimerization of a tetracyclic precursor in order to minimize double processing.  
To this end, oxanorbornanone tricycle 62 was synthesized20 and our key oxidative enolate 
dimerization reaction was investigated (Scheme 2.4). Unfortunately, the conditions utilized in our 
model system (Ag2O, DMSO, 100 °C) did not translate to the trimethylsilyl enol ether derived from 
62.23 Other oxidants, including Cu(OTf)2 and CAN did not afford any desired dimerization product. 
We next turned our attention to the oxidative dimerization of the enolate generated from 62. 
 
Scheme 2.4. Synthesis of the lomaiviticin core in the form of a stable cyclic hydrate. 
                                                                                                                                                 
23 In all cases the TMS group was compromised and starting ketone 62 was recovered. 
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A screen11b of oxidants (CuCl2, Cu(OTf)2, Cu(2-ethylhexanoate)2, FeCl3, Fe(acac)3, AgCl, 
PhI(OAc)2, and I2) for the dimerization of the enolate derived from 62 was next conducted. In all 
cases, no desired dimer 63 was obtained. One common problem of the aforementioned oxidants is 
that they all require temperatures of 0 °C or higher for enolate oxidation to occur. Unfortunately, 
however, the enolate generated from 62 was not stable above –20 °C and would undergo undesired 
β-elimination of the oxygen bridge. We rationalized that an oxidant capable of conducting single 
electron transfer at temperatures below –20 °C was necessary in order to achieve successful 
dimerization.  
We next turned our attention to [Cp2Fe]PF6, a powerful outer-sphere, single-electron 
oxidant. There was precedence24 in the literature that [Cp2Fe]PF6 was capable of oxidizing enolates 
at –78 °C. Gratifyingly, exposure of the lithium enolate of 62, generated from deprotonation by 
LiHMDS, to [Cp2Fe]PF6 in the presence of HMPA at –78 °C, followed by subsequent warming to –
20 °C and stirring for an additional 20 h, yielded the desired dimerization product 63 as a single 
diastereomer in 45-51% yield. Unfortunately, dimer 63 was only moderately stable to silica gel 
chromatography,25 which likely accounted for the diminished yield of 63.  
With dimer 63 in hand, we next focused our attention on β-elimination of the oxygen bridge. 
To this end, global silyl deprotection, followed by DMP oxidation of the corresponding secondary 
carbinols, afforded cyclic hydrate 64, where a single molecule of H2O had added to the C1- and C1'-
ketones. We hypothesized that a possible explanation for cyclic hydrate formation is the relief of ring 
strain introduced into the system by the newly formed sp2 carbon after DMP oxidation. Another 
possible rationale is that the C5- and C5'-ketones may inductively make the C1- and C1'-ketones 
                                                                                                                                                 
24 (a) Jahn, U. J. Org. Chem. 1998, 63, 7130–7131. (b) Jahn, U.; Hartmann, P. Chem. Commun. 1998, 209–
210. (c) Jahn, U.; Hartmann, P.; Kaasalainen, E. Org. Lett. 2004, 6, 257–260. 
 
25 Re-exposure of pure isolated dimer product 63 to a silica gel column resulted in loss of one-third of the 
material. 
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more electron deficient, thus promoting cyclic hydrate formation. Exposure of 64 to K2CO3 in 
MeOH at 0 °C furnished bisenone 65 in good yield (85%). Re-exposure of 65 to K2CO3 in MeOH at 
room temperature resulted in displacement of the allylic phenylsulfone groups with methoxide with 
inversion of configuration, albeit in low yield (17%), to provide bisenone 66. Both transformations 
could be combined into a single one-pot operation (K2CO3, MeOH, 0 °C → RT) to afford 66 in 14% 
yield. Attempts to dehydrate 66 to the lomaiviticin B core system under acidic conditions proved 
unsuccessful and either resulted in recovery or decomposition of starting material. 
In summary, we have demonstrated that the key C2−C2' bond could be stereoselectively 
constructed via an oxidative enolate dimerization of an oxanorbornanone system without undesired 
β-elimination of the oxygen bridge. Specifically, we discovered that [Cp2Fe]PF6 promoted oxidative 
dimerization at sufficiently low temperatures at which oxygen bridge fragmentation did not occur. 
Furthermore, we were able to subsequently β-eliminate the oxygen bridge via an exocyclic enolate to 
reveal the lomaiviticin core system in the form of a cyclic hydrate. With the success of these 
discoveries in hand, we next embarked on a synthesis of the full carbon skeleton of the lomaiviticin 
aglycon.  
In order to minimize double-processing, the optimal strategy was to utilize a late-stage 
oxidative dimerization of a tetracyclic enolate intermediate such as 69 (Scheme 2.5).26 Tetracycle 70 
could be prepared from enone 71 and a phthalide derivative, such as 72 or 73, via an anionic 
annulation reaction.27 Enone 71 could be synthesized from a common intermediate utilized in our 
original model studies. 
                                                                                                                                                 
26 Lee, H. G.; Ahn, J. Y.; Lee, A. S.; Shair, M. D. Chem. Eur. J. 2010, 16, 13058–13062. 
 
27 (a) Mal, D.; Pahari, P. Chem. Rev. 2007, 107, 1892–1918. (b) Rathwell, K.; Brimble, M. A. Synthesis 2007, 
643–662. 
 22 
 
Scheme 2.5. Second-generation retrosynthesis of the lomaiviticin aglycon. 
 
In work by Dr. Hong Geun Lee, enone 7128 and cyanophthalide 74 underwent efficient 
Kraus annulation29 to afford hydroquinone 75 in 85% yield. Ketal-protection of the C5-ketone using 
Noyori30 conditions, followed by allyl-protection of the hydroquinone phenols, furnished allylated 
product 77. Finally, cleavage of the pivaloyl group and subsequent Ley oxidation of the resulting 
secondary carbinol yielded dimerization precursor 78. 78 was subjected to our optimized oxidative 
dimerization conditions. 31  Quite surprisingly, the enolate of 78 did not undergo oxidative 
dimerization to provide the lomaiviticin full carbon skeleton 79. Indeed, only starting material was 
recovered (>80%). Other permutations of oxidants and solvents were investigated but yielded no 
desired product. 
                                                                                                                                                 
28 The synthesis of enone 71 will not be discussed here for brevity. Please see ref. 26 for details. 
 
29 Kraus, G. A.; Sugimoto, H. Tetrahedron Lett. 1978, 19, 2263–2266. 
 
30 Isunoda, T.; Suzuki, M.; Noyori, R. Tetrahedron Lett. 1980, 21, 1357–1358. 
 
31 The enolate of 78 was not stable above −60 °C and would undergo undesired oxygen bridge fragmentation. 
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Scheme 2.6. Attempted oxidative dimerization of tetracycle 78. 
 
We speculated that non-bonding interactions could be disfavoring dimerization by 
preventing favorable approach of the two reacting partners in the transition state (Figure 2.2). In 
model 80, we postulated that non-bonding interactions between the C3 and C11', and C3' and C11, 
ethyl and allyloxy groups, respectively, may be disfavoring dimerization. In the approach depicted in 
81, severe steric interactions between the C3- and C3'-ethyl groups and the C11- and C11'-allyloxy 
groups exist. Thus, we rationalized that a smaller C11/C11'-alkoxy group may remedy this problem. 
Instead of protecting the hydroquinone phenols in 76 as the allyl ethers, the corresponding methyl 
ether derivative was synthesized. Unfortunately, however, only trace quantities of the desired 
dimerization product were isolated. Predicated on these results, we believed that replacing the 
C11/C11'-alkoxy groups with the smallest substituent possible—a hydrogen atom—may circumvent 
these problems and facilitate dimerization.  
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Figure 2.2. Postulated steric interactions during the dimerization event. 
 
To this end, a modified Hauser annulation32 using a sulfoxide donor (82) was employed in 
order to access tetracycle 83 (Scheme 2.7). Deprotonation of sulfoxide donor 82 with LiHMDS, 
followed by addition of enone 71, furnished tetracycle 83 in 79% yield via: (1) initial 1,4-conjugate 
addition of the sulfoxide anion to the enone, (2) subsequent Claisen condensation, (3) sulfoxide syn 
elimination, and (4) tautomerization to the corresponding phenol. Utilizing the same sequence for the 
synthesis of 78, tetracycle 83 was converted to our targeted dimerization substrate 86 in four 
straightforward steps. 
  
Scheme 2.7. Successful oxidative dimerization of tetracycle 86. 
 
 Gratifyingly, tetracycle 86 underwent successful dimerization utilizing our optimal oxidative 
enolate coupling protocol to afford dimerization product 87 in 80% yield as a single diastereomer. 
                                                                                                                                                 
32 Hauser, F. M.; Rhee, R. P. J. Org. Chem. 1978, 43, 178–180. 
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Single crystal X-ray diffraction analysis of derivative 88 (Figure 2.3), obtained from cleavage of the 
allyl ethers in 87, unequivocally established the structure of 88. Interestingly, the C1−C2−C2'−C1' 
dihedral angle in crystal 88 is 29° and the C11-hydrogen atom and C1'-ketone oxygen (and 
analogously, C11'-hydrogen atom and C1-ketone oxygen) were in very close proximity, which could 
potentially disfavor the dimerization reaction if the C11/C11'-substituent was larger than a hydrogen 
atom. 
 
Figure 2.3. Single crystal X-ray diffraction analysis confirmed the structure of 88. 
 
Finally, with the desired dimerization product 87 in hand, we were ready to test the next 
crucial step in our strategy—fragmentation of the oxygen bridge. As expected, treatment of 87 with 
TfOH (Scheme 2.8) provided diketone dimer 89 in the form of a cyclic hydrate. Unfortunately, 
despite a wide screen of conditions by Dr. Hong Geun Lee, 89 did not undergo oxygen bridge 
fragmentation. Investigation of a variety of bases in protic solvents, including MeOH, EtOH, t-
BuOH, and H2O, only resulted in decomposition of starting material 89. Similar results were 
obtained when stronger bases such as LDA, LiHMDS, and t-BuOK were used. At the time, it was 
believed that one possible explanation for unsuccessful oxygen bridge fragmentation of 89 was due 
to the base-sensitivity of the cyclic hydrate. 
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Scheme 2.8. Attempted oxygen bridge fragmentation of cyclic hydrate 89. 
 
Protection of the cyclic hydrate hydroxyl groups as the corresponding methyl ethers afforded 
cyclic hydrate 91 (Scheme 2.9). Exposure of 91 to KOH in THF/H2O did not provide the desired 
oxygen bridge fragmentation product, but instead diol 92, which was formed by initial β-elimination 
of the C4/C4'-phenylsulfone groups followed by addition of hydroxide to the resultant enone, was 
isolated. Resubjection of 92 to a variety of basic conditions did not result in oxygen bridge β-
elimination but only in recovered starting material or decomposition under more forcing conditions. 
Even 1,3-diketone dimer 93, synthesized from 92 via a Swern oxidation, did not undergo oxygen 
bridge fragmentation. 
 
Scheme 2.9. Attempted oxygen bridge fragmentation of cyclic hydrates 92 and 93. 
 
 We next turned our attention towards a reductive approach for oxygen bridge fragmentation  
via α-elimination 33 from the C1/C1'-ketones (Scheme 2.10). However, instead of the desired 
                                                                                                                                                 
33 (a) De Schrijver, J.; De Clercq, P. J. Tetrahedron Lett. 1993, 34, 4369–4372. (b) Padwa, A.; Sandanayaka, 
V. P.; Curtis, E. A. J. Am. Chem. Soc. 1994, 116, 2667−2668. 
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diketone product 94, only cyclobutanediol 96,34 the result of an intramolecular pinacol coupling 
between the proximal C1 and C1' ketones, was isolated. This was not surprising, since the crystal 
structure of 88 suggested that the dimer preferentially adopts a conformation that places the C1/C1'-
ketones in close proximity to each other. 
 
 
Scheme 2.10. Attempted reductive oxygen bridge fragmentation. 
 
We next decided to pursue a strategy that would utilize the electron-rich nature of the 
AB/A'B'-naphthalene systems to facilitate oxygen bridge fragmentation (Scheme 2.11). This strategy 
would first involve oxidation of the B/B'-rings in 87 to the corresponding hydroquinones in 97. 
Electron donation from the electron-rich AB/A'B'-naphthalene systems (specifically, the C11- and 
C11'-phenol groups), should assist in oxygen bridge fragmentation to provide intermediate 98, which 
can undergo tautomerization to afford the desired product 99.  
                                                                                                                                                 
34 The pinacol product was also isolated in an analogous reaction on the model system by Dr. Evan S. 
Krygowski. See ref. 11b. 
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Scheme 2.11. Proposed oxygen bridge fragmentation via the electron-rich AB/A'B'-naphthalene 
systems. 
 
Oxidation of the B/B'-rings proved to be challenging. After extensive experimentation,35 it 
was eventually discovered that substrate 101, where the C5- and C5'-carbonyl groups have been 
removed, could be oxidized to quinone dimer 106 (Scheme 2.12). Diketone 102 was synthesized 
from diol 92 via: (1) LiEt3BH reduction of the C5- and C5'-carbonyl groups, (2) acetylation of the 
resulting tetraol to provide the corresponding tetra-acetate, (3) ionic reduction in the presence of 
Et3SiH and TfOH, (4) cleavage of the C4- and C4'-acetate groups, and (5) Ley oxidation of the C4- 
and C4'-secondary carbinol groups to the corresponding ketones. Diastereoselective reduction of the 
C4- and C4'-ketones in 10236 afforded diol 103 with the correct stereochemistry found in the natural 
product. As expected, hydride delivery occurred from the convex face of the molecule, anti to the 
oxygen bridge. 
                                                                                                                                                 
35 In compounds where C5 existed as a ketone, ketal, or hydrazone, the B- and B'-rings could not be oxidized 
to the corresponding quinone. An electron-withdrawing group at C5 and C5' is likely responsible for 
suppressing oxidation of the B- and B'-rings. See ref. 11c. 
 
36 Attempted oxygen bridge fragmentation via the C4- and C4'-ketones under basic or acidic conditions proved 
unsuccessful. 
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Scheme 2.12. Attempted synthesis of hydroquinone dimer 107. 
 
Cleavage of the allyl ethers in 103 occurred smoothly to provide naphthol dimer 104. 
Surprisingly, treatment of 104 with PhI(OCOCF3)2, afforded the unaromatized hydroquinone 
tautomer 105.37 Exposure of 105 to a second oxidant, DDQ, then afforded the desired quinone dimer 
106. In order to test our proposed strategy for fragmentation of the oxygen bridge via the electron-
rich naphthalene systems, the quinone functions in 106 must be reduced to the corresponding 
                                                                                                                                                 
37 For an example where the unaromatized hydroquinone tautomer was isolated, see: Chikashita, H.; Porco, J. 
A.; Stout, T. J.; Clardy, J.; Schreiber, S. L. J. Org. Chem. 1991, 56, 1692–1694. 
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hydroquinone. Unfortunately, quinone reduction proved to be challenging and we were never able to 
isolate hydroquinone 107. 
At this point, Dr. Hong Geun Lee decided to no longer pursue this route due to our inability 
to β-eliminate the oxygen bridge. Both the model systems investigated by Dr. Evan S. Krygowski 
and Dr. Kerry-Murphy Benenato and the full carbon skeleton of the aglycon studied by Dr. Hong 
Geun Lee have provided valuable insight into designing a new route to circumvent the previously 
observed challenges. A summary of our previous discussion is provided below (Scheme 2.13). 
 
Scheme 2.13. Summary of previous work in the Shair group. 
 
To summarize, in model system 64, we demonstrated that stereoselective oxidative enolate 
dimerization of an oxanorbornanone system could be achieved without undesired β-elimination. 
Furthermore, we were able to subsequently fragment the oxygen bridge in 64 at the appropriate time. 
However, displacement of the C4-phenylsulfone with various oxygen nucleophiles was extremely 
low-yielding and the resulting product could not be converted to the lomaiviticin core from the cyclic 
hydrate. Unexpectedly, in our most advanced system containing the full aglycon carbon skeleton, we 
were unable to fragment the oxygen bridge. I attributed the unsuccessful fragmentation to the 
additional strain and rigidity that the AB/A'B'-naphthalenes introduce to the system. In 64, C5a and 
C11a are both sp3-hybridized, whereas in the case of 108 they are sp2-hybridized. The sp2-
hybridization introduces more strain into an already strained and rigid system and may thus prevent 
attainment of the requisite orbital overlap for β-elimination of the oxygen bridge.  
Predicated on the aforementioned observations, I embarked on a new route to synthesize a 
substrate with the correct C4- and C4'-stereochemistry in order to obviate the need for a late-stage 
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allylic phenylsulfone displacement. Additionally, I planned to introduce the AB/A'B'-naphthalene 
systems after β-elimination of the oxygen bridge because of the aforementioned discussion.  
 32 
Development of a New Route to the Core of Lomaiviticin A and B 
 Based on the observations and results discussed in the previous section by my predecessors, 
I embarked on a new route to the lomaiviticin core system. My first-generation retrosynthesis of the 
lomaiviticin aglycon (47) is outlined in Scheme 2.14. 38  We envisioned that the AB/A'B'-
naphthalenes of 109 could be constructed from lomaiviticin B core 110 via a late-stage double 
annulation reaction, such as a cyclopentadienyl anion bisannulation. 39  110 could arise from 
oxanorbornanone dimer 111, where the key C2–C2' bond would be established by a stereoselective 
oxidative enolate dimerization of monomer 112. The oxanorbornanone system could be constructed 
from an intramolecular exo-selective furan Diels–Alder reaction of a suitable precursor such as 
furanone 114 or related derivative. 114 can be readily assembled from commercially available (S)-
malic acid and furan 115.40 
 
 
Scheme 2.14. First-generation retrosynthesis of the lomaiviticin aglycon. 
 
                                                                                                                                                 
38 Lee, A. S.; Shair, M. D. Org. Lett. 2013, 15, 2390–2393. 
 
39 Birman, V. B.; Zhao, Z.; Guo, L. Org. Lett. 2007, 9, 1223–1225. 
 
40 For a synthesis of furan 115, see ref. 11b. 
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Two key differences between the new proposed route and the previous systems investigated 
by Dr. Evan S. Krygowski and Dr. Hong Geun Lee are: (1) a substrate with the correct C4 and C4'-
stereochemistry and oxygenation (111) would be utilized, obviating the need for displacement of a 
C4- and C4'-phenylsulfone group and (2) the AB/A'B'-naphthalene systems would be introduced 
after β-elimination of the oxygen bridge due to the aforementioned challenges faced by Dr. Hong 
Geun Lee in his studies when C5a and C11a were sp2-hybridized.  
The synthesis commenced with the formation of the dimethyl ester of commercially 
available (S)-malic acid (Scheme 2.15). Selective monoreduction with BH3•SMe2 in the presence of 
catalytic NaBH4,41 followed by protection of the resultant 1,2-diol afforded acetal 116. Reduction of 
the methyl ester in 116 with LiBH4, followed by formation of the corresponding iodide, occurred 
smoothly to yield alkyl iodide 117. Lithiation of furan 115, followed by alkylation with 117, 
afforded coupled product 118. DIBAL-H regioselective opening of the acetal afforded primary 
alcohol 119 in 46% yield (66% brsm). Attempts to oxidize primary alcohol 119 were met with 
surprising difficulty. Standard DMP, Swern, and Ley oxidation conditions resulted in decomposition. 
In all cases, the siloxy furan was most likely compromised, possibly via an intramolecular or 
intermolecular aldol reaction with the putative aldehyde intermediate.  
 
Scheme 2.15. Synthesis of furan Diels–Alder substrate 121. 
                                                                                                                                                 
41 (a) Gaunt, M. J.; Jessiman, A. S.; Orsini, P.; Tanner, H. R.; Hook, D. F.; Ley, S. V. Org. Lett. 2003, 5, 4819–
4822. (b) Saito, S.; Ishikawa, T.; Kuroda, A.; Koga, K.; Moriwake, T. Tetrahedron 1992, 48, 4067–4086. 
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To circumvent this problem, the TIPS ether was cleaved upon treatment with TBAF to 
provide the corresponding furanone alcohol, which underwent subsequent Swern oxidation to 
provide furanone aldehyde 120. Aldehyde 120 was then converted to (Z)-enoate 121 (19:1 Z/E), the 
desired Diels–Alder substrate, via the Ando variant of the Still modification of the Horner-
Wadsworth-Emmons olefination with Masamune and Roush’s adapted mild conditions.42 With 121 
in hand, we were ready to test our key intramolecular exo-selective furan Diels–Alder reaction. 
We anticipated that the stereoselectivity of the exo-selective43 intramolecular furan Diels–
Alder reaction would be controlled by the single C5-stereocenter, which enforced a conformation 
where 1,3-allylic strain was minimized (Scheme 2.16). The exo transition state (122), which results 
in cis-5,5-fusion product 123, should be favored over the endo transition state (124), which would 
result in highly strained trans-5,5-fusion product 125. 
 
Scheme 2.16. Rationale for the stereoselectivity of the intramolecular furan Diels–Alder reaction. 
 
Initial attempts to promote the Diels–Alder reaction by conventional thermal (PhMe, 50 → 
                                                                                                                                                 
42 Ando, K.; Oishi, T.; Hirama, M.; Ohno, H.; Ibuka, T. J. Org. Chem. 2000, 65, 4745–4749. 
 
43 Kappe, C. O.; Murphree, S. S.; Padwa, A. Tetrahedron 1997, 53, 14179–14233. 
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100 °C)44 and Lewis acidic conditions (e.g., MeAlCl2) failed to provide the desired cycloadduct in 
synthetically useful yields (<25%). We rationalized that tautomerization of the furanone to the 
requisite furan may be slow and that basic conditions may therefore promote the desired 
transformation. Addition of DBU to promote enolization resulted in complete conversion of 121 to 
two new compounds (Scheme 2.17), determined to be the desired product 126 and Michael adduct 
127, in a 1.2:1 ratio, respectively. Both products were each isolated as single diastereomers. 
 
Scheme 2.17. Formal intramolecular furan Diels–Alder reaction. 
 
These results suggested a stepwise Diels–Alder mechanism, i.e., a Michael–Michael 
sequence (Scheme 2.18). A stepwise “exo” mechanism (128 and 129) would lead to formation of the 
desired Diels–Alder product 126. A stepwise “endo” mechanism should result in initial Michael 
adduct intermediate 130, which cannot undergo a second Michael reaction to provide the highly 
strained, trans-5,5-fused endo product 125 due to poor orbital overlap, thus resulting in isolation of 
Michael adduct 127.45 Separate resubjection of pure 126 and 127 to the reaction conditions resulted 
in complete recovery of starting material 126 or 127, respectively, suggesting that formation of 
Diels–Alder product 126 and Michael adduct 127 is irreversible under the given reaction conditions. 
In order to drive the reaction to Diels–Alder product 126 formation and prevent isolation of Michael 
adduct 127, conditions under which formation of 127 was reversible were required. We hypothesized 
                                                                                                                                                 
44 See ref. 20. 
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that a stronger base such that the ester enolate of 127 could be regenerated may provide such a 
solution. 
 
Scheme 2.18. Rationale for formation of Diels–Alder product 126 and Michael adduct 127. 
 
Gratifyingly, we discovered that treatment of 121 with LDA46 (Scheme 2.19) provided the 
Diels–Alder product 126 as a 10:1 mixture of separable diastereomers, favoring the expected cis-5,5-
fusion product (64% isolated yield). This process presumably occurs via a stepwise Michael–
Michael reaction sequence. No Michael adduct 127 was observed under these conditions. 
 
Scheme 2.19. Successful formal intramolecular exo-selective furan Diels–Alder reaction. 
 
For reasons that will not be discussed in detail here, we revised our protecting group strategy 
due to challenges associated with removal of the PMB protecting group in 126 and cleavage of the 
ethyl ester to the corresponding carboxylic acid (Scheme 2.20). Instead of protecting the 1,2-diol as 
                                                                                                                                                 
46 Caine, D. S.; Paige, M. A. Synlett 1999, 9, 1391−1394. 
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the corresponding PMP acetal, the two hydroxyl groups were differentially protected. Selective TBS-
protection of the primary hydroxyl, followed by benzyl protection of the secondary hydroxyl group, 
reduction of the methyl ester in 133, and formation of the corresponding iodide occurred smoothly to 
yield alkyl iodide 134. Following the same sequence of operations utilized previously, lithiation of 
furan 115, followed by alkylation with 134, afforded coupled product 135. Global silyl deprotection 
with TBAF provided the corresponding furanone alcohol, which upon Swern oxidation47 cleanly 
delivered aldehyde 136. A (Z)-selective modified Horner-Emmons reaction then delivered (Z)-enoate 
137. Treatment of 137 with LDA provided the Diels−Alder product 138 as a 10:1 mixture of 
diastereomers, once again favoring the desired cis-5,5-fusion product (64% isolated yield of 138). 
We were able to prepare over 10 g of 138 using this protocol. It was imperative to conduct this 
reaction under extremely dilute conditions (0.02 M) in order to suppress undesired intermolecular 
pathways. 
 
Scheme 2.20. Revised protecting group scheme and synthesis of oxanorbornanone 138. 
 
 With oxanorbornanone 138 in hand, an oxidative “carboxy-inversion” sequence for 
converting the C4-ester to a hydroxyl group with retention of configuration was required (Scheme 
                                                                                                                                                 
47 It was imperative to remove all i-Pr2NEt during workup of the reaction. Residual i-Pr2NEt promoted 136 to 
undergo undesired intra-and intermolecular pathways via addition of the furanone moiety to the newly formed 
aldehyde. 
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2.21).48 First, the allyl ester of Diels−Alder product 138 was deprotected to carboxylic acid 139. 
Next, m-chloroperbenzoic acid (m-CPBA) was coupled to carboxylic acid 139 via the acid chloride 
intermediate to afford diacyl peroxide 140, which underwent ionic rearrangement (“carboxy-
inversion”) upon heating in benzene to afford the corresponding acyl carbonate species 141. 
Methanolysis of this crude intermediate provided the desired secondary carbinol 142 as a single 
diastereomer. Attempted optimization of the carboxy-inversion sequence proved to be extremely 
challenging and the optimal yield obtained (33%, 4 steps) was irreproducible, especially on larger 
scale. Lewis acids (e.g., ZnCl2, Sc(OTf)3, MgBr2), Brönsted acids (e.g., trichloroacetic acid), and 
more polar solvents (e.g., CCl4, PhCF3), all factors which are known to accelerate this ionic process, 
did not improve the yield.49 Indeed, in most cases, lower yields were observed.  
 
Scheme 2.21. Carboxy-inversion reaction to install the C4-oxygenation with retention of 
stereochemistry. 
 
Eventually, it was discovered that heating p-nitrobenzoyl peroxide 143 (Scheme 2.22), 
                                                                                                                                                 
48 (a) Denney, D. B.; Sherman, N. J. Org. Chem. 1965, 30, 3760−3761. (b) Fujimori, K.; Shigeru, O. J. Chem. 
Soc., Perkin Trans. 2 1989, 1335−1348. (c) Meng, Z.; Danishefsky, S. J. Angew. Chem. Int. Ed. 2005, 44, 
1511−1513. 
 
49 Numerous minor byproducts resulted from the carboxy-inversion reaction, although none were present in 
significant quantities for characterization. 
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synthesized via coupling of p-nitroperbenzoic acid (p-NPBA)50 with carboxylic acid 139, afforded 
desired alcohol 142 in 38% yield (4 steps). While this reaction did not significantly improve the 
yield, it was reproducible on scale. Furthermore, while m-chlorobenzoyl peroxide 140 required silica 
gel column chromatography, p-nitrobenzoyl peroxide 143 did not, obviating the need for an 
additional purification step. Protection of the hydroxyl group in 142 as a TBS ether yielded the 
dimerization precursor, oxanorbornanone 144. 
 
Scheme 2.22. Use of p-nitrobenzoyl peroxide 143 in the carboxy-inversion reaction. 
 
Utilizing the optimal oxidative enolate dimerization conditions developed in our group 
(Scheme 2.23), ketone 144 was added to LiHMDS and HMPA in THF at −78 °C to generate the 
corresponding lithium enolate, which was then exposed to [Cp2Fe]PF6 and allowed to stir at −55 °C 
for 4 days. Contrary to our prior studies where only exo-exo dimerization was observed, 
unsymmetrical exo-endo dimer 145 was obtained exclusively (44%). The structure of 145 was 
further confirmed by the nOe’s depicted in Scheme 2.23. 
 
Scheme 2.23. Stereoselective oxidative enolate dimerization affords the exo-endo dimer exclusively. 
                                                                                                                                                 
50 Vilkas, M. Bull. Soc. Chim. Fr. 1959, 1401. 
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It appeared that although dimerization occurred with complete exo facial selectivity in the 
absence of any substitution on the oxanorbornanone carbon framework (Eq. 2, Scheme 2.24), the 
C4-substituent (pseudoaxial phenylsulfone) played a crucial role in reinforcing exo-exo selectivity 
(Eq. 3 and Eq. 4) in our prior more complex polycyclic systems.  
 
Scheme 2.24. Effect of the relative stereochemisty at C4 on the stereoselectivity of the oxidative 
dimerization reaction. *The opposite enantiomer to that which is shown was synthesized, but is 
drawn as such for ease of comparison. 
 
 In the current system (Eq. 1), the C4-substituent was a sterically large pseudoequatorial TBS 
ether group, which likely disfavors exo-exo dimerization due to steric interactions, which may cause 
the ethyl groups to gear towards each other in the transition state. Use of a sterically smaller MOM 
protecting group on the C4-hydroxyl resulted in a 1:1 exo-endo:exo-exo mixture of diastereomers, 
suggesting that not only does the relative stereochemistry at C4 play an important role in the 
trajectory of the dimerization, but also the size of the substituent. 
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Attempts to improve the yield of dimerization product 145 above 44% proved to be 
challenging. Typically 10-15% of starting ketone 144 was recovered from the dimerization reactions. 
Increasing the reaction temperature (up to −40 °C), varying the concentration (0.05 M−0.20 M), 
varying the amount of LiHMDS used (1.2−2.2 equiv) or the use of LDA, and allowing the reaction 
to proceed longer (up to 5 days) did not result in increased yields. Byproducts were not present in 
sufficient quantities for characterization. 
Fortunately, exo-endo dimer 145 could be selectively epimerized to the desired and 
thermodynamically favored exo-exo dimer 146 by treatment with 2-t-butyl-1,1,3,3-
tetramethylguanidine (Barton’s base) (Scheme 2.25). With exo-exo dimer 146 in hand, the benzyl 
ethers were cleaved and the corresponding diol 147 was oxidized to 1,4-diketone dimer 148. 
Surprisingly, and quite fortuitously, 148 did not exist as a cyclic hydrate if silica gel column 
chromatography was avoided; this is in contrast to our previously discussed systems where the 
analogous C5-ketone substrates (Scheme 2.13) existed exclusively as the cyclic hydrates. One 
possible explanation was that the sterically large pseudoequatorial C4- and C4'-TBS ethers may 
cause the ethyl groups to orient towards each other such that the cyclic hydrate, where the ethyl 
groups are in close proximity, would be disfavored. Regardless, the C4-stereochemistry has subtle 
yet far-reaching stereoelectronic consequences on the system. 
 
 
Scheme 2.25. Selective epimerization of exo-endo dimer 145 to the desired exo-exo dimer 146. 
With a successful synthesis of 1,4-diketone dimer 148 completed, the key oxygen bridge 
fragmentation was next investigated (Scheme 2.26). Quite surprisingly, all attempts to fragment the 
oxygen bridge of 148 or the cyclic hydrate form of 148 were unsuccessful. Exposure of 148 to acidic 
O
BnO
O
OTBS
H
Et
O
Et
O
TBSO
H
H
H OBn
exo-endo
145
O
RO
O
OTBS
H
Et
O
Et
O
TBSO
H
H
H OR
146: R = Bn
 147: R = H
 exo-exo
Pd(OH)2/C, H2 
THF, RT
(quant., 2 steps)
O
O
O
OTBS
H
Et
O
Et
O
TBSO
H
H
H O
44a5
SO3•Py, i-Pr2NEt
148
DMSO, CH2Cl2
−10 °C
N
Me2N NMe2
tBu
MeCN, −5 °C
4
1
1"
 42 
(e.g., PPTS, BF3•OEt2, BCl3) and basic (e.g., K2CO3/MeOH, DBU, Barton’s base, KHMDS, 
KOH/THF/H2O) conditions either resulted in nonspecific decomposition or no reaction. These 
results were especially surprising when compared to the model system studied by Dr. Evan S. 
Krygowski (Scheme 2.4). The only difference, aside from the absolute stereochemistry, between the 
current system and the previous model system is the stereochemistry and substituent at C4 
(pseudoaxial phenylsulfone vs. pseudoequatorial TBS ether). Interestingly, deuterium incorporation 
studies (KOD in THF) revealed 100% deuterium incorporation at C4a/C4a' of 150 and 151. 
 
 
Scheme 2.26. Attempted oxygen bridge fragmentation. 
Unlike the original successful model studies where the dimer contained a pseudoaxial C4-
phenylsulfone (Scheme 2.4), we rationalized that fragmentation is disfavored due to a 1,3-allylic 
interaction (Scheme 2.27) between the enolate (C5−C4a) oxygen of 152 and the pseudoequatorial 
C4-TBS-ether that must occur during the transition state in order to achieve proper orbital overlap 
for fragmentation to occur. Unfortunately, moving to a sterically smaller protecting group (MOM) or 
even the free hydroxyl did not remedy this problem. In line with our hypothesis, we predicted that 
the C4-epimer of 148 would not suffer from an unfavorable 1,3-allylic-type interaction during 
oxygen bridge fragmentation. However, before we discuss a synthesis of the C4-epimer of 148, other 
strategies we explored for β-eliminating the oxygen bridge in 148 will first be presented.  
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Scheme 2.27. Rationale for unsuccessful oxygen bridge fragmentation. 
One strategy we considered was utilizing the electron-rich naphthalene system to facilitate 
oxygen bridge fragmentation (Scheme 2.28). This strategy was conceived prior to Dr. Hong Geun 
Lee’s discovery that reduction of the B-ring quinone to the corresponding hydroquinone was 
extremely challenging (Scheme 2.12). 
 
 
Scheme 2.28. Proposed oxygen bridge fragmentation via the electron-rich AB/A'B'-naphthalene 
systems. 
 
To this end, 1,4-diketone dimer 148 was converted to bisenone 156 via formation of the bis-
trimethylsilyl enol ether followed by Saegusa oxidation (Scheme 2.29). A double Hauser or Kraus 
annulation should then deliver hydroquinone dimer 158. Several annulation donors were synthesized, 
including the cyanophthalide (157, X = CN), phenylsulfonylphthalide (157, X = SO2Ph) and 
phenylsulfenylphthalide (157, X = SPh). Unfortunately, however, treatment of these annulation 
donors with base (e.g., t-BuOLi, LiHMDS), followed by addition of enone 156 under a variety of 
conditions, including the use of additives (e.g., ZnCl2, HMPA), were unsuccessful. 51  We 
hypothesized that the C1- and C1'-ketones and the C2- and C2'-protons may not be compatible with 
                                                                                                                                                 
51 We also attempted to stop the reaction at just the initial Michael addition, but this unfortunately also yielded 
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the basic reaction conditions and that the use of “neutral” annulation conditions may potentially 
circumvent this problem. We generated the corresponding siloxyisobenzofuran52 intermediate in situ 
from 157 by treating 157 with base, followed by trapping with TMSCl. Unfortunately, addition of 
enone 156 to this intermediate also afforded a complex product mixture. We did not attempt 
bisannulation of the cyclic hydrate form of 156 because this would result in a product that is highly 
similar to the system extensively studied by Dr. Hong Geun Lee (89, Scheme 2.8), which did not 
undergo oxygen bridge fragmentation. 
 
 
Scheme 2.29. Attempted bisannulation reactions to construct the naphthalene system. 
We next turned our attention to reductively fragmenting the oxygen bridge from bisenone 
156 and 159 (Scheme 2.30). Treatment of enone 156 or 159 with SmI2 resulted in complete 
decomposition. No reaction was observed when 156 was treated with freshly activated Zn in 
AcOH,53 even at high temperatures. Exposure of a derivative of cyclic hydrate 159, where the 
hydroxyl groups were protected as the corresponding TMS ethers, to Birch reduction conditions 
(Li(0) or Na(0) in NH3, THF, −78 °C) also resulted in decomposition. 
 
                                                                                                                                                 
52 (a) Evans, J. C.; Klix, R. C.; Bach, R. D. J. Org. Chem. 1988, 53, 5519−5527. (b) Sutherland, H. S.; Souza, 
F. E. S.; Rodrigo, R. G. A. J. Org. Chem. 2001, 66, 3639−3641. 
 
53 Bao, G.; Liu, C.; Burnell, D. J. J. Chem. Soc., Perkin Trans. 1 2001, 2657−2668. 
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Scheme 2.30. Attempted reductive fragmentation of the oxygen bridge in bisenone 156 and 159. 
 At this juncture, we decided to no longer pursue strategies for β-eliminating the oxygen 
bridge of 148, 156, and derivatives thereof. In summary, a highly efficient and scaleable route, 
featuring a “carboxy-inversion” sequence for installing the C4-oxygenation and an intramolecular 
exo-selective furan Diels−Alder reaction, to oxanorbornanone 144 was developed. Furthermore, a 
stereoselective oxidative dimerization of the enolate derived from 144 was achieved. Unfortunately, 
attempts to fragment the oxygen bridge to reveal the lomaiviticin core were unsuccessful. 
 The main obstacle preventing us from achieving a synthesis of the lomaiviticin core was β-
elimination of the oxygen bridge. As discussed previously, we postulated that the C4-epimer of 148 
would not suffer from the 1,3-allylic-type interaction during oxygen bridge fragmentation depicted in 
Scheme 2.27. Hence, we next turned our focus toward the development of a synthesis of the C4-
epimer of 148.  
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Synthesis of the C4-Epi-Lomaiviticin A and B Cores and Studies Toward the Aglycon 
 Due to our unsuccessful attempts to achieve β-elimination of the oxygen bridge in 148, we 
decided to embark on a synthesis of the C4-epimer of 148. Based on our previous observation that 
reagents approach from the convex face of the cis-5,5-fused system (Scheme 2.9, 92), anti to the 
oxygen bridge, we believed that a Barton radical decarboxylation−oxidation reaction may afford the 
C4-epimer of 148. To this end, the Barton ester was formed from carboxylic acid 139 by using S-(1-
oxido-2-pyridinyl) 1,1,3,3-tetramethylthiouronium hexafluorophosphate (HOTT) (Scheme 2.31).54 
Upon complete formation of the Barton ester, the reaction was saturated with O2 and Sb(SPh)3 was 
added.55 This one-pot protocol afforded alcohol 162 as a 2:1 mixture of diastereomers, favoring the 
desired epimer in 46% isolated yield. The HOTT reagent was very effective in facilitating the 
formation of hindered carboxylic acids, as was the case in 139.56  Use of the more conventional 
Barton radical decarboxylation−oxidation conditions (Barton ester formation, followed by exposure 
to O2, t-BuSH, and a sunlamp, then reduction with PPh3)57 afforded the alcohol product in higher 
diastereoselectivity (4:1 dr) but in lower isolated yields of the desired diastereomer (37−40%). While 
the use of O2 and Sb(SPh)3 did not significantly improve the yield (46%), it permitted easier 
purification of the desired alcohol 162. 
 Alcohol 162 was protected as the corresponding TBS-ether, affording oxanorbornanone 163, 
the dimerization substrate. 163 underwent successful oxidative enolate dimerization to provide exo-
exo dimer 164 exclusively. Benzyl ether cleavage and subsequent Parikh-Doering oxidation afforded 
                                                                                                                                                 
54 Garner, P.; Anderson, J. T.; Dey, S. J. Org. Chem. 1998, 63, 5732–5733. 
 
55 (a) Barton, D. H. R.; Bridon, D.; Zard, S. Z. Tetrahedron 1989, 45, 2615–2626. (b) Zhu, J.; Klunder, A. J. 
H.; Zwanenburg, B. Tetrahedron 1995, 51, 5099–5116. 
 
56 We experienced difficulty in driving the Barton ester formation to completion via addition of the sodium salt 
of 2-mercaptopyridine N-oxide to the acid chloride derived from carboxylic acid 139. 
 
57 Corey, E. J.; Hong, B. J. Am. Chem. Soc. 1994, 116, 3149–3150. 
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cyclic hydrate 166 in 47−57% yield over 3 steps. Due to the instability of dimeric intermediates 164 
and 165 to silica gel column chromatography, purification could only be conducted on cyclic hydrate 
166 after the 3-step sequence.58 Optimization efforts to improve the yield beyond 57% were 
unsuccessful. Varying the concentration (0.07−0.16 M), varying the amount of HMPA used (0−5.0 
equiv), purifying the [Cp2Fe]PF6, and carefully deoxygenating the THF solvent, were all 
investigated. The diminished yield likely reflected the instability of dimeric products 164 and 165. 
With a successful synthesis of cyclic hydrate 166 completed, the key oxygen bridge fragmentation 
reaction was next investigated. Gratifyingly, a screen of basic conditions revealed that cyclic hydrate 
166 underwent successful oxygen bridge fragmentation upon treatment with KOH in THF/H2O at 0 
°C, confirming our suspicion that the C4-stereocenter has far-reaching stereoelectronic effects. 
 
 
Scheme 2.31. Successful oxygen bridge fragmentation and conversion to C4-epi-lomaiviticin A 
(168) and B (169) cores.  
 
                                                                                                                                                 
58 A very quick silica gel plug after the dimerization reaction to remove as much [Cp2Fe]PF6 and ferrocene 
byproduct as possible was conducted. 
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Bisenone product 167 was then converted to C4-epi-lomaiviticin B core 169 in two steps, 
involving (1) dehydration of cyclic hydrate 167 in the presence of MgSO459 to yield C4-epi-
lomaiviticin A core 168 and (2) stirring 168 with catalytic p-TsOH to provide C4-epi-lomaiviticin B 
core 169 (62%, 3 steps). The latter step required extensive optimization and use of various acidic 
(e.g., PPTS, CSA, Sc(OTf)3, HCl, MgBr2•OEt2) and basic (e.g., K2CO3/MeOH, Et3N, Barton’s base) 
conditions resulted in either low conversion or decomposition. Some byproducts isolated appeared to 
be the result of D-ring aromatization. With a successful synthesis of lomaiviticin B core 169, the 
stage was set for testing our key bisannulation strategy to install the AB/A'B'-naphthalene systems. 
Despite the challenging aspects of double processing, our initial strategy was to pursue a 
cyclopentadienyl anion bisannulation (Scheme 2.32). We envisioned that a cyclopentadiene 
derivative (170) could be synthesized from 169. Exposure of cyclopentadiene 170 to excess base 
should result in formation of the cyclopentadienyl anion dimer 172, which upon treatment with two 
equivalents of an electrophilic phthalate derivative 171 should result in double addition to afford 
adduct 173 or 174. A second nucleophilic addition of the anion to the remaining ester of the 
electrophile should then afford the desired hydroquinone dimer 175. The closest literature 
precedence in support for such a transformation was a methodology developed by Birman and 
coworkers for the synthesis of benzofluorenes via an indanone dianion annulation,39 which was 
applied to a synthesis of prekinamycin. 
                                                                                                                                                 
59 In addition to serving as a dehydrating agent, MgSO4 likely also facilitated the reaction by acting as a mild 
Lewis acid. Furthermore, Dr. Evan S. Krygowski attempted a very similar set of reaction conditions to 
dehydrate his model system 66 (MgSO4, DCE, Scheme 2.4), but did not observe any desired product. 
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Scheme 2.32. Proposed cyclopentadienyl anion bisannulation strategy. 
 In preparation for our key annulation, lomaiviticin B core 169 was treated with TMSOTf and 
Et3N (Scheme 2.33), which resulted in both silyl enol ether formation and protection of the bis-
hemiketal core to furnish cyclopentadiene dimer 176. In the event that 176 did not undergo 
cyclopentadienyl anion bisannulation, protected lomaiviticin B core 177 was synthesized from 169 
by heating in neat TMSCN. 
 
 
Scheme 2.33. Protection of the C4-epi-lomaiviticin B core 169. 
A variety of phthalate derivatives were synthesized (Figure 2.4) as potential annulation 
electrophiles. We originally anticipated that 2,2,2-trifluoroethanol (TFE) diester 179 would be the 
optimal electrophile for the bisannulation reaction, since it was most similar to the diester 
electrophile utilized in the indanone dianion annulation developed by Birman and coworkers.39 A 
control experiment where 179 was utilized as the electrophile in the presence of the dianion 
generated from indanone was performed and complete conversion to the hydroquinone product was 
observed. In the event that 179 was not a sufficiently reactive electrophile due to electronic 
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deactivation of the esters by the electron-donating MOM-protected phenols on the aryl ring, we 
attempted to synthesize phthalate derivatives dialdehyde 184, diacyl chloride 185, and diacyl 
fluoride 186. Unfortunately, however, dialdehyde 184 was prone to rapid polymerization and a 
synthesis of 185 and 186 was not realized due to insolubility problems encountered with the 
corresponding dicarboxylic acid precursor. Regardless, we believed TFE diester 179 was a 
promising electrophile with which to commence our cyclopentadienyl anion bisannulation studies. 
 
 
Figure 2.4. Successful (highlighted in blue) and attempted (in black) syntheses of annulation 
electrophiles. 
 
The typical procedure employed involved premixing cyclopentadiene 176 and electrophile 
179 (Scheme 2.34), followed by addition of base (e.g., KHMDS, LDA) and slow warming of the 
reaction to room temperature or higher (up to 50 °C). However, only unreacted starting material was 
recovered. Exposure of 177 to the described procedures also resulted in complete recovery of starting 
material. These results were not altogether surprising, as nucleophile 176 and 177 were extremely 
hindered and diester 179 was not very electrophilic. We rationalized that phthalate 178 (Figure 2.4), 
in which the phenol groups of the aryl ring are Boc-protected, would be a more reactive electrophile 
than 179. Another electrophile we considered was 180, where we believed initial cyclopentadienyl 
anion addition would occur on the aldehyde. Unfortunately, however, use of either electrophile 178 
or 180 in the indanone annulation control system failed to produce any hydroquinone product. 
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Scheme 2.34. Attempted cyclopentadienyl anion annulation to synthesize hydroquinone 190. 
Eventually, we discovered that deprotonation of cyclopentadiene 176, followed by addition 
of aldehyde 183 (Scheme 2.35), afforded a mixture of monoaddition products, the regiochemistry of 
which were unverified, in low conversion. Efforts to obtain the double addition product and improve 
the conversion of the reaction proved unsuccessful. We suspected that the low conversion was due to 
incomplete deprotonation of 176. However, warming of 176 with base (e.g., LiHMDS, LDA, 
LiTMP, n-BuLi) to higher temperatures resulted in decomposition of starting material. 
 
 
Scheme 2.35. Attempted cyclopentadienyl anion addition to aldehyde 183. 
We discovered that we could perform a double aldol reaction (Scheme 2.36) with the enolate 
dimer generated from 177 and either aldehyde 183 or 181, furnishing the full carbon skeleton of the 
lomaiviticin aglycon (193 and 194). Next, we attempted to oxidize the newly generated β-hydroxy60 
groups in 193 and 194 to afford the corresponding 1,3-dicarbonyl function. Unfortunately, however, 
use of conventional oxidation conditions (e.g., Swern, DMP, Parikh-Doering) resulted in either 
decomposition or recovery of starting material. While we were excited at having finally obtained the 
                                                                                                                                                 
60 The β-hydroxy groups were prone to β-elimination, especially under basic conditions. 
O
O
TBSO
OTBS
TMSO
Et
Et
OTMSH
H
TMSO
OTMS
O
O
TBSO
OTBS
TMSO
Et
Et
OTMSH
H
O
O
MOMO
MOMO
O
OTFE
O
OTFE
or
O
O
TBSO
OTBS
O
O
Base
HO
OH
MOMO
OMOM
HO
OH
MOMO
OMOM
H
H
Et
Et
O
O
TMS
TMS
176 177 190
×
179
O
O
TBSO
OTBS
TMSO
Et
Et
OTMSH
H
TIPSO
OTIPS
Base
MeO
MeO
O
H
H
O O176
×
183
O
O
TBSO
OTBS
TIPSO
OTIPS
HO
PO
PO
OH
OP
OP
H
H
Et
Et
O
O
TMS
H
O
O
TMS
H
O
O
191
O
O
TBSO
OTBS
O
Et
Et
OH
H
TIPSO
OTIPS
TMS
TMS
O
O
PO
OP
PO
OP
192
H
H
H
H
O
O
O
Oor
P = MeP = Me
 52 
full lomaiviticin aglycon carbon skeleton, it was difficult to envision a straightforward strategy for 
converting 193 or 194 to the desired hydroquinone 175. Hence, we decided to embark on a new 
strategy where instead of utilizing 177 as the nucleophile, it would instead serve as the electrophilic 
component. 
 
 
Scheme 2.36. Successful double aldol reaction to yield the full lomaiviticin aglycon carbon skeleton. 
 Due to their anti-aromatic nature, cyclopentadienones are highly reactive and tend to self-
dimerize rapidly in a [4+2] pathway.61,62 Although unprecedented, we hoped to exploit the reactivity 
of cyclopentadienones63 to our advantage (197) by generating cyclopentadienone intermediate 197 in 
situ (Scheme 2.37) in the presence of a suitable nucleophile such as cyanophthalide anion 196 to 
immediately trap this reactive species, affording double Michael adduct 198. A Claisen 
condensation, followed by elimination of cyanide and tautomerization, could then furnish desired 
hydroquinone dimer 200. Furthermore, we hypothesized that since 197 was relatively hindered, it 
may be less prone to self-dimerization. 
                                                                                                                                                 
61 For review, see: Ogliaruso, M. A.; Romanelli, M. G.; Becker, E. I. Chem. Rev. 1965, 65, 261−367. 
 
62 West, F. G.; Gunawardena, G. U. J. Org. Chem. 1993, 58, 5043−5044. 
 
63 For examples of 1,4-conjugate additions of Grignard reagents to cyclopentadienones, see: Pearson, A. J.; 
Kim, J. B. Org. Lett. 2003, 5, 2457−2459. 
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Scheme 2.37. Proposed cyclopentadienone bisannulation strategy. 
To this end, several potential cyclopentadienone precursors were synthesized (Scheme 2.38). 
Treatment of cyclopentadiene 201 with NBS afforded α-bromide dimer 202 (Eq.1).64 However, 
exposure of 202 to basic conditions resulted in only α-epimerization and no cyclopentadienone was 
observed. Next, we attempted to synthesize tetrabromide 204 from 177 by treatment with LiHMDS, 
followed by addition of NBS (Eq.2). Tetrabromide 204 was obtained only in minor quantities, with 
dibromide 203 being the major product. For reasons not entirely clear, efforts to drive the 
bromination reaction to completion were unsuccessful. Lastly, β-bromide dimer 205 was synthesized 
from 177 via a modified Wohl−Ziegler radical bromination with 1,3-dibromo-5,5-dimethylhydantoin 
(Eq.3). The major diastereomer obtained was unsymmetrical, an observation which will become 
important later (vide infra). 
                                                                                                                                                 
64 Reaction was conducted on small-scale and yield was not determined. 
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Scheme 2.38. Synthesis of several cyclopentadienone precursors. 
For ease of analysis, a 1H NMR experiment with dibromide 203 was conducted in order to 
determine whether a cyclopentadienone intermediate could be accessed from such a precursor 
(Scheme 2.39). Addition of DBU to dibromide 203 in CD2Cl2 resulted in formation of putative 
cyclopentadienone intermediate 206, with the diagnostic cyclopentadienone proton at δ = 7.00 ppm.  
 
 
Scheme 2.39. Observation of cyclopentadienone intermediate in 1H NMR experiment. 
Encouraged by this result, but with only very limited quantities of tetrabromide 204 in hand, 
we decided to explore a Diels−Alder reaction of a suitable diene with the cyclopentadienone 
intermediate generated from 204 (Scheme 2.40), since cyclopentadienones are often utilized in the 
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literature65 in Diels−Alder reactions. Although unprecedented, we decided to add tetrabromide 204 to 
the siloxyisobenzofuran generated from phthalide 20766 in the presence of DBU. All starting material 
was consumed and a new compound, where no nucleophile had been incorporated, was isolated. 
Unfortunately, we were unable to determine the structure of this new compound,67 which was no 
longer C2-symmetric and appeared to have undergone a skeletal rearrangement. The decision was 
made that pursuing this strategy was ultimately impractical due to the low yield and lack of 
scaleability in the synthesis of tetrabromide 204.  
 
 
Scheme 2.40. Attempted cyclopentadienone annulation to access double Diels−Alder adduct 208. 
Next, we investigated generation of cyclopentadienone from β-bromide dimer 205 (Scheme 
2.41). Cyanophthalide anion was preformed by stirring 15.0 equivalents of cyanophthalide 209 with 
17.0 equivalents of LiHMDS (note two equivalents excess base). β-bromide dimer 205 was 
subsequently added, under the hypothesis that the two extra equivalents of LiHMDS would generate 
the corresponding cyclopentadienone intermediate in situ. Unfortunately, a new compound, no 
longer C2-symmetric, was isolated. No nucleophile was incorporated and once again, the molecule 
appeared to have undergone a skeletal rearrangement. It became apparent that a common observation 
                                                                                                                                                 
65 (a) Harmata, M.; Gomes, M. G. Eur. J. Org. Chem. 2006, 2273−2277. (b) Ranier, J. D.; Imbriglio, J. E. Org. 
Lett. 1999, 1, 2037−2039. 
 
66 Myers, A. G.; Tom, N. J.; Fraley, M. K.; Cohen, S. B.; Madar, D. J. J. Am. Chem. Soc. 1997, 119, 
6072−6094. 
 
67 This new compound was not the result of self-dimerization. 
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was that when excess base was used in an attempt to generate the cyclopentadienone intermediate, 
the molecule would undergo a skeletal rearrangement without incorporation of nucleophile (see also 
Scheme 2.40). In consideration of this observation, another experiment in which cyanophthalide 
anion was preformed by stirring 12.0 equivalents of 209 with 11.8 equivalents of LiHMDS was 
conducted. Gratifyingly, monoadduct 230 was isolated in 45% yield and no rearranged byproducts 
were observed. 
 
 
Scheme 2.41. Attempted cyclopentadienone bisannulation with cyanophthalide 209. 
Efforts to obtain the corresponding double addition product by resubjecting monoadduct 230 
to the reaction conditions and using more polar solvents (e.g., DMF) and various additives (e.g., 
TBAI) were unsuccessful. 68  When DBU was used as an additive to discretely generate the 
cyclopentadienone from monoadduct 230, a new compound was isolated in which a second 
equivalent of nucleophile was not incorporated and the molecule appeared to have undergone a 
skeletal rearrangement, in line with our previous observations when excess base was used. We 
hypothesized that under the given reaction conditions, it was unlikely that the cyclopentadienone 
intermediate was generated, since the cyanophthalide anion is not very basic (pKa ~14). Rather, we 
believed that monoadduct 230 was the result of SN2 displacement of the allylic bromide in 205 by 
the cyanophthalide anion. This notion appeared to be supported by two observations: (1) when DBU 
was used to discretely generate the cyclopentadienone intermediate, no nucleophile was incorporated 
                                                                                                                                                 
68 Cyanophthalide anion was not stable under these conditions and rapidly decomposed. 
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and (2) only the monoaddition product was obtained. Recall the aforementioned observation that the 
major diastereomer of 205 was unsymmetrical. The shape of the lomaiviticin core exists in the form 
of a deep bowl, indicating that in the unsymmetrical β-bromide dimer 205, one bromide is on the 
convex face and one bromide is on the concave face. If the formation of 230 occurs via an SN2 
mechanism, only the concave bromide could be displaced via convex approach of the cyanophthalide 
anion. Displacement of the convex bromide would require concave approach by the nucleophile, 
which is highly disfavored, resulting in the isolation of only monoadduct 230. Predicated on the 
aforementioned hypothesis, we attempted to displace the allylic bromide in 230 with NaI and KI but 
without success. At this point, we decided to revise our strategy for introducing the AB/A'B'-
naphthalene systems. 
One of the main challenges involved in constructing the naphthalene system is the presence 
of the C5−C6 and C5'−C6' internal double bonds in 177 (Scheme 2.42, highlighted in red), which 
prevented us from employing conventional Hauser, Kraus, and related annulations. We therefore 
next planned on reductively removing the C5−C6 and C5'−C6' double bonds in 177 and subsequently 
oxidizing the resultant ketone 231 to enone 232, the desired annulation substrate. Unfortunately, 177 
was completely inert to the hydrogenation conditions we screened (H2, from 1 to 20 atm, and Pd/C, 
PtO2, Rh/C, and Crabtree’s catalyst). These results were not surprising, as the internal double bonds 
in 177 are extremely hindered. 
 
 
 
Scheme 2.42. Attempted reductive removal of the C5−C6 and C5'−C6' internal double bonds in 177. 
 
 Interestingly, exposure of 177 to Birch reduction conditions cleanly afforded ketone 235 
(Scheme 2.43), the result of C5−C6 (or C5'−C6') enone reduction followed by intramolecular 1,4-
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conjugate addition of the resultant anion at the C6 (or C6') position to the C5'−C6' (or C5−C6) enone 
on the other half of the molecule. Closer examination of a 3D hand-held molecular model of 177 
revealed that C6 and C6' are in very close proximity due to the bowl-shaped structure of the 
lomaiviticin B core 177. While disappointing, this result further highlighted the unique reactivity of 
the lomaiviticin system. 
 
 
 
Scheme 2.43. Birch reduction of 177. 
 
 Due to our unsuccessful attempts to reductively remove the C5−C6 and C5'−C6' double 
bonds, we next focused our attention on introducing nucleophiles to the C6 and C6' positions of 177 
or 169 via 1,4-conjugate addition to the enone. However, our endeavors to add nucleophiles such as 
Et2AlCN, Stryker’s reagent, TBHP, PhSH, and EtSH under a variety of conditions resulted in no 
reaction. Eventually, we discovered that 169 underwent double nucleophilic epoxidation when 
treated with H2O2 and NaOH, providing bisepoxide 237 (Scheme 2.44). The bis-hemiketal core was 
protected as the TMS ethers, providing diketone substrate 238. For reasons not entirely clear, 
attempts to oxidize bisepoxide 238, including Saegusa oxidation of the corresponding TMS enol 
ether of 238 and α-selenation-elimination of the ketone in 238, to enone dimer 239 were 
unsuccessful. 
 
 
Scheme 2.44. Synthesis of bisepoxide 237 via a double nucleophilic epoxidation. 
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 At this point, a reevaluation of our strategy was necessary. Based on our unsuccessful 
bisannulation studies, it was evident that a new approach to installing the AB/A'B'-naphthalene 
systems was required. From our investigation, it was apparent that the main challenge was forming 
the C11a−C11 and C11a'−C11' bonds after β-elimination of the oxygen bridge. Thus, in our revised 
strategy we envisioned preforming the C11a−C11 and C11a'−C11' bonds prior to the dimerization 
event (Scheme 2.45). Not only does this minimize double processing, but also provides a handle for 
introduction of the naphthalene system after oxygen bridge fragmentation. 
  
Scheme 2.45. Revised strategy involving preforming the C11a−C11 and C11a'−C11' bonds prior to 
the dimerization event. 
 
In order to address the pressing question of whether a system such as oxanorbornanone 240 
can undergo oxygen bridge fragmentation with a pendant substituent at C11a, enone 246 was 
synthesized from oxanorbonanone 163 in a few straightforward steps (Scheme 2.46). Reduction of 
ketone 163 with NaBH4, followed by pivaloyl protection of the resultant secondary hydroxyl group, 
afforded pivaloyl ester 244. Hydrogenolysis of the benzyl ether group and subsequent Parikh-
Doering oxidation of the secondary carbinol provided ketone 245. Saegusa oxidation of the TMS 
enol ether of 245 afforded enone 246. Transmetallation of the (α-benzyloxymethyl)stannane 247 
upon treatment with n-butyllithium, followed by addition of CuBr•SMe2, resulted in formation of the 
corresponding ((benzyloxy)methyl)copper reagent. 69  Exposure of enone 246 to this 
                                                                                                                                                 
69 (a) Hutchinson, D. K.; Fuchs, P. L. J. Am. Chem. Soc. 1987, 109, 4930−4939. (b) Yamamoto, Y.; 
Maruyama, K. J. Am. Chem. Soc. 1978, 100, 3240−3241.  
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((benzyloxy)methyl)copper reagent, followed by addition of BF3•OEt2, resulted in successful 1,4-
conjugate addition to afford adduct 248 as a single diastereomer. 
 
Scheme 2.46. Synthesis of oxygen bridge fragmentation substrate 252. 
Formation of the TIPS enol ether of 248, reductive cleavage of the pivaloyl ester with 
LiAlH4, and oxidation of the resultant secondary carbinol with TPAP and NMO yielded the desired 
dimerization substrate 250. Exposure of monomer 250 to the optimal oxidative enolate dimerization 
conditions developed in our lab yielded dimer 251.70 Cleavage of the TIPS enol ether groups then 
cleanly afforded cyclic hydrate 252.  
The key oxygen bridge fragmentation reaction was next tested (Scheme 2.47). Quite 
surprisingly, exposure of cyclic hydrate 252 to the optimal β-elimination conditions (KOH, 
THF/H2O) discovered earlier for a highly similar substrate (166), resulted in nonspecific 
decomposition. The only difference between 252 and 166, which underwent successful oxygen 
bridge fragmentation, was the presence of a substituent at C11a and C11a'. Disappointingly, this 
result further highlighted the idiosyncratic nature of the oxanorbornanone system and the highly 
case-dependent success of β-elimination of the oxygen bridge. 
                                                                                                                                                 
70 Due to the small-scale nature of the dimerization reaction, an accurate yield was not determined. 
O H
O
OTBS
Et
OPiv
246
BnO SnBu3
CuBr•SMe2;
then 246;
then BF3•OEt2
−78 → 0 °C
(72%)
247
n-BuLi;
O H
O
OTBS
Et
OPiv
248
OBn
TIPSOTf
Et3N
CH2Cl2
0 °C → RT
(quant.)
TIPSO H
O
OTBS
Et
OPiv
249
OBn
BnO H
O
OTBS
Et
O
163
1. NaBH4
    EtOH, 0 °C
2. PivCl, Py
    CH2Cl2, 40 °C
  (82%, 2 steps)
BnO H
O
OTBS
Et
OPiv
244
1. H2, Pd(OH)2/C
    THF, RT
2. SO3•Py
    i-Pr2NEt, DMSO
    CH2Cl2, 0 °C
    (94%, 2 steps)
O H
O
OTBS
Et
OPiv
245
1. TMSOTf
    Et3N, CH2Cl2
    0 °C → RT
2. Pd(OAc)2
    MeCN, 50 °C
 (99%, 2 steps)
1. LiAlH4
    THF, 0 °C
2. TPAP, NMO
    CH2Cl2, RT
 (69%, 2 steps)
TIPSO H
O
OTBS
Et
O
250
OBn
LiHMDS, HMPA
THF, −78 °C;
then [Cp2Fe]PF6
 −78 → −60 °C
3 d
TIPSO H
O
OTBS
Et
O
OBn
O
H
H
O
OTIPS
BnO
TBSO
H
Et
251
HCl
THF/H2O
RT
O H
O
OTBS
Et
O
H
HO
Et
OTBS
H
O
H
HO
O
OBn
BnO
252
4
 61 
 
Scheme 2.47. Unsuccessful oxygen bridge fragmentation of cyclic hydrate 252. 
At this point, one last strategy involving an intermediate synthesized by Jae Young Ahn 
from the original model system was investigated (Scheme 2.48). Due to readily accessible material 
and the highly successful oxygen bridge fragmentation of 64 in Dr. Evan S. Krygowski’s model 
system, we decided to explore the possibility of whether 257, in which the C11−C11a bond was 
preformed, could undergo β-elimination of the oxygen bridge. Although downstream manipulations 
would be necessary in order to construct the B- and B'-ring systems in the correct oxidation state, we 
believed this strategy was superior to that illustrated in Scheme 2.45 because the aryl ring has 
already been introduced, obviating the need to install the naphthalene system de novo via late-stage 
double-processing.  
 
 
Scheme 2.48. Unsuccessful oxygen bridge fragmentation of cyclic hydrate 257. 
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Reductive cleavage of the pivaloyl ester of 25471 and subsequent Ley oxidation of the 
resultant secondary carbinol afforded ketone 255, the dimerization precursor. Oxanorbornanone 255 
underwent successful oxidative enolate dimerization to furnish dimer 256, which contained the full 
carbon skeleton of the lomaiviticin aglycon, in 80% yield. Ketal cleavage occurred smoothly upon 
exposure of 256 to TfOH in acetone/H2O to provide cyclic hydrate 257. Treatment of 257 with a 
variety of basic conditions (KOH/THF/H2O, DBU/THF, K2CO3/MeOH) in an attempt to fragment 
the oxygen bridge resulted in nonspecific decomposition of 257. These results were quite 
unexpected, given the highly successful oxygen bridge β-elimination (85%) of 64 to 65 (Scheme 2.4) 
in Dr. Evan Krygowski’s original model system. 
Due to the highly unpredictable and extremely case-dependent nature of β-elimination of the 
oxygen bridge, coupled with the lack of success in introducing the AB/A'B'-naphthalene systems, the 
difficult decision was made to cease pursuing a synthesis of the lomaiviticin aglycon. Although we 
successfully achieved a synthesis of the lomaiviticin core, which necessitated oxygen bridge 
fragmentation prior to installation of the naphthalene system, we were forced to utilize exotic and 
unprecedented bisannulation strategies, which not only involved challenging double-processing but 
were ultimately unsuccessful. Furthermore, installation of functionality at C11a and C11a' pre-
dimerization, which would help enable subsequent introduction of the naphthalene ring systems after 
β-elimination of the oxygen bridge, again prevented oxygen bridge fragmentation. In fact, β-
elimination could only be achieved in substrates containing the unnatural C4/C4'-stereochemistry 
and which lacked the C11a/C11a' substitution. Two important take-home lessons were realized from 
working on the lomaiviticin project: (1) the success of model systems rarely translate to the real 
system in a complex molecule setting and (2) double-processing is extremely challenging and when 
possible, should be avoided.  
                                                                                                                                                 
71 Courtesy of Jae Young Ahn. 254 was synthesized from intermediate 71. 
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Concluding Remarks 
 In conclusion, a synthesis of the C4-epi-lomaiviticin A and B cores was accomplished. A 
first-generation synthetic route featuring an intramolecular exo-selective furan Diels−Alder reaction 
to construct the oxanorbornanone system, a “carboxy-inversion” sequence for installing the correct 
C4-stereochemistry, and a stereoselective oxidative enolate dimerization reaction to establish the key 
C2−C2' bond, allowed us to access an oxygen bridge fragmentation precursor substrate. However, 
the discovery of subtle stereoelectronic effects imparted by the C4/C4'-stereocenters necessitated a 
second-generation synthesis of a substrate with the opposite C4-stereochemistry to that found in the 
natural product, which ultimately resulted in successful β-elimination of the oxygen bridge, an 
accomplishment which had eluded our lab for more than four years. This constituted the first time a 
synthesis of the lomaiviticin A and B cores had been achieved in our lab since we first began 
pursuing a total synthesis of the lomaiviticin aglycon more than ten years ago. 
Unfortunately, efforts to elaborate the lomaiviticin B core to the full carbon skeleton of the 
lomaiviticin aglycon proved extremely challenging and were ultimately unsuccessful. Because the 
success of oxygen bridge β-elimination hinged on fragmenting the oxygen bridge prior to 
installation of the naphthalenes, we were forced to explore unprecedented bisannulation strategies.  
A variety of approaches for introducing the naphthalene ring systems were pursued, including a 
cyclopentadienyl anion bisannulation, double aldol reaction, and cyclopentadienone bisannulation. 
Introduction of a handle in order to simplify installation of the naphthalene system after oxygen 
bridge fragmentation was also investigated. All of the strategies investigated, which involved 
challenging late-stage double-processing, ultimately did not provide the desired hydroquinone dimer 
product. 
At this stage in the lomaiviticin project, the difficult decision was made to no longer pursue a 
total synthesis of the lomaiviticin aglycon due to the highly unpredictable and idiosyncratic oxygen 
bridge fragmentation and inability to introduce the AB/A'B'-naphthalene ring systems. In retrospect, 
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the oxanorbornanone system was an elegant strategy for stereoselectively establishing the key 
C2−C2' central bond without undesired β-elimination of the oxygen bridge during the dimerization 
event. However, unexpected downstream complications were encountered when attempting to 
fragment the oxygen bridge at the appropriate time. In most systems investigated by our lab during 
the course of the past four years, we were unable to β-eliminate the oxygen bridge.  
However, we are still optimistic that a successful synthesis of the aglycon can be achieved 
with our oxanorbornanone dimerization strategy from the knowledge we have obtained from our 
combined synthetic effort during the past ten years. We believe that the challenges associated with β-
elimination of the oxygen bridge arise from the 5-membered C-ring (see 1, Figure 1.1), which 
significantly restricts the conformational flexibility of the oxanorbornanone system. We speculate, 
however, that if the C5a–C11a bond was not preformed prior to β-elimination of the oxygen bridge, 
we could potentially overcome the challenges we encountered and achieve a synthesis of the 
aglycon.  
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Experimental Section 
 General Procedures. All reactions were performed in flame-dried glassware under a 
positive pressure of argon unless otherwise noted. Flash column chromatography was performed as 
described by Still et al. employing silica gel 60 (40-63 µm, Whatman).72 Analytical thin-layer 
chromatography (TLC) was performed using 0.25 mm silica gel 60 F254 plates purchased from EMD 
Chemicals. Where necessary (so noted), silica gel was neutralized by treatment of the silica gel prior 
to chromatography with the eluent containing triethylamine (Et3N) or 30% (w/v) ammonium 
hydroxide (NH4OH). TLC plates were visualized by exposure to ultraviolet light (UV) and/or 
exposure to an acidic solution of p-anisaldehyde (Anis) or an aqueous solution of potassium 
permanganate (KMnO4), followed by heating on a hot plate.  
 
Materials. Commercial reagents and solvents were used as received with the following 
exceptions: tetrahydrofuran (THF), diethyl ether (Et2O), dichloromethane (CH2Cl2), acetonitrile 
(MeCN), hexamethyldisilazane (HMDS), toluene (PhMe), benzene (PhH), and N,N-
dimethylformamide (DMF) were degassed with argon and passed through a solvent purification 
system (designed by J. C. Meyer of Glass Contour) utilizing alumina columns as described by 
Grubbs et al.73 Triethylamine, diisopropylethylamine, pyridine, and hexamethylphosphoramide were 
distilled over calcium hydride before use. TMSOTf was also distilled prior to use. The celite used 
was Celite® 545, purchased from J.T. Baker. The molarities of n-butyllithium solutions were 
determined by titration using 1,10-phenanthroline as an indicator (average of three determinations).  
 
Instrumentation. 1H NMR spectra were recorded with a Varian INOVA-600 or Varian 
                                                                                                                                                 
72 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
 
73 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 
1518–1520. 
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INOVA-500 spectrometer. Proton chemical shifts are reported in parts per million (δ scale) and are 
calibrated using residual undeuterated solvent as an internal reference (CDCl3: δ 7.26 (CHCl3), C6D6: 
δ 7.15 (C6D5H)). Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent, or combinations 
thereof. 13C NMR spectra were recorded with a Varian INOVA-500 spectrometer. Carbon chemical 
shifts are reported in parts per million (δ scale) and are referenced from the carbon resonances of the 
solvent (CDCl3: δ 77.00, C6D6: δ 128.39). Infrared (FTIR) spectra were recorded on a Bruker Alpha 
FT-IR spectrophotometer referenced to a polystyrene standard. FTIR data is reported in frequency of 
absorption (cm-1). High-resolution mass spectra (HRMS) were obtained from the Harvard University 
Mass Spectrometry Laboratory where electrospray ionization (ESI) mass spectroscopy (MS) 
experiments were performed on an Agilent 6210 TOF LC/MS instrument. Optical rotations were 
measured on a Jasco P-2000 digital polarimeter with a sodium lamp. Reported readings are the 
average of three measurements for each sample.  
 
 (For clarity, intermediates that have not been assigned numbers in the text are numbered 
sequentially in the experimental section beginning with S1). 
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(S)-Methyl 3-benzyloxy-4-(tert-butyl)dimethylsilyloxybutanoate (S2):  
To a round-bottom flask was added (S)-Methyl 4-[(tert-butyl)dimethylsilyloxy]-3-
hydroxybutanoate (S1) 74  (1.00 g, 4.03 mmol, 1.00 equiv) and Et2O (40 mL). Benzyl 2,2,2-
trichloroacetimidate (1.12 mL, 6.04 mmol, 1.50 equiv) was then added via syringe and the solution 
was cooled to 0 °C. Catalytic trifluoromethanesulfonic acid (18.0 µL, 0.201 mmol, 0.05 equiv) was 
then added dropwise via syringe to the reaction mixture. Vigorous bubbling was observed. After 30 
min, the reaction was allowed to warm to room temperature. After an additional 20 h, saturated 
aqueous NaHCO3 solution (30 mL) and Et2O (30 mL) were added to the stirred reaction mixture. 
The layers were separated and the organic layer was washed with brine. The aqueous layers were 
combined and further extracted with Et2O (3 × 30 mL). The organic layers were combined, dried 
over anhydrous MgSO4, and concentrated under reduced pressure. The resulting oil was then purified 
by flash column chromatography (silica gel, eluent: gradient, 12:1 → 7:1 hexanes:EtOAc) to afford 
(S)-methyl 3-benzyloxy-4-(tert-butyl)dimethylsilyloxybutanoate S2 (1.10 g, 81%) as a colorless oil.  
 
1H NMR (500 MHz, CDCl3) δ: 7.35–7.30 (m, 4H), 7.29–7.27 (m, 1H), 4.66 (d, J = 11.7 Hz, 1H), 
4.61 (d, J = 11.7 Hz, 1H), 4.01–3.93 (m, 1H), 3.72 (dd, J = 5.4, 10.3 Hz, 1H), 3.67 (s, 3H), 3.59 (dd, 
J = 6.0, 10.4 Hz, 1H), 2.64 (dd, J = 5.1, 15.9 Hz, 1H), 2.53 (dd, J = 8.3, 15.6 Hz, 1H), 0.89 (s, 9H), 
0.05 (s, 6 H). 13C NMR (126 MHz, CDCl3) δ: 172.1, 138.5, 128.3, 127.8, 127.6, 76.7, 72.6, 64.7, 
51.6, 37.3, 25.9, 18.3, –5.4, –5.5. FTIR (thin film) cm-1: 2953, 2928, 2857, 1741, 1437, 1254, 1113, 
1086, 836, 778. HRMS (ESI) (m/z) calc’d for C18H30NaO4Si [M+Na]+: 361.1806, found 361.1815. 
TLC (4:1 hexanes:EtOAc), Rf : 0.63 (UV, KMnO4).  
                                                                                                                                                 
74 (a) Szpilman, A. M.; Cereghetti, D. M.; Wurtz, N. R.; Manthorpe, J. M.; Carreira, E. M. Angew. Chem. Int. 
Ed. 2008, 47, 4335-4338. (b) Gaunt, M. J.; Jessiman, A. S.; Orsini, P.; Tanner, H. R.; Hook, D. F.; Ley, S. Org. 
Lett. 2003, 5, 4819-4822. 
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(S)-3-Benzyloxy-4-(tert-butyl)dimethylsilyloxybutan-1-ol (S3):  
A suspension of LiAlH4 (2.36 g, 59.0 mmol, 1.10 equiv) in THF (170 mL) was cooled to 
−40 °C. A solution of (S)-methyl 3-benzyloxy-4-(tert-butyl)dimethylsilyloxybutanoate S2 (18.2 g, 
53.6 mmol, 1.00 equiv) in THF (240 mL) was then added dropwise via syringe to the stirred 
suspension. After 40 min, a saturated aqueous NH4Cl solution (250 mL) and EtOAc (200 mL) were 
added to the reaction mixture. The layers were separated and the aqueous layer was extracted with 
EtOAc (3 × 150 mL). The organic layers were combined, washed with brine (200 mL), dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The resulting oil was then purified by 
flash column chromatography (silica gel plug, eluent: 2:1 hexanes:EtOAc) to afford alcohol S3 (15.6 
g, 94%) as a colorless oil.  
 
1H NMR (500 MHz, CDCl3) δ: 7.39–7.32 (m, 4H), 7.32–7.27 (m, 1H), 4.73 (d, J = 11.7 Hz, 1H), 
4.59 (d, J = 11.7 Hz, 1H), 3.81–3.71 (m, 3H), 3.71–3.63 (m, 2H), 2.46 (t, J = 5.6 Hz, 1H), 1.92–1.71 
(m, 2H), 0.91 (s, 9H), 0.07 (s, 6H). 13C NMR (126 MHz, CDCl3) δ: 138.4, 128.4, 127.8, 127.7, 78.9, 
72.2, 65.4, 60.3, 34.4, 25.9, 18.2, –5.4, –5.5. FTIR (thin film) cm-1: 3403, 2954, 2928, 2857, 1472, 
1255, 1091, 836, 776, 697. HRMS (ESI) (m/z) calc’d for C17H30NaO3Si [M+Na]+: 333.1856, found 
333.1858. TLC (2:1 hexanes:EtOAc), Rf : 0.57 (KMnO4). 
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Iodide 134:  
Triphenylphosphine (4.69 g, 17.7 mmol, 1.10 equiv) and iodine (5.32 g, 20.9 mmol, 1.30 
equiv) were added sequentially in single portions to a stirred solution of imidazole (1.66 g, 24.2 
mmol, 1.50 equiv) in CH2Cl2 (35 mL). After 20 min, a solution of alcohol S3 (5.00 g, 16.1 mmol, 
1.00 equiv) in CH2Cl2 (35 mL) was added dropwise via cannula to the reaction mixture. After 1 h, 
saturated aqueous Na2SO3 solution (50 mL) and EtOAc (20 mL) were sequentially added to the 
reaction. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 50 mL). 
The organic layers were combined, washed with brine (50 mL), dried over anhydrous MgSO4, and 
concentrated under reduced pressure. The residue was dissolved in Et2O and triphenylphosphine 
oxide precipitated upon standing. The suspension was then filtered through a thin pad of silica gel 
and all volatiles were removed in vacuo. The resulting oil was then purified by flash column 
chromatography (silica gel, eluent: gradient, 20:1 → 15:1 hexanes:EtOAc) to afford iodide 134 (5.93 
g, 88%) as a colorless oil.  
 
1H NMR (600 MHz, CDCl3) δ: 7.40–7.32 (m, 4H), 7.32–7.27 (m, 1H), 4.74 (d, J = 11.4 Hz, 1H), 
4.58 (d, J = 11.4 Hz, 1H), 3.72 (q, J = 5.3 Hz, 1H), 3.64–3.56 (m, 2H), 3.34–3.25 (m, 2H), 2.14–1.94 
(m, 2H), 0.91 (s, 9H), 0.06 (s, 6H). 13C NMR (126 MHz, CDCl3) δ: 138.6, 128.4, 127.9, 127.7, 79.5, 
72.7, 64.9, 36.1, 25.9, 18.3, 3.1, –5.37, –5.40. FTIR (thin film) cm-1: 2953, 2928, 2856, 1471, 1256, 
1116, 837, 777, 734, 697. HRMS (ESI) (m/z) calc’d for C17H29INaO2Si [M+Na]+: 443.0874, found 
443.0830. TLC (7:1 hexanes:EtOAc), Rf : 0.71 (UV, Anis). 
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TIPS furan 115:  
A solution of furanone S475 (309 mg, 2.76 mmol, 1.00 equiv) in CH2Cl2 (5.5 mL) was cooled 
to 0 °C. i-Pr2NEt (1.06 mL, 6.06 mmol, 2.20 equiv) and TIPSOTf (815 µL, 3.03 mmol, 1.10 equiv) 
were then added dropwise sequentially via syringe to the stirred reaction mixture, which was 
subsequently allowed to warm slowly to room temperature. After 2 h, saturated aqueous NH4Cl 
solution (5 mL) and CH2Cl2 (5 mL) were added sequentially to the reaction. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 3 mL). The organic layers were 
combined, washed with brine (5 mL), dried over anhydrous MgSO4, and concentrated under reduced 
pressure. The resulting oil was then purified by flash column chromatography (silica gel, eluent: 
hexanes, 1% Et3N) to afford TIPS furan 115 (455 mg, 61%) as a yellow oil.  
 
1H NMR (500 MHz, CDCl3) δ: 7.08–6.86 (m, 1H), 5.78 (q, J = 1.0 Hz, 1H), 2.53 (dq, J = 1.0, 7.6 
Hz, 2H), 1.24–1.15 (m, 6H), 1.09 (d, J = 6.8 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ: 156.3, 
144.4, 126.1, 101.8, 21.8, 17.8, 12.3, 11.9. FTIR (thin film) cm-1: 2944, 2867, 1617, 1463, 1384, 
1149, 999, 882, 859, 683. HRMS (ESI) (m/z) calc’d for C15H29O2Si [M+H]+: 269.1931, found 
269.1934. TLC (2:1 hexanes:EtOAc), Rf : 0.95 (UV, Anis). 
  
                                                                                                                                                 
75 Wasserman, H. H.; Lee, G. M. Tet. Lett. 1994, 35, 9783-9786. 
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Alkylated furan 135:  
A solution of TIPS furan 115 (5.40 g, 20.1 mmol, 1.30 equiv), which was azeotropically 
dried with benzene (3 × 10 mL), in THF (26 mL) was cooled to −78 °C. A solution of n-butyllithium 
in hexanes (2.62 M, 7.08 mL, 18.6 mmol, 1.20 equiv) was then added dropwise. After 10 min, the 
reaction mixture was allowed to warm to 0 °C. After an additional 75 min, the reaction was cooled to 
−78 °C and a solution of alkyl iodide 134 (6.50 g, 15.5 mmol, 1.00 equiv) in THF (26 mL) was 
added dropwise via syringe over 10 min. The reaction mixture was then allowed to warm slowly to 0 
°C over 4 h, at which point brine (50 mL) and Et2O (30 mL) were sequentially added. The organic 
and aqueous layers were separated and the aqueous layer was extracted with EtOAc (3 × 30 mL). 
The organic layers were combined, washed with brine (50 mL), dried over anhydrous MgSO4, and 
concentrated under reduced pressure. The resulting oil was then purified by flash column 
chromatography (silica gel, eluent: 80:1 → 50:1 → 20:1 hexanes:EtOAc, 1% Et3N) to afford 
alkylated furan 135 (8.84 g) as a yellow oil. Due to difficulties in removing trace TIPS furan 115 
from product 135, an accurate yield was determined after the next step.  
 
1H NMR (600 MHz, CDCl3) δ: 7.36 (d, J = 6.7 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 7.26–7.23 (m, 1H), 
5.67 (s, 1H), 4.69 (d, J = 11.7 Hz, 1H), 4.60 (d, J = 11.4 Hz, 1H), 3.71 (dd, J = 6.2, 10.5 Hz, 1H), 
3.61 (dd, J = 5.0, 10.5 Hz, 1H), 3.52–3.46 (m, 1H), 2.74–2.67 (m, 1H), 2.61 (ddd, J = 6.6, 8.9, 15.2 
Hz, 1H), 2.49 (q, J = 7.6 Hz, 2H), 1.91–1.81 (m, 1H), 1.81–1.70 (m, 1H), 1.22–1.13 (m, 6H), 1.08 
(d, J = 7.3 Hz, 18H), 0.89 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H). 13C NMR (126 MHz, CDCl3) δ: 153.1, 
139.2, 138.1, 138.0, 128.2, 127.7, 127.3, 101.2, 79.5, 72.3, 65.9, 30.0, 25.9, 21.8, 21.0, 18.3, 17.9, 
12.5, 12.1, –5.35, –5.41. FTIR (thin film) cm-1: 2944, 2866, 1641, 1463, 1409, 1251, 1072, 997, 883, 
115
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836, 776, 684. HRMS (ESI) (m/z) calc’d for C32H56NaO4Si2 [M+Na]+: 583.3609, found 583.3611. 
TLC (12:1 hexanes:EtOAc), Rf : 0.57 (UV, Anis). 
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Furanone alcohol S5:  
A solution of furan 135 (8.84 g, 15.8 mmol, 1.00 equiv) in THF (79 mL) was cooled to 0 °C. 
A solution of TBAF in THF (1.00 M, 39.4 mL, 39.4 mmol, 2.50 equiv) was then added dropwise via 
syringe to the solution. After 2 h, the reaction mixture was allowed to warm to room temperature. 
After an additional 10 min, brine (50 mL) and Et2O (50 mL) were added sequentially to the reaction. 
The layers were separated and the aqueous layer was extracted with EtOAc (3 × 40 mL). The organic 
layers were combined, washed with brine (50 mL), dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The resulting oil was then purified by flash column chromatography (silica 
gel, eluent: gradient, 1:1 → 2:1 → 4:1 → 8:1 → 1:0 EtOAc:hexanes) to afford an inseparable 1:1 
mixture of C6-diastereomers of furanone alcohol S5 (4.16 g, 93% over 2 steps) as a yellow oil. 
 
1H NMR (600 MHz, CDCl3) δ: 7.38–7.28 (m, 10H), 5.44 (s, 2H), 4.61 (d, J = 11.4 Hz, 2H), 4.56 (m, 
2H), 4.47–4.39 (m, 2H), 3.76–3.68 (m, 2H), 3.60–3.51 (m, 4H), 2.52 (m, 4H), 2.12–2.04 (m, 1H), 
2.03–1.94 (m, 1H), 1.88–1.61 (m, 6H), 1.24 (t, J = 7.5 Hz, 3H), 1.23 (t, J = 7.5 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ: 204.75, 204.72, 195.4, 195.3, 138.1, 128.5, 128.3, 127.83, 127.80, 126.9, 
102.78, 102.76, 85.9, 85.8, 79.0, 78.8, 71.63, 71.60, 63.9, 63.8, 27.0, 26.9, 25.8, 25.7, 24.2, 10.2. 
FTIR (thin film) cm-1: 3435, 2939, 2878, 1693, 1590, 1390, 1108, 1059, 740, 699. HRMS (ESI) 
(m/z) calc’d for C17H22NaO4 [M+Na]+: 313.1410, found 313.1418. TLC (2:1 EtOAc:hexanes), Rf : 
0.25 (UV, Anis). 
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Furanone (Z)-enoate 137:  
A solution of oxalyl chloride (6.86 mL, 79.5 mmol, 2.00 equiv) in CH2Cl2 (397 mL) was 
cooled to −78 °C. DMSO (11.3 mL, 159 mmol, 4.00 equiv) was then added dropwise. After 1.5 h, a 
solution of furanone alcohol S5 (11.5 g, 39.8 mmol, 1.00 equiv) in CH2Cl2 (173 mL) at –78 °C was 
added dropwise via a dry-ice wrapped cannula to the stirred reaction. After 1 h, i-Pr2NEt (41.5 mL, 
239 mmol, 6.00 equiv) was added dropwise via syringe to the reaction mixture. After 15 min, the 
reaction was allowed to warm slowly to −20 °C over 30 min. After an additional 40 min, saturated 
aqueous NH4Cl solution (500 mL) was added to the reaction, and the resultant mixture was allowed 
to warm to room temperature. EtOAc (1 L) was then added and the layers were separated. The 
aqueous layer was extracted with EtOAc (3 × 300 mL). The organic layers were combined, washed 
with saturated aqueous NH4Cl solution (8 × 700 mL), then brine (500 mL), and dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The crude aldehyde 136 was carried forward to the 
next step without further purification. 
A solution of allyl diphenylphosphonoacetate76 (14.5 g, 43.7 mmol, 1.10 equiv) in THF (300 
mL) was cooled to 0 °C. NaI (7.29 g, 47.7 mmol, 1.20 equiv) and DBU (6.54 mL, 43.7 mmol, 1.10 
equiv) were then added sequentially to the solution. After 20 min, the reaction was cooled to −78 °C 
before a solution of crude aldehyde 136 in THF (100 mL) was added dropwise via cannula. After 2.5 
h, saturated aqueous NH4Cl solution (300 mL) was added to the stirred reaction mixture, which was 
then allowed to warm to room temperature. The mixture was diluted with EtOAc (600 mL) and the 
layers were separated. The aqueous layer was extracted with EtOAc (3 × 300 mL) and the organic 
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layers were combined, washed with saturated aqueous NH4Cl solution (5 × 300 mL), then brine (300 
mL), and dried over anhydrous MgSO4 and concentrated. The resulting oil was then purified by flash 
column chromatography twice using different eluent conditions (silica gel, eluent: (a) gradient, 20:1 
→ 15:1 → 10:1 → 7:1 → 5:1 → 2:1 CH2Cl2:EtOAc (removes unreacted allyl 
diphenylphosphonoacetate), (b) gradient, 6:1 → 4:1 → 2:1 hexanes:EtOAc) to afford an inseparable 
1:1 mixture of C6-diastereomers of furanone (Z)-enoate 137 (11.0 g, 74% over 2 steps) as a pale 
yellow oil. 
 
1H NMR (600 MHz, CDCl3) δ: 7.36–7.24 (m, 10H), 6.21 (dd, J = 2.3, 8.5 Hz, 1H), 6.19 (dd, J = 2.3, 
8.5 Hz, 1H), 5.98–5.88 (m, 4H), 5.41 (m, 2H), 5.33 (m, 2H), 5.26 (m, 2H), 5.11–5.05 (m, 2H), 4.64–
4.57 (m, 4H), 4.52 (m, 2H), 4.46 (dd, J = 4.1, 7.9 Hz, 1H), 4.44–4.39 (m, 3H), 2.50 (q, J = 7.6 Hz, 
4H), 2.20–2.09 (m, 1H), 2.06–1.96 (m, 1H), 1.92–1.78 (m, 3H), 1.78–1.64 (m, 3H), 1.22 (t, J = 7.6 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ: 204.68, 204.65, 195.13, 195.09, 165.29, 165.26, 150.81, 
150.79, 138.23, 138.19, 132.0, 128.3, 127.8, 127.7, 127.62, 127.60, 121.5, 121.4, 118.5, 102.6, 86.0, 
85.8, 74.5, 74.3, 71.4, 71.3, 65.1, 65.0, 30.0, 29.9, 27.1, 27.0, 24.1, 10.2. FTIR (thin film) cm-1: 
2981, 2942, 1718, 1698, 1595, 1389, 1181, 1071, 986, 824, 698. HRMS (ESI) (m/z) calc’d for 
C22H26NaO5 [M+Na]+: 393.1673, found 393.1676. TLC (1:1 hexanes:EtOAc), Rf : 0.41 (UV, Anis). 
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Oxanorbornanone allyl ester 138: 
A solution of diisopropylamine (1.85 mL, 13.2 mmol, 1.40 equiv) in THF (140 mL) was 
cooled to −78 °C. A solution of n-butyllithium in hexanes (2.56 M, 4.78 mL, 12.3 mmol, 1.30 equiv) 
was then added dropwise via syringe to the solution. After 15 min, the reaction was allowed to warm 
to 0 °C for 20 min before recooling to −78 °C. Additional THF (210 mL) was added to the reaction 
at −78 °C. A solution of furanone (Z)-enoate 137 (3.49 g, 9.42 mmol, 1.00 equiv) in THF (120 mL) 
at –78 °C was added dropwise via a dry-ice wrapped cannula to the solution of LDA. After an 
additional 8.5 h, a solution of AcOH (3.5 mL) in THF (70 mL) was added via cannula to the stirred 
reaction. After an additional 15 min, saturated aqueous NH4Cl solution (400 mL) was added to the 
mixture, which was then allowed to warm to room temperature. The resultant mixture was diluted 
with EtOAc (400 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (3 
× 300 mL) and the organic layers were combined, washed with saturated aqueous NaHCO3 solution 
(3 × 200 mL) and brine (300 mL). The organic layers were then dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The resulting oil was then purified by flash column 
chromatography (silica gel, eluent: gradient, 9:1 → 8:1 → 7:1 → 5:1 hexanes:EtOAc) to afford 
oxanorbornanone allyl ester 138 (2.24 g, 64%) as a colorless oil. 
 
1H NMR (600 MHz, CDCl3) δ: 7.33–7.24 (m, 5H), 5.90–5.82 (m, 1H), 5.30 (qd, J = 1.5, 17.0 Hz, 
1H), 5.21 (qd, J = 1.1, 10.4 Hz, 1H), 4.61 (tdd, J = 1.3, 6.0, 13.0 Hz, 1H), 4.46 (tdd, J = 1.3, 6.0, 13.0 
Hz, 1H), 4.42 (d, J = 11.4 Hz, 1H), 4.37 (d, J = 11.1 Hz, 1H), 4.28 (dd, J = 7.3, 13.5 Hz, 1H), 3.13 
(d, J = 9.1 Hz, 1H), 2.62 (dd, J = 7.2, 9.2 Hz, 1H), 2.41–2.25 (m, 4H), 2.12–2.00 (m, 1H), 1.94–1.80 
(m, 3H), 0.97 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 208.1, 170.1, 138.2, 131.7, 128.3, 
O
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127.6, 127.5, 119.0, 95.6, 89.2, 80.2, 71.9, 65.4, 55.3, 51.6, 47.5, 32.5, 25.6, 21.2, 8.8. FTIR (thin 
film) cm-1: 2938, 1761, 1733, 1455, 1354, 1184, 1152, 698. HRMS (ESI) (m/z) calc’d for 
C22H26NaO5 [M+Na]+: 393.1673, found 393.1657. TLC (2:1 hexanes:EtOAc), Rf : 0.66 (Anis). 
1D NOESY (600 MHz, CDCl3): 
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Carboxylic acid 139: 
Pd(PPh3)4 (2.67 g, 2.28 mmol, 0.10 equiv) in THF (85 mL) was added via cannula to a 
stirred solution of oxanorbornanone allyl ester 138 (8.43 g, 22.8 mmol, 1.00 equiv) in THF (191 
mL). Morpholine (19.9 mL, 228 mmol, 10.0 equiv) was then added via syringe to the reaction 
mixture. After 4 h, the reaction was concentrated under reduced pressure. The resultant residue was 
then dissolved in CH2Cl2 (100 mL) and washed with saturated aqueous NaHCO3 solution (5 × 75 
mL). The aqueous layers were combined and acidified by careful dropwise addition of 10% aqueous 
HCl until the pH reached 2. The aqueous layers were then extracted with CH2Cl2 (5 × 120 mL). The 
organic layers were combined, dried over anhydrous MgSO4, and concentrated under reduced 
pressure to afford crude carboxylic acid 139 as a white solid (6.44 g, 86% mass recovery). The crude 
product was carried forward to the next step without further purification. 
 
1H NMR (500 MHz, CDCl3) δ: 7.35–7.27 (m, 5H), 4.43 (d, J = 11.5 Hz, 1H), 4.38 (d, J = 11.2 Hz, 
1H), 4.24 (q, J = 6.8 Hz, 1H), 3.17 (d, J = 9.0 Hz, 1H), 2.67 (dd, J = 6.8, 9.0 Hz, 1H), 2.43–2.27 (m, 
4H), 2.17–2.06 (m, 1H), 2.00–1.83 (m, 3H), 1.00 (t, J = 7.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ: 207.4, 173.9, 138.0, 128.4, 127.74, 127.68, 95.8, 89.3, 80.3, 71.8, 55.4, 51.7, 47.2, 32.6, 25.7, 
21.3, 8.9. FTIR (thin film) cm-1: 2972, 2942, 1762, 1706, 1358, 1160, 1119, 1099, 965, 740, 
699. HRMS (ESI) (m/z) calc’d for C19H22NaO5 [M+Na]+: 353.1359, found 353.1363. TLC (1:1 
hexanes:EtOAc and 1 drop of AcOH), Rf : 0.36 (Anis).  
O
BnO
O
CO2AllylH
Et
138
O
BnO
O
CO2HH
Et
139
10 mol %
Pd(PPh3)4
morpholine
THF, RT
 79 
 
Alcohol 142: 
A solution of carboxylic acid 139 (50.0 mg, 0.151 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (3 × 0.5 mL) in CH2Cl2 (1.5 mL) was cooled to 0 °C. Oxalyl 
chloride (16.0 µL, 0.189 mmol, 1.25 equiv) and a single drop of DMF were then sequentially added 
via syringe to the stirred solution, which was subsequently allowed to warm to room temperature 
after 10 min. After 3 h, the reaction mixture was recooled to 0 °C. p-Nitroperbenzoic acid77 (37.0 
mg, 0.197 mmol, 1.30 equiv), pyridine (28.0 µL, 0.348 mmol, 2.30 equiv), and a single crystal of 4-
DMAP were then added sequentially to the stirred reaction mixture. After 1 h, CH2Cl2 (1 mL) and 
10% aqueous HCl (1 mL) were sequentially added to the reaction. The mixture was further diluted 
with CH2Cl2 (1 mL) and the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 
× 1 mL). The organic layers were combined, washed with a saturated aqueous NaHCO3 solution (3 × 
1 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure to afford crude 
diacyl peroxide 143, which was carried forward immediately to the next step without further 
purification. 
A pressure tube was charged with crude 143 and benzene (5 mL), sealed, and heated to 80 
°C. After 5.5 h, the reaction was allowed to cool to room temperature and was subsequently 
concentrated under reduced pressure. The crude residue was then suspended in methanol (3 mL) and 
the resultant mixture was cooled to 0 °C. K2CO3 (22.0 mg, 0.159 mmol, 1.05 equiv) was then added 
in a single portion. After 1 h, the reaction mixture was filtered and concentrated under reduced 
pressure. The residue was dissolved in EtOAc (3 mL) and washed with a saturated aqueous NaHCO3 
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solution (2 mL) and brine (2 mL), dried over anhydrous MgSO4, and concentrated under reduced 
pressure. The resulting crude residue was then purified by flash column chromatography (silica gel, 
eluent: gradient, 8:1 → 6:1 → 4:1 → 3:1 → 2:1 hexanes:EtOAc) to afford alcohol 142 (19.6 mg, 
43% over 3 steps) as a pale yellow solid. 
 
1H NMR (500 MHz, CDCl3) δ: 7.38–7.27 (m, 5H), 4.56 (d, J = 12.0 Hz, 1H), 4.48 (d, J = 11.7 Hz, 
1H), 4.29 (dd, J = 6.8, 13.2 Hz, 1H), 4.20 (d, J = 6.8 Hz, 1H), 2.42 (t, J = 7.0 Hz, 1H), 2.37–2.30 (m, 
2H), 2.27 (d, J = 17.8 Hz, 1H), 2.17 (d, J = 18.1 Hz, 1H), 2.08–1.92 (m, 2H), 1.89–1.75 (m, 2H), 
1.01 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 207.9, 138.3, 128.5, 127.8, 127.7, 95.7, 
90.1, 77.8, 74.5, 71.7, 56.7, 42.9, 33.2, 23.7, 21.4, 8.5. FTIR (thin film) cm-1: 3482, 2970, 2938, 
1760, 1454, 1358, 1115, 1065, 739, 698. HRMS (ESI) (m/z) calc’d for C18H22NaO4 [M+Na]+: 
325.1410, found 325.1405. TLC (2:1 hexanes:EtOAc), Rf : 0.36 (Anis). [α]D25: –4.1 (c = 1.41, 
CH2Cl2). 
1D NOESY (600 MHz, CDCl3): 
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Oxanorbornanone dimerization precursor 144: 
A solution of alcohol 142 (517 mg, 1.71 mmol, 1.00 equiv), which was azeotropically dried 
with benzene (5 × 2 mL) in CH2Cl2 (19 mL) was cooled to 0 °C. i-Pr2NEt (1.19 mL, 6.85 mmol, 4.00 
equiv) and TBSOTf (590 µL, 2.56 mmol, 1.50 equiv) were then added dropwise sequentially via 
syringe to the stirred reaction, which was subsequently allowed to warm slowly to room temperature. 
After 11 h, additional i-Pr2NEt (306 µL, 1.71 mmol, 1.00 equiv) and TBSOTf (152 µL, 0.684 mmol, 
0.40 equiv) were added dropwise sequentially via syringe to the reaction. After an additional 16 h, 
saturated aqueous NH4Cl solution (10 mL) was added and the resultant mixture was diluted with 
EtOAc (25 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 × 15 
mL). The organic layers were combined, washed with brine (15 mL), dried over anhydrous MgSO4, 
and concentrated under reduced pressure. The resulting crude residue was then purified by flash 
column chromatography (silica gel, eluent: gradient, 20:1 → 17:1 → 15:1 → 12:1 → 9:1 → 7:1 
hexanes:EtOAc) to afford oxanorbornanone dimerization precursor 144 (570 mg, 80%) as a clear oil. 
 
1H NMR (500 MHz, CDCl3) δ: 7.36–7.24 (m, 5H), 4.47 (d, J = 11.2 Hz, 1H), 4.39 (d, J = 11.2 Hz, 
1H), 4.32 (td, J = 4.2, 6.0 Hz, 1H), 4.15 (d, J = 7.1 Hz, 1H), 2.47 (dd, J = 4.4, 7.1 Hz, 1H), 2.36 (d, J 
= 17.8 Hz, 1H), 2.33–2.19 (m, 1H), 2.10–1.94 (m, 2H), 1.92–1.84 (m, 1H), 1.76 (qd, J = 7.4, 14.4 
Hz, 1H), 0.99 (t, J = 7.6 Hz, 3H), 0.94 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ: 209.0, 138.5, 128.32, 128.30, 127.4, 96.3, 89.8, 78.6, 76.4, 71.1, 58.0, 42.2, 32.1, 25.9, 
25.8, 22.6, 18.3, 8.4, –4.6, –4.7. FTIR (thin film) cm-1: 2956, 2929, 2856, 1763, 1463, 1254, 1122, 
837, 776. HRMS (ESI) (m/z) calc’d for C24H37O4Si [M+Na]+: 417.2456, found 417.2454. TLC (2:1 
hexanes:EtOAc), Rf : 0.77 (Anis). 
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Exo-endo dimer 145: 
A two-neck flask was equipped with a solid addition adaptor containing ferrocenium 
hexafluorophosphate [Cp2Fe]PF6 (661 mg, 2.00 mmol, 5.00 equiv). HMDS (150 µL, 0.719 mmol, 
1.80 equiv) and THF (1.35 mL) were then added sequentially to the two-neck flask and the resultant 
solution was cooled to −78 °C. A solution of n-butyllithium in hexanes (2.56 M, 265 µL, 0.679 
mmol, 1.70 equiv) was then added dropwise via syringe to the stirred solution. After 1 h, HMPA 
(140 µL, 0.799 mmol, 2.00 equiv) was added dropwise via syringe to the solution of LiHMDS. After 
an additional 1 h, a solution of oxanorbornanone monomer 144 (166 mg, 0.399 mmol, 1.00 equiv) in 
THF (1.35 mL) was slowly added down the vessel wall via syringe to the reaction mixture. After an 
additional 2 h, [Cp2Fe]PF6 was added to the reaction via the solid addition adaptor, yielding a deep 
blue suspension that turned green in color within 30 min. The reaction mixture was allowed to warm 
to −55 °C. After 4 d, a saturated aqueous NH4Cl solution (2 mL) was added to the reaction, which 
was then allowed to warm to room temperature. The mixture was diluted with Et2O (2 mL), EtOAc 
(2 mL), and water (2 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (3 × 2 mL). The organic layers were combined, dried over anhydrous MgSO4, and 
concentrated under reduced pressure. The crude product was then purified by flash column 
chromatography (silica gel, eluent: gradient, 20:1 → 9:1 hexanes:EtOAc) to afford exo-endo dimer 
145 (72.6 mg, 44%) as a white flocculent solid. 
 
1H NMR (600 MHz, CDCl3) δ: 7.35–7.28 (m, 10H), 4.61 (d, J = 7.6 Hz, 1H), 4.48–4.43 (m, 2H), 
4.41–4.36 (m, 2H), 4.36–4.30 (m, 2H), 4.22 (d, J = 7.6 Hz, 1H), 2.91 (d, J = 7.6 Hz, 1H), 2.39 (dt, J 
= 4.8, 7.5 Hz, 2H), 2.36–2.27 (m, 3H), 2.26–2.18 (m, 2H), 2.14–2.00 (m, 4H), 1.99–1.83 (m, 3H), 
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1.40 (dd, J = 7.8, 15.1 Hz, 1H), 1.05 (t, J = 7.6 Hz, 3H), 0.98 (t, J = 7.5 Hz, 3H), 0.94 (s, 9H), 0.91 
(s, 9H), 0.17 (s, 3H), 0.13 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ: 211.9, 
211.7, 138.6, 138.5, 128.30, 128.25, 128.1, 127.39, 127.35, 127.3, 96.5, 96.3, 94.3, 92.8, 78.9, 78.83, 
78.76, 74.1, 71.3, 70.8, 59.7, 58.3, 52.0, 51.0, 32.4, 31.7, 26.1, 25.9, 23.9, 23.7, 22.1, 21.1, 18.2, 
18.2, 8.8, 8.1, –4.5, –4.6, –4.8, –4.9. FTIR (thin film) cm-1: 2929, 2856, 1753, 1462, 1359, 1253, 
1109, 836, 776, 733, 696. HRMS (ESI) (m/z) calc’d for C48H70NaO8Si2 [M+Na]+: 853.4501, found 
853.4508. TLC (4:1 hexanes:EtOAc), Rf : 0.62 (UV, Anis). 
1D NOESY (500 MHz, CDCl3): 
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Exo-exo dimer 146: 
A solution of exo-endo dimer 145 (102 mg, 0.123 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (5 × 1 mL), in MeCN (7.2 mL) was cooled to −5 °C. Two drops of 
2-tert-butyl-1,1,3,3-tetramethylguanidine (Barton’s base) was then added via syringe to the solution. 
After 24 h, saturated aqueous NH4Cl solution (5 mL) was added to the reaction, which was then 
allowed to warm to room temperature. The resultant mixture was diluted with CH2Cl2 (15 mL) and 
the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL) and the organic 
layers were combined, washed with saturated aqueous NH4Cl solution (3 × 5 mL), dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The resulting crude exo-exo dimer 146 
was then carried forward to the next step without further purification. 
 
1H NMR (500 MHz, CDCl3) δ: 7.35–7.29 (m, 8H), 7.26–7.22 (m, 2H), 4.46 (d, J = 11.5 Hz, 2H), 
4.43 (d, J = 11.5 Hz, 2H), 4.41–4.36 (m, 4H), 2.97 (dd, J = 5.7, 7.4 Hz, 2H), 2.38–2.26 (m, 6H), 2.24 
(s, 2H), 2.02–1.93 (m, 2H), 1.92–1.83 (m, 2H), 1.43 (qd, J = 7.4, 15.1 Hz, 2H), 1.03 (t, J = 7.4 Hz, 
6H), 0.91 (s, 18H), 0.05 (s, 6H), 0.04 (s, 6H). 13C NMR (126 MHz, CDCl3) δ: 209.1, 138.7, 128.1, 
127.3, 127.2, 97.8, 92.1, 78.8, 74.4, 71.1, 58.2, 47.8, 31.8, 25.9, 23.4, 20.9, 18.3, 7.9, –4.8, –
5.0. FTIR (thin film) cm-1: 2954, 2929, 2857, 1757, 1462, 1357, 1252, 1123, 963, 837, 776, 
697. HRMS (ESI) (m/z) calc’d for C48H70NaO8Si2 [M+Na]+: 853.4501, found 853.4516. TLC (4:1 
hexanes:EtOAc), Rf : 0.60 (UV, Anis). [α]D25: –48.3 (c = 0.43, CH2Cl2).  
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Diol dimer 147: 
Pd(OH)2 on carbon (20 wt%, 79.4 mg, 0.113 mmol, 1.00 equiv) was added in a single 
portion to a stirred solution of exo-exo dimer 146 (94.0 mg, 0.113 mmol, 1.00 equiv) in THF (5.65 
mL). The reaction vessel was purged with H2 and placed under an atmosphere of H2. After 4 h, celite 
was poured into the stirred reaction mixture and the resultant slurry was filtered through a pad of 
celite. The solution was concentrated under reduced pressure and the residue was then purified by 
flash column chromatography (silica gel, eluent: gradient, 3:1 → 2:1 hexanes:EtOAc) to afford diol 
dimer 147 (73.6 mg, quant. over 2 steps) as a white crystalline solid. 
 
1H NMR (600 MHz, C6D6) δ: 4.69 (d, J = 7.3 Hz, 2H), 4.65 (app. t, J = 7.0 Hz, 2H), 2.90 (t, J = 7.5 
Hz, 2H), 2.54–2.45 (m, 4H), 2.30 (ddd, J = 4.4, 10.8, 15.3 Hz, 2H), 2.07–2.00 (m, 2H), 1.78–1.68 
(m, 2H), 1.58–1.48 (m, 2H), 1.43–1.33 (m, 2H), 1.09 (t, J = 7.5 Hz, 6H), 0.98 (s, 18H), 0.68 (d, J = 
7.0 Hz, 2H), 0.19 (s, 6H), 0.04 (s, 6H). 13C NMR (126 MHz, C6D6) δ: 209.8, 98.5, 92.7, 75.0, 72.5, 
60.1, 48.8, 36.1, 26.4, 22.7, 21.9, 18.8, 8.4, –4.3, –4.6. FTIR (thin film) cm-1: 2951, 2930, 2858, 
1757, 1462, 1254, 1126, 1065, 840, 776. HRMS (ESI) (m/z) calc’d for C34H58NaO8Si2 [M+Na]+: 
673.3562, found 673.3550. TLC (4:1 hexanes:EtOAc), Rf : 0.15 (Anis).  
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Tetracarbonyl oxanorbornanone dimer 148: 
A solution of diol dimer 147 (73.2 mg, 0.112 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (3 × 0.5 mL) in CH2Cl2 (2.8 mL) was cooled to −10 °C. DMSO (160 µL, 2.25 
mmol, 20.0 equiv), i-Pr2NEt (196 µL, 1.12 mmol, 10.0 equiv), and SO3•Py (107 mg, 0.675 mmol, 
6.00 equiv) were then added sequentially to the solution, which was then allowed to warm slowly to 
room temperature after stirring at 0 °C for 30 min. After an additional 90 min, water (3 mL), Et2O (2 
mL), and EtOAc (2 mL) were added sequentially to the reaction. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 2 mL). The organic layers were combined and washed 
with 10% aqueous HCl solution (3 × 5 mL), saturated aqueous NaHCO3 solution (5 mL), and brine 
(5 mL). The organic layers were dried over anhydrous MgSO4 and concentrated under reduced 
pressure to afford crude tetracarbonyl oxanorbornanone dimer 148 as a flocculent white solid (68.4 
mg, crude mass). 
 
1H NMR (500 MHz, C6D6) δ: 4.77 (d, J = 7.6 Hz, 2H), 3.14 (d, J = 7.6 Hz, 2H), 2.62–2.47 (m, 4H), 
2.40–2.26 (m, 2H), 1.90–1.80 (m, 4H), 1.74 (dd, J = 9.5, 12.7 Hz, 2H), 1.53 (qd, J = 7.4, 15.2 Hz, 
2H), 1.06 (t, J = 7.4 Hz, 6H), 1.00 (s, 18H), 0.41 (s, 6H), 0.16 (s, 6H). 13C NMR (126 MHz, C6D6) δ: 
208.9, 207.5, 96.3, 93.2, 77.5, 58.6, 48.6, 39.0, 26.5, 21.8, 20.8, 19.0, 8.4, –4.3, –5.0. FTIR (thin 
film) cm-1: 2951, 2928, 2856, 1749, 1472, 1257, 1119, 886, 837. HRMS (ESI) (m/z) calc’d for 
C34H55O8Si2 [M+H]+: 647.3430, found 647.3434. TLC (2:1 hexanes:EtOAc), Rf : 0.69 (Anis).   
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Alcohol 162: 
Carboxylic acid 139 (300 mg, 0.908 mmol, 1.00 equiv) was azeotropically dried with CHCl3 
(4 × 2 mL) and benzene (5 × 2 mL) before THF (11.2 mL) was added. Et3N (507 µL, 3.63 mmol, 
4.00 equiv) was then added to the solution. The resultant solution of 139 and Et3N in THF was added 
dropwise via cannula to a stirred solution of S-(1-oxido-2-pyridinyl) 1,1,3,3-tetramethylthiouronium 
hexafluorophosphate (HOTT)54 (674 mg, 1.82 mmol, 2.00 equiv) and 4-DMAP (11.1 mg, 0.0910 
mmol, 0.10 equiv) in THF (7.1 mL) at room temperature. After 5 h, additional THF (27.6 mL) was 
added to the reaction mixture. The reaction was then saturated with O2 before Sb(SPh)355 (1.22 g, 
2.72 mmol, 3.00 equiv) was added in a single portion. The reaction flask was protected from light 
with aluminum foil. After 2 h, water (0.25 mL) was added to the reaction. After an additional 45 
min, the mixture was filtered through celite and concentrated under reduced pressure. The resulting 
crude product was then purified by flash column chromatography (silica gel, eluent: gradient, 4:1 → 
3:1 → 2:1 hexanes:EtOAc) to afford alcohol 162 (131.8 mg, 48%) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 7.39–7.33 (m, 4H), 7.33–7.29 (m, 1H), 4.62 (d, J = 12.0 Hz, 1H), 
4.47 (d, J = 12.0 Hz, 1H), 3.97 (app. q, J = 6.8 Hz, 1H), 3.94 (app. t, J = 2.9 Hz, 1H), 2.74 (d, J = 
17.8 Hz, 1H), 2.36–2.25 (m, 2H), 2.14 (dd, J = 1.0, 17.8 Hz, 1H), 1.99 (dd, J = 2.7, 6.8 Hz, 1H), 
1.93–1.85 (m, 1H), 1.83 (dq, J = 1.6, 7.5 Hz, 2H), 1.78 (d, J = 3.7 Hz, 1H), 1.76–1.68 (m, 1H), 1.00 
(t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 208.8, 138.4, 128.6, 127.9, 127.7, 97.0, 88.4, 
84.7, 80.1, 72.1, 62.0, 40.5, 32.3, 26.4, 21.9, 8.0. FTIR (thin film) cm-1: 3441, 2969, 2933, 1758, 
1574, 1453, 1418, 1097, 1060, 738, 699. HRMS (ESI) (m/z) calc’d for C18H22NaO4 [M+Na]+: 
325.1410, found 325.1407. TLC (2:1 hexanes:EtOAc and 1 drop of AcOH), Rf : 0.24 (Anis). 
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Oxanorbornanone dimerization precursor 163: 
A solution of alcohol 162 (150 mg, 0.496 mmol, 1.00 equiv), which was azeotropically dried 
with benzene (5 × 0.5 mL), in CH2Cl2 (5.5 mL) was cooled to 0 °C. i-Pr2NEt (475 µL, 2.73 mmol, 
5.50 equiv) and TBSOTf (233 µL, 0.992 mmol, 2.00 equiv) were then added dropwise sequentially 
via syringe to the stirred solution, which was subsequently allowed to warm slowly to room 
temperature. After 1.5 h, saturated aqueous NH4Cl solution (5 mL) was added to the reaction. The 
resultant mixture was diluted with EtOAc (5 mL) and the layers were separated. The aqueous layer 
was extracted with EtOAc (3 × 3 mL). The organic layers were combined, washed with brine (5 
mL), dried over anhydrous MgSO4, and concentrated under reduced pressure. The crude residue was 
then purified by flash column chromatography (silica gel, eluent: 16:1 hexanes:EtOAc) to afford 
oxanorbornanone dimerization precursor 163 (185 mg, 89%) as a pale yellow solid. 
 
1H NMR (500 MHz, C6D6) δ: 7.24 (d, J = 7.8 Hz, 2H), 7.19 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 
1H), 4.27 (d, J = 11.7 Hz, 1H), 4.13 (d, J = 11.7 Hz, 1H), 3.95 (d, J = 2.0 Hz, 1H), 3.79 (app. q, J = 
6.5 Hz, 1H), 2.78 (d, J = 17.6 Hz, 1H), 2.40 (ddd, J = 6.1, 10.0, 14.6 Hz, 1H), 2.18 (dd, J = 2.7, 6.6 
Hz, 1H), 2.00 (dd, J = 1.0, 17.6 Hz, 1H), 1.91 (tdd, J = 6.3, 8.2, 12.8 Hz, 1H), 1.71 (ddd, J = 6.2, 8.2, 
14.6 Hz, 1H), 1.64 (q, J = 7.4 Hz, 2H), 1.61–1.52 (m, 1H), 0.89 (t, J = 7.4 Hz, 3H), 0.84 (s, 9H), 0.06 
(s, 3H), 0.00 (s, 3H). 13C NMR (126 MHz, CDCl3) δ: 209.5, 137.9, 128.3, 127.8, 127.6, 96.8, 88.6, 
84.3, 80.3, 71.8, 62.1, 40.8, 31.3, 25.9, 25.7, 22.4, 17.8, 7.9, –4.6, –5.2. FTIR (thin film) cm-1: 2955, 
2929, 2857, 1764, 1252, 1117, 1062, 863, 838, 778. HRMS (ESI) (m/z) calc’d for C24H36NaO4Si 
[M+Na]+: 439.2275, found 439.2291. TLC (4:1 hexanes:EtOAc), Rf : 0.63 (Anis). [α]D25: +28.3 (c = 
0.12, CH2Cl2). 
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Cyclic hydrate 166: 
A two-neck flask was equipped with a solid addition adaptor containing ferrocenium 
hexafluorophosphate [Cp2Fe]PF6 (199 mg, 0.600 mmol, 5.00 equiv). HMDS (48.0 µL, 0.228 mmol, 
1.90 equiv) and THF (477 µL) were added to the two-neck flask and the resultant stirred solution 
was cooled to −78 °C. A solution of n-butyllithium in hexanes (2.56 M, 80.0 µL, 0.204 mmol, 1.70 
equiv) was then added dropwise via syringe to the solution. After 30 min, HMPA (105 µL, 0.600 
mmol, 5.00 equiv) was added dropwise via syringe to the solution of LiHMDS. After an additional 1 
h, a solution of oxanorbornanone monomer 163 (50.0 mg, 0.120 mmol, 1.00 equiv) in THF (293 µL) 
was then slowly added down the vessel wall to the reaction. After another 2 h, [Cp2Fe]PF6 was added 
from the solid addition adaptor. The initially deep blue suspension turned green within 30 min and 
was allowed to stir at –60 °C. After 5 d, saturated aqueous NH4Cl solution (1 mL) was added to the 
stirred reaction mixture, which was allowed to warm to room temperature. The mixture was diluted 
with Et2O (1 mL), EtOAc (1 mL), and water (0.5 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 × 1 mL). The organic layers were combined, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. Due to the high instability of crude 
dimer 164 to silica gel column chromatography, the crude product was quickly plugged through 
silica gel using 20:1 hexanes:EtOAc (removes ferrocene) and 2:1 hexanes:EtOAc (elutes product) 
within 10 min to afford crude dimer 164, which was carried forward without further purification. 
Pd(OH)2 on carbon (20 wt.%, 253 mg, 0.360 mmol, 3.00 equiv) was added in a single 
portion to a stirred solution of crude dimer 164 in THF (4 mL). The reaction vessel was purged with 
H2 and placed under an atmosphere of H2. After 4 h, celite (100 mg) was poured into the reaction, 
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and the resultant slurry was filtered through a pad of celite and concentrated under reduced pressure 
to afford crude diol 165, which was carried forward without further purification. 
A solution of crude diol 165, which was azeotropically dried with benzene (5 × 0.5 mL), in 
CH2Cl2 (3 mL) was cooled to 0 °C. DMSO (228 µL, 3.20 mmol, 26.7 equiv), i-Pr2NEt (278 µL, 1.60 
mmol, 13.3 equiv), and SO3•Py (153 mg, 0.960 mmol, 8.00 equiv) were then added sequentially to 
the reaction, which was allowed to warm slowly to room temperature after 30 min. After an 
additional 90 min, water (3 mL), Et2O (2 mL), and EtOAc (2 mL) were added sequentially to the 
reaction mixture. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 2 
mL). The organic layers were combined and washed with 10% aqueous HCl solution (3 × 5 mL), 
saturated aqueous NaHCO3 solution (5 mL), and brine (5 mL). The organic layers were dried over 
anhydrous MgSO4 and concentrated under reduced pressure. The resulting crude product was then 
purified by flash column chromatography (silica gel, eluent: gradient, 4:1 → 3:1 → 2:1 
hexanes:EtOAc) to afford cyclic hydrate 166 (22.7 mg, 57% over 3 steps) as a white solid. 
 
1H NMR (600 MHz, C6D6) δ: 4.32 (d, J = 2.6 Hz, 2H), 3.21 (s, 2H), 3.18 (s, 2H), 2.71 (d, J = 2.6 
Hz, 2H), 2.20–2.12 (m, 2H), 2.11–1.98 (m, 4H), 1.95–1.88 (m, 2H), 1.85–1.79 (m, 2H), 1.79–1.70 
(m, 2H), 0.96 (t, J = 7.6 Hz, 6H), 0.94 (s, 18H), 0.33 (s, 6H), 0.19 (s, 6H). 13C NMR (126 MHz, 
C6D6) δ: 215.0, 115.6, 94.4, 90.5, 79.5, 61.0, 49.9, 36.9, 26.2, 24.8, 21.4, 18.2, 8.6, –4.3, –4.9. FTIR 
(thin film) cm-1: 3397, 2928, 2856, 1743, 1463, 1251, 1109, 1060, 839, 778. HRMS (ESI) (m/z) 
calc’d for C34H56NaO9Si2 [M+Na]+: 687.3355, found 687.3399. TLC (2:1 hexanes:EtOAc), Rf : 0.28 
(Anis). [α]D25: +61.4 (c = 0.14, CH2Cl2). 
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Epi-lomaiviticin B core 169: 
A 1 M solution of KOH in water (339 µL, 0.339 mmol, 7.00 equiv) was added dropwise via 
syringe to a solution of cyclic hydrate 166 (32.2 mg, 0.0480 mmol, 1.00 equiv) in 3:1 THF/water 
(4.85 mL) at 0 °C. After 24 h, saturated aqueous NH4Cl solution (1 mL) was added to the stirred 
reaction mixture, which was then allowed to warm to room temperature. The resultant mixture was 
diluted with EtOAc (3 mL) and the layers were separated. The aqueous layer was extracted with 
EtOAc (3 × 3 mL). The organic layers were combined and washed with brine (5 mL), dried over 
anhydrous MgSO4, and concentrated under reduced pressure to afford crude bisenone cyclic hydrate 
product 167, which was carried forward to the next step without further purification. 
MgSO4 (70.0 mg, 0.581 mmol, 12.0 equiv) was added in a single portion to a stirred solution 
of crude 167 in benzene (6.9 mL), and the resultant slurry was heated to 80 °C. After 24 h, the slurry 
was filtered and concentrated under reduced pressure to afford crude epi-lomaiviticin A core 168, 
which was carried forward to the next step without further purification. 
p-TsOH⋅H2O (1.9 mg, 0.010 mmol, 0.20 equiv) was added in a single portion to a stirred 
solution of crude 168 in benzene (6.9 mL). After 24 h, saturated aqueous NaHCO3 solution was 
added to the stirred reaction mixture. The resultant mixture was diluted with EtOAc (4 mL) and the 
layers were separated. The aqueous layer was extracted with EtOAc (3 × 4 mL) and the organic 
layers were combined, washed with brine (6 mL), dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The crude residue was then purified by flash column chromatography (silica 
gel, eluent: gradient, 4:1 → 3:1 → 2:1 hexanes:EtOAc) to afford epi-lomaiviticin B core 169 (19.4 
mg, 62% over 3 steps) as a white solid. 
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1H NMR (600 MHz, C6D6) δ: 4.73 (s, 2H), 3.18 (s, 2H), 2.17–2.07 (m, 2H), 2.00–1.91 (m, 4H), 
1.90–1.78 (m, 6H), 1.08 (t, J = 7.3 Hz, 6H), 0.93 (s, 18H), 0.26 (s, 6H), 0.08 (s, 6H). 13C NMR (126 
MHz, C6D6) δ: 206.4, 170.2, 139.8, 102.9, 90.3, 61.6, 60.6, 35.5, 30.4, 26.3, 23.1, 18.6, 7.7, –4.0, –
4.9. FTIR (thin film) cm-1: 3400, 2956, 2929, 2856, 1690, 1658, 1253, 1097, 1041, 838, 777. HRMS 
(ESI) (m/z) calc’d for C34H54NaO8Si2 [M+Na]+: 669.3249, found 669.3262. TLC (2:1 
hexanes:EtOAc), Rf : 0.27 (UV, Anis). [α]D25: +35.0 (c = 0.53, CH2Cl2). 
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Introduction 
 The Lycopodium alkaloids, isolated from the Lycopodium club mosses, are a diverse family 
of complex polycyclic natural products that have long attracted interest in synthetic chemistry due to 
their fascinating structures and interesting biological activity.78 Since the isolation of the first 
Lycopodium alkaloid, lycopodine79 (1, Figure 3.1), by Bödeker from Lycopodium complanatum in 
1881, over 250 Lycopodium alkaloids have been isolated and characterized to date.78 Not only have 
the Lycopodium alkaloids served as challenging targets for total synthesis, but their complex 
structures have also provided ample opportunities for new synthetic methodology development. 
 
 
Figure 3.1. Representative members of the four Lycopodium alkaloid structural classes.80 
 The Lycopodium alkaloids have been categorized into four general structural classes, 
comprising the lycopodine, lycodine, fawcettimine, and the miscellaneous classes,78 representative 
members of which are shown in Figure 3.1 The lycopodine structural class (1) is characterized by 
four fused six-membered rings, two of which (A- and C-rings) form a quinolizidine. In the lycodine 
class (2), members characteristically contain four rings, with the B-, C-, and D-rings being the same 
as in the lycopodine class. However, the A-ring is rearranged (no Nβ–C1 connectivity) and typically 
                                                                                                                                                 
78 For reviews on the Lycopodium alkaloids, see: (a) Kobayashi, J.; Morita, H. In The Alkaloids; Cordell, G. A., 
Ed.; Academic Press: New York, 2005; Vol. 61, pp 1–57. (b) Ma, X.; Gang, D. R. Nat. Prod. Rep. 2004, 21, 
752–772. (c) Ayer, W. A.; Trifonov, L. S. In The Alkaloids; Cordell, G. A., Brossi, A., Ed.; Academic Press: 
New York, 1994; Vol. 45, pp 233–266. 
 
79 Bödeker, K. Justus Liebigs Ann. Chem. 1881, 208, 363–367. 
 
80 The positional numbering system is represented in accordance with Conroy’s original proposed biosynthesis. 
Please see: Conroy, H. Tetrahedron Lett. 1960, 1, 34–37. 
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exists as a pyridine or pyridone ring. Thus far, all of the Lycopodium alkaloids, notably huperzine 
A,81 with biological activity associated with acetylcholinesterase inhibition belong to the lycopodine 
class. The fawcettimine class (3) can be derived from the lycopodine class via C4–C13 to C4–C12 
bond migration. Lastly, the miscellaneous class (4) encompasses all of the Lycopodium alkaloids that 
do not fall into the category of the three aforementioned classes. In particular, members of the 
miscellaneous class do not contain either C4–C13 or C4–C12 connectivity. 
Since Conroy’s original biosynthetic hypothesis, a revised biosynthesis of the Lycopodium 
alkaloids based on 14C- and 13C-feeding studies has been proposed.82 Lysine could initially undergo 
decarboxylation and subsequent oxidative cyclization to afford Δ1-piperideine (7, Figure 3.2). Next, 
a Mannich reaction between 7 and 3-oxoglutaric acid, followed by decarboxylation, could provide 
pelleterine (9). 9 may then undergo dimerization via an intermolecular aldol reaction to furnish dimer 
10. Phlegmarine carbon skeleton 12 could then arise from 10 via oxidation and a subsequent 
intramolecular aldol reaction to form the C7–C12 bond. An intramolecular Mannich reaction could 
then establish the C4–C13 bond, resulting in tetracycle 13, from which the lycodine structural class 
may arise. Alternatively, the lycopodine class (1) could be derived from 13 via: (1) hydrolysis of the 
Nα–C5 imine, (2) deamination, and (3) formation of the Nβ–C1 bond. Subsequent oxidation of 1 at 
C12 could then result in the formation of lycodoline (14). The fawcettimine class may be accessed 
from 14 via migration of C4 from C13 to C12.83 Further rearrangement and oxidation of members of 
each structural class could then engender the vast and diverse Lycopodium alkaloid natural products.  
                                                                                                                                                 
81 (a) Tang, X. C.; Han, Y. F.; Chen, X. P.; Zhu, X. D. Acta Pharmacol. Sin. 1986, 7, 507–510. (b) Tang, X. C.; 
Sarno, P. D.; Sugaya, K.; Giacobini, E. J. Neurosci. Res. 1989, 24, 276–285. (c) Liu, J. S.; Yu, C. M.; Zhou, Y. 
Z.; Han, Y. Y.; Wu, F. W.; Qi, B. F.; Zhu, Y. L. Acta Chim. Sin. Eng. Ed. 1986, 44, 1035–1040. (d) Liu, J. S.; 
Zhu, Y. L.; Yu, C. M.; Zhou, Y. Z.; Han, Y. Y.; Wu, F. W.; Qi, B. F. Can. J. Chem. 1986, 64, 837–839. 
 
82 (a) Hemscheidt, T.; Spenser, I. D. J. Am. Chem. Soc. 1996, 118, 1799–1800. (b) Hemscheidt, T.; Spenser, I. 
D. J. Am. Chem. Soc. 1993, 115, 3020–3021, and references therein. 
 
83 Blumenkopf, T. A.; Heathcock, C. H. In Alkaloids: Chemical and Biological Perspectives; Pelletier, S. W., 
Ed.; John Wiley and Sons: New York, 1983; Chapter 5. 
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Figure 3.2. Proposal for the biosynthesis of the Lycopodium alkaloids. 
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Selected Total Syntheses of the Lycopodium Alkaloids 
The structurally diverse Lycopodium alkaloids have had an established history in the field of 
organic synthesis ever since the foundational syntheses of lycopodine (1) by Stork84 and Ayer85 in 
1968; they continue to attract widespread interest due to their fascinating and complex polycyclic 
structures and promising bioactivity. A survey of relevant total syntheses of various Lycopodium 
alkaloids will be presented. 
 Highlights from the inaugural synthesis of (±)-lycopodine (1) by Stork and coworkers will 
first be discussed. The synthesis commenced with the diastereoselective 1,4-conjugate addition of 
methylcuprate, generated from MeMgI and CuCl, to cyclohexenone 15, furnishing cyclohexanone 16 
(Scheme 3.1).86 The diastereoselectivity of this reaction was controlled through stereoelectronically 
favored axial attack by the methylcuprate anti to the pseudoequatorial C7-substituent. Condensation 
of 16 with pyrrolidine in the presence of p-TsOH resulted in formation of the corresponding 
pyrrolidinenamine. Treatment with acrylamide then yielded two separable regioisomeric quinolones. 
Upon exposure to H3PO4/HCO2H, desired quinolone 17 underwent an intramolecular Friedel–Crafts 
alkylation to afford tetracycle 20 as a single diastereomer. This transformation occurred via initial 
formation of N-acyliminium ions 18 and 19, which could then undergo an intramolecular Friedel–
Crafts reaction to establish the C4–C13 bond by trapping with the pendant p-methoxybenzyl group, 
leading to two possible epimeric products at C12, 21 and 20, respectively. Stork and coworkers 
postulated that a Curtin-Hammett situation could be operative and if initial protonation of enamide 
17 was reversible and faster than the ensuing intramolecular Friedel–Crafts reaction, then only the 
desired C12-epimer 20 would be obtained from N-acyliminium 19, since the reactive conformation 
of 18 is unfavorable. A total synthesis of lycopodine (1) was then accomplished from 20.  
                                                                                                                                                 
84 Stork, G.; Kretchmer, R. H.; Schlessinger, J. J. Am. Chem. Soc. 1968, 90, 1647–1648. 
 
85 Ayer, W. A.; Bowman, W. R.; Joseph, T. C.; Smith, P. J. Am. Chem. Soc. 1968, 90, 1648–1650. 
 
86 Allinger, N. L.; Riew, C. K. Tetrahedron Lett. 1966, 12, 1269–1272. 
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Scheme 3.1. Stork’s total synthesis of (±)-lycopodine (1). 
 In 1978, Heathcock and coworkers also achieved a synthesis of (±)-lycopodine (1).87 The 
synthesis commenced with stereoelectronically favored 1,4-conjugate addition of the lithium anion 
of N,N-dimethylhydrazone 23 to cyclohexenone 22 anti to the C16-methyl group,86 furnishing 
cyclohexanone 24 upon hydrolysis of the hydrazone (Scheme 3.2). A ~1:1 mixture of 
inconsequential C12-epimers (vide infra) was obtained as a result of unselective protonation of the 
copper enolate intermediate. Ketal-protection of the carbonyl groups followed by nitrile reduction 
afforded primary amine 25. Heating 25 in the presence of HCl then furnished tricycle 26 as a single 
diastereomer via a cascade set of reactions. This cascade occurred via: (1) cleavage of the ketal 
groups, (2) condensation of the primary amine with the C13-ketone to form the corresponding 
iminium ion intermediate, and (3) an intramolecular Mannich reaction to establish the C4–C13 bond. 
Although 25 existed as a ~1:1 mixture of C12-epimers, Heathcock postulated that rapid 
interconversion of the C12-epimers of the C13-iminium ion intermediate could occur via the Nβ–
                                                                                                                                                 
87 (a) Heathcock, C. H.; Kleinman, E.; Binkley, E. S. J. Am. Chem. Soc. 1978, 100, 8036–8037; (b) Heathcock, 
C. H.; Kleinman, E.; Binkley, E. S. J. Am. Chem. Soc. 1982, 104, 1054–1068. 
12
N
O
Me
Lycopodine (1)
O
OMe
MeMgI,
CuCl
(90%)
7
O
OMeMe 1. p-TsOH
    pyrrolidine
2.
(20–25%)
13
12
HN
4
OMeMe
O
12 13
4
Me
NH
O
H OMe 13 4
Me
OMe
N
O HH
18
Disfavored
19
Favored
80% H3PO4
HCO2H
(55%)
12
13
4
Me
NH
O
OMe
20
Observed
12 13
4
Me
OMe
N
O H
21
Not Observed
Friedel-Crafts Alkylation
Fast
15 16 17
O
NH2
X
 100 
C13–C12 enamine tautomer. However, only one C12-epimer of the C13-iminium ion could undergo 
a favorable intramolecular Mannich cyclization reaction.84 Tricycle 26 was then converted to (±)-
lycopodine (1) in two steps.  
 
 
Scheme 3.2. Heathcock’s total synthesis of (±)-lycopodine (1). 
More recently, Smith and Beshore achieved the total syntheses of (+)-lyconadin A (31) and 
(–)-lyconadin B (32),88 members of the miscellaneous class (Scheme 3.3). The lyconadins contain an 
additional C4–C10 linkage, resulting in a 7-membered ring. The key transformation involved 
exposure of ketoaldehyde 27 to HCl to afford tricycle 30 as a single diastereomer (84% yield) via: 
(1) a Robinson annulation to construct cyclohexenone intermediate 28, (2) intramoleculer 7-endo-
trig 1,4-conjugate addition to form the C6–C7 bond via stereoelectronically favored axial attack89 
anti to the C16-methyl group, and (3) protonation of the resultant enol intermediate 29 to provide the 
incorrect C12-stereocenter. Unfortunately, the C12-stereocenter could not be directly epimerized, 
and several synthetic operations were required to invert the configuration of this stereocenter. 
 
                                                                                                                                                 
88 (a) Beshore, D. C.; Smith, A. B., III. J. Am. Chem. Soc. 2007, 129, 4148–4149; (b) Beshore, D. C.; Smith, A. 
B., III. J. Am. Chem. Soc. 2008, 130, 13778–13789. 
 
89 Pseudoequatorial attack of cyclohexenone intermediate 28 is disfavored due to a developing 1,2-allylic strain 
between the C7- and C12-substituents in the transition state. This rationale likely accounts for the 
stereoselectivity of the conjugate addition in the key step of Heathcock’s synthesis of lycopodine (22 to 24). 
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Scheme 3.3. Key step from Smith’s syntheses of (+)-lyconadin A (31) and (–)-lyconadin B (32). 
In 2009, Sarpong and coworkers also completed a total synthesis of (+)-lyconadin A (31) 
(Scheme 3.4).90 Hydrogenolysis of advanced intermediate 33, followed by addition of NaBH4, 
delivered secondary amine 34 via: (1) cleavage of the Cbz group, (2) condensation of the resultant 
amine with the ketone to form the corresponding imine, and (3) reduction of the imine intermediate. 
Treatment of 34 with n-BuLi resulted in deprotonation of the amine and the pseudobenzylic position 
to form the corresponding dianion, which upon addition of I2, furnished desired pentacycle 36. 
Alternatively, 36 could also be accessed via a two-step protocol involving: (1) addition of NIS to the 
dianion generated from n-BuLi at −78 °C to afford iodide 35, and (2) heating 35 with t-BuOK to 
yield the tertiary amine with the desired C6−N connectivity. Finally, cleavage of the methyl ether in 
36 with NaSEt delivered (+)-lyconadin A (31). 
 
 
                                                                                                                                                 
90 (a) Bisai, A.; West, S. W.; Sarpong, R. J. Am. Chem. Soc. 2008, 130, 7222–7223. (b) West, S. P.; Bisai, A.; 
Lim, A. D.; Narayan, R. R.; Sarpong, R. J. Am. Chem. Soc. 2009, 131, 11187–11194. 
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Scheme 3.4. Key transformations from Sarpong’s synthesis of (+)-lyconadin A (31). 
To summarize this chapter, a brief introduction and background for the Lycopodium alkaloid 
family of natural products was presented. Selected relevant syntheses, including Stork and 
Heathcock’s respective total syntheses of (±)-lycopodine (1) and Smith and Sarpong’s respective 
syntheses of lyconadins A and B (31 and 32, respectively), were reviewed. Key lessons learned from 
the syntheses presented, which are relevant to our own syntheses of himeradine A (38), lycopecurine 
(39), and lyconadins A (31) and B (32), include: (1) introduction of the C6–C7 bond anti to the C16-
methyl group could be accomplished stereoselectively, (2) the C4–C13 bond could be established via 
a biomimetic Mannich reaction, and (3) the C6–N bond of the lyconadins could be introduced at a 
late-stage through an oxidative amination reaction. 
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II. A Biomimetic Unified Strategy for the Synthesis of 7-Membered Ring-Containing 
Lycopodium Alkaloids 
 
 
 
 
 
 
Chapter 4 
Total Synthesis of the Proposed Structure of (–)-Himeradine A 
  
 104 
Introduction 
 A unique subset of the lycodine structural class, including (+)-fastigiatine (37)91 and (–)-
himeradine A (38),92 contains an unprecedented pentacyclic core with a C4–C10 or C14–C3 bond, 
respectively, in contrast to lycodine (2) (Figure 4.1). The C4–C10 or C14–C3 linkage introduces 
significant strain and complexity to these structures, resulting in five contiguous stereocenters and a 
densely functionalized pyrrolidine ring. From a synthetic perspective, (–)-himeradine A (38) is 
arguably the most challenging Lycopodium alkaloid and contains seven rings, three potentially basic 
nitrogens, ten stereocenters, and a quinolizidine subunit appended to the pentacyclic core via a 
methylene linker.  
 
  
Figure 4.1. Examples of Lycopodium alkaloids containing an unprecedented pentacyclic core. 
Although the relative stereochemistry of fastigiatine (37) was unambiguously established by 
single crystal X-ray diffraction analysis,91 the structure and relative stereochemistry of each 
individual subunit of himeradine A (38), the pentacyclic core and the quinolizidine, were elucidated 
by 1H, 13C, COSY, HMQC, HMBC, and NOESY NMR experiments in addition to IR and 
FABMS/MS data.92 However, the relative stereochemistry between the pentacyclic core and the 
quinolizidine remains ambiguous due to their relative isolation from one another. The large vicinal 
coupling constants observed between H11'b/H17 and H11'b/H10' suggest that the relative 
conformation between the two individual subunits is rigidly locked through H11'. Furthermore, a 
                                                                                                                                                 
91 (a) Gerard, R. V.; MacLean, D. B.; Fagianni, R.; Lock, C. J. Can. J. Chem. 1986, 64, 943–949; (b) Gerard, 
R. V.; MacLean D. B. Phytochemistry 1986, 25, 1143–1150. 
 
92 Morita, H.; Hirasawa, Y.; Kobayashi, J. J. Org. Chem. 2003, 68, 4563–4566. 
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Monte Carlo simulation followed by minimization was consistent with the observed NOESY data 
and proton vicinal coupling constants. Thus, the relative stereochemistry of himeradine A (38) was 
assigned as illustrated in Figure 4.1. 
 MacLean and coworkers originally proposed a biosynthesis of the pentacyclic core of 
fastigiatine (37) and himeradine A (38)91a (Figure 4.2). Iminium ion intermediate 41 was postulated 
to undergo an intramolecular Mannich reaction,82,83 forming the C4–C13 bond to afford lycodane 
skeleton 42. 42 could then undergo oxidative functionalization at C10 to yield tetracycle 43. Next, it 
was proposed that an enamine SN2 cyclization to form the key C4–C10 bond occurs, furnishing the 
desired pentacyclic core 44. We speculated, however, that this proposed SN2 alkylation requires 
accessing an unfavorable, strained boat-like conformation in order to achieve requisite orbital 
overlap. Furthermore, 43 is not a particularly reactive electrophile. 
 
 
Figure 4.2. MacLean’s proposal for the biosynthesis of the pentacyclic core of fastigiatine (37) and 
himeradine A (38) and our revised biosynthesis.  
 
Hence, we proposed an alternative biosynthetic pathway for accessing the strained 
pentacyclic core of 37 and 38. We speculated that the C4–C10 bond of 41 is installed prior to the 
formation of the C4–C13 bond, potentially via an intramolecular enamine SN2 reaction of an 
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oxidatively functionalized derivative of 41 at C10. The proposed reactive conformation for this 
intramolecular SN2 reaction to occur is less strained than that required for 43. Drawing analogy to 
MacLean’s proposed biosynthesis, tetracycle 45 (redrawn in 3D as 46) could now undergo a key 
intramolecular transannular Mannich reaction to construct the pentacyclic core of fastigiatine (37) 
and himeradine A (38). Other Lycopodium alkaloids could also be accessed from intermediate 45, 
including lyconadin A (31), lucidine B (47), and nankakurine A (48) via reduction of the C13-
iminium ion. Our proposed biosynthetic hypothesis straightforwardly illuminates both the common 
origin and divergence of 7-membered ring-containing Lycopodium alkaloids. MacLean’s 
biosynthetic proposal, however, would require 44 to undergo a retro-Mannich reaction to 46, which 
although plausible, seems circuitous. 
We were attracted to a synthesis of fastigiatine (37) and himeradine A (38) not only because 
of their structural complexity and unprecedented pentacyclic cores, but we also wanted to address 
our proposed biosynthetic hypothesis and whether a transannular Mannich reaction could be 
employed. Furthermore, due to their low abundance from natural sources, extensive biological 
testing of 37 and 38 has not been conducted. Himeradine A (38) has been demonstrated to exhibit 
cytotoxicity against murine lymphoma L1210 cells in vitro with IC50 = 10 µg/mL,92 and related 
members have shown promising neurological bioactivity. At the outset of this project, a synthesis of 
fastigiatine (37) and himeradine A (38) had not yet been achieved in the literature. In 2010, Dr. Brian 
B. Liau93 in the Shair group accomplished the first total synthesis of (+)-fastigiatine, which will be 
discussed in the next section. 
  
                                                                                                                                                 
93 Liau, B. B.; Shair, M. D. J. Am. Chem. Soc. 2010, 132, 9594–9595 
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Total Synthesis of (+)-Fastigiatine 
Dr. Brian B. Liau’s proposed cascade sequence94 for the synthesis of (+)-fastigiatine (37) is 
illustrated in Scheme 4.1. As discussed previously, we envisioned installing the C4–C13 bond in 
tetracycle 57 via a biomimetic transannular Mannich reaction to afford the strained pentacyclic core 
58. Tetracycle 57 could be accessed from enone 49 via initial condensation of Nα with the C5-
ketone to form imine 50, followed by tautomerization to the exocyclic Nα–C5–C6 enamine,95,96 
which is now poised to undergo a 7-endo-trig intramolecular cyclization88 to form the C6–C7 bond. 
Two possible reactive conformations exist, 51 and 52, which result from either stereoelectronically 
favored pseudoaxial97 1,4-conjugate addition syn or anti to the C16-methyl group, respectively. 
Based on a steric argument, addition anti to the C16-methyl group should be favored.88 Next, 
stereoelectronically favored axial protonation of the resultant enol 53 (redrawn as 54) at C12 could 
then afford tricycle 55. At this stage of synthetic planning, the exact order of bond-forming events 
was considered flexible and hence, numerous strategies could be possible depending on a judicious 
selection of nitrogen protecting groups.  
Tricycle 55 could either exist as the keto-enamine form or undergo a subsequent 
transannular aldol reaction to afford tetracycle 56. However, if the C13-ketone is kinetically 
accessible from 56, then condensation of Nβ with the C13-ketone could occur to provide iminium 
ion intermediate 57, which could then undergo the key biomimetic transannular Mannich reaction to 
furnish the desired pentacyclic core 58. This cascade sequence, which constitutes a formal [3+3]-
                                                                                                                                                 
94 Liau, B. B. Ph.D. Thesis, Harvard University, 2013. 
 
95 Although the endocyclic enamine tautomer is thermodynamically favored over the exocyclic tautomer in 
related systems, the exocyclic enamine tautomer can be accessed. Please see: Movassaghi, M.; Chen, B. 
Angew. Chem. Int. Ed. 2007, 46, 565–568. 
 
96 This would render the C4-stereocenter inconsequential to the cascade reaction. 
 
97 Pseudo-equatorial attack would result in an intermediate that suffers 1,2-allylic strain. 
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cycloaddition,98 could potentially occur in a one-pot operation to generate up to two σ C–C bonds, 
two σ C–N bonds, and one σ C–H bond. (+)-Fastigiatine (37) could then be synthesized from 
pentacycle 58 in a few straightforward steps. 
 
Scheme 4.1. Proposed cascade sequence for the total synthesis of (+)-fastigiatine (37). 
Our retrosynthetic analysis of the cascade precursor 59 is shown in Scheme 4.2. Diamine 59 
could be accessed from a pyrrolidinone precursor such as 60, which could be assembled in a highly 
convergent fashion from three building blocks via nucleophilic opening of cyclopropane99 62 by 
organometallic 61 to form the C12–C11 bond, followed by alkylation of the resultant dicarbonyl 
anion intermediate with electrophile 63. 
 
                                                                                                                                                 
98 Schumann, D.; Naumann, A. Liebigs Ann. Chem. 1983, 220–225. 
 
99 For a review on electrophilic cyclopropanes, see: Danishefsky, S. Acc. Chem. Res. 1979, 12, 66–72. 
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Scheme 4.2. Retrosynthetic analysis of cascade precursor 59. 
 In beautiful work by Dr. Brian B. Liau, the synthesis commenced with the nucleophilic 
opening of cyclopropane 64, which was prepared in six steps from (S)-epichlorohydrin, by 
organometallic 65 (Scheme 4.3).93,100 Upon treatment with mixed dioorganocuprate 65, cyclopropane 
64 underwent regioselective opening at C11 to afford carboxyimide 66 in excellent yield (93%). This 
convergent coupling could be conducted on greater than 5-g scale. Carboxyimide 66 underwent 
efficient alkylation with 1-chloro-3-iodopropane and the resultant primary chloride was then 
displaced with NaN3 to yield azide 67. Exposure of 67 to TBAF in the presence of DBU resulted in 
cleavage of the 2-(trimethylsilyl)ethyl (TMSE) ester with concomitant decarboxylation,101 followed 
by in situ base-catalyzed epimerization at C4. Next, the C6-carbon was introduced by addition of 
MeMgBr to the C5-carbonyl, affording hemiaminal 69 as a mixture of diastereomers. Dehydration 
and ketal deprotection of 69 with CSA occurred smoothly to furnish the corresponding 
dihydropyrrole. Staudinger reduction of the azide then yielded primary amine 70.  
                                                                                                                                                 
100 Majetich, G.; Leigh, A. J.; Condon, S. Tetrahedron Lett. 1991, 32, 605–608. 
 
101 Knobloch, E.; Brückner, R. Synlett 2008, 12, 1865–1869. 
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Scheme 4.3. Synthesis of cascade precursor dihydropyrrole 70. 
 Although the C–N bond connectivity was incorrect, 70 could still potentially serve as a 
cascade substrate since the more nucleophilic Nα-amine could theoretically exchange with the Nβ-
carbamate to provide imine 74 (Scheme 4.4). At the time, we assumed that 70 could not undergo 5-
endo-trig cyclization to form the undesired C4–C7 bond since this would be in violation of 
Baldwin’s rules.102 Imine 74 could then undergo 7-endo-trig cyclization to afford tricycle 75, which, 
after a subsequent transannular aldol reaction, should result in the formation of tetracycle 71 or 72. 
Heating 70 with PPTS in EtOH resulted in the formation of a single new product. However, instead 
of obtaining desired tetracycle 71 or 72, constitutional isomer 73 was isolated instead. 
                                                                                                                                                 
102 (a) Baldwin, J. E. J. Chem. Soc., Chem. Commun., 1976, 734–736. (b) Johnson, C. D. Acc. Chem. Res. 
1993, 26, 476–482. 
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Scheme 4.4. Attempted cascade with dihydropyrrole 70. 
 Our proposed mechanism for the formation of 73 is illustrated in Scheme 4.5. Formation of 
the corresponding oxocarbenium from dihydropyrrole 70 resulted in a 5-endo-trig cyclization to 
establish the undesired C4–C7 bond anti to the C16-methyl group in the cis-5,5-bicyclic iminium ion 
intermediate 76. The highly charged oxocarbenium intermediate most likely allowed an exception to 
Baldwin’s rules, which generally disfavors 5-endo-trig cyclizations. Nα and Nβ could then undergo 
transamination to provide imine 77, which upon tautomerization to the corresponding exocyclic 
enamine, could undergo cyclization via a transannular aldol reaction to yield 73. Two important 
lessons were learned from such a disappointing result: (1) the correct C–N bond connectivity was 
required for the cascade reaction because (2) the 5-endo-trig cyclization was facile. 
 
 
Scheme 4.5. 5-Endo-trig cyclization to form tetracycle 73. 
 To this end, we next focused our attention on installing the correct C–N bond connectivity 
(Scheme 4.6). Unfortunately, however, efforts to form the 6-membered imine 78 with the correct 
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C5–Nα bond connectivity from 69 proved unsuccessful (Eq. 1). We speculate that these results were 
suggestive of a strong thermodynamic preference for the 5-membered ring system containing the 
incorrect C5–Nβ bond.103 Hydrolysis of the C5–Nβ bond or formation of the corresponding Weinreb 
amide from 68 (Eq. 2) were also explored. Unsurprisingly, recyclization back to 68 was a recurring 
problem. Eventually we discovered that Staudinger reduction of the azide in 68 resulted in formation 
of valerolactam 79, which possessed the desired C5–Nα bond connectivity. 
 
 
Scheme 4.6. Efforts to install the correct C5–Nα bond connectivity. 
 Attempted introduction of the C6-carbon unit proved challenging (Scheme 4.7). We initially 
planned to synthesize the corresponding thioamide of 79, followed by a subsequent Eschenmoser 
coupling reaction. However, thioamide formation proved unsuccessful. Efforts to synthesize the 
exocyclic enamide 104  of Boc-protected lactam 80 with Petasis reagent 105  resulted in 
translactamization to 81. 
                                                                                                                                                 
103 A very similar thermodynamic preference to form the 5-membered ring system was also observed with the 
butyrolactone series. See ref. 94. 
 
104 Langlois, N. Org. Lett. 2002, 4, 185–187. 
 
105 Petasis, N. A.; Bzowej, E. I. J. Am. Chem. Soc. 1990, 112, 6392–6394. 
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Scheme 4.7. Attempted incorporation of the C6-carbon unit. 
 At this point, it became apparent that a revised protecting group strategy was necessary in 
order to reduce the propensity of our system to form the cyclic 5-membered ring with the incorrect 
C5–Nβ bond connectivity. We postulated that such a solution could be realized by replacing the Nβ-
Boc group with a 2-nitrobenzenesulfonyl (Ns) group, 106 which should inductively deactivate the 
nitrogen atom. To this end, chemoselective cleavage of the N-Boc group of 68 with Mg(ClO4)2 in the 
presence of the C13-ketal occurred smoothly (Scheme 4.8). 107  Protection of the resultant 
pyrrolidinone with a Ns group afforded N-Ns-2-pyrrolidinone 82. Gratifyingly, addition of the 
lithium enolate of t-butylacetate to the C5-carbonyl occurred smoothly to furnish β-keto ester 83, 
with Nβ completely disengaged from C5. Heating 83 with PPh3 resulted in a Staudinger reaction108 
to provide vinylogous urethane 84 as an inconsequential ~3:2 mixture of C4-epimers. The C6-t-
butyloxycarbonyl serves two crucial functions, one of which was to induce preferential formation of 
the exocyclic Nα–C5–C6 enamine in order to suppress undesired 5-endo-trig cyclization. Secondly, 
vinylogous urethanes are easier to handle in comparison to their enamine counterparts because they 
are stable, non-basic, and can be readily purified. 
All that remained in order to test the key cascade sequence included: (1) deprotection of the 
Nβ-Ns group, (2) cleavage of the C13-ketal, and (3) condensation of Nβ with the C13-carbonyl to 
                                                                                                                                                 
106 Fukuyama, T.; Jow, C.-K.; Cheung, M. Tetrahedron Lett. 1995, 35, 6373–6374. 
 
107 Stafford, J. A.; Brackeen, M. F.; Karanewsky, D. S.; Valvano, N. L. Tetrahedron Lett. 1993, 34, 7873–
7876. 
 
108 Lambert, P. H.; Vaultier, M.; Carrié, R. J. Org. Chem. 1985, 50, 5352–5356. 
 
Cp2TiMe2
PhMe, 65 °C
5
NBoc
β
OMe
O O
NHBocα
79
Me
O O NHBoc
5
NH
α
O4
β
Boc2O
4-DMAP
Et3N, CH2Cl2
(75%)
80
Me
O O NHBoc
5
NBoc
α
O4
β
81
 114 
form the corresponding iminium ion intermediate. Attempted cleavage of the Nβ-Ns group, however, 
resulted in the formation of 5-membered vinylogous urethane 85, the product of a facile 
transamination reaction. Hence, it was clear from these results that the Nβ-Ns group would have to 
be removed at a later stage. 
  
Scheme 4.8. Installation of the correct C5–Nα connectivity via inductive deactivation of Nβ. 
 Instead, vinylogous urethane 84 was directly exposed to aqueous HCl (Scheme 4.9), which 
furnished tetracycle 92 as a single diastereomer in 92% yield via: (1) initial C13-dioxolane cleavage, 
(2) 7-endo-trig intramolecular 1,4-conjugate addition88 to form the C6–C7 bond via 
stereoelectronically favored axial attack anti to the C16-methyl group, (3) tautomerization to secure 
the C12-stereocenter via stereoelectronically favored axial protonation, and (4) a transannular aldol 
reaction to form the C4–C13 bond. This transformation constitutes a formal [3+3]-cycloaddition.109 
                                                                                                                                                 
109 (a) Gosh, S. K.; Buchanan, G. S.; Long, Q. A.; Wei, Y.; Al-Rashid, Z. F.; Sklenicka, H. M.; Hsung, R. P. 
Tetrahedron 2008, 64, 883–893, and references therein. (b) See ref 95. 
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Scheme 4.9. A formal [3+3]-cycloaddition reaction to construct tetracycle 92. 
 All that remained in order to complete a synthesis of the pentacyclic core of fastigiatine (37) 
was to formally exchange the C13-hydroxyl with Nβ (Scheme 4.10). This was accomplished via 
initial alkylation of 92 with MeI in the presence of K2CO3, followed by addition of PhSH, to yield N-
methylamine 93. Heating 93 in 2,2,2-trifluoroethanol (TFEOH) cleanly delivered pentacycle 96 in 
85% yield via: (1) an initial retro-aldol reaction, (2) condensation of Nβ with the C13-ketone to form 
the corresponding iminium ion, and (3) the pivotal biomimetic transannular Mannich reaction. Use 
of TFEOH, a strong hydrogen-bond donor but not a strong acid, as solvent was crucial to the success 
of this reaction. We speculated that under acidic conditions, protonation of Nβ would occur, thus 
disfavoring the formation of the positively charged intermediates involved in the retro-aldol reaction. 
Next, heating 96 in the presence of p-TsOH induced t-butyloxycarbonyl removal to afford the 
corresponding imine. Finally, exposure of the resultant imine to Ac2O in the presence of Et3N 
cleanly delivered (+)-fastigiatine (37). The structure of 37 was unambiguously confirmed by single 
crystal X-ray diffraction analysis. 
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Scheme 4.10. Completed total synthesis of (+)-fastigiatine (37). 
 Key lessons learned from Dr. Brian B. Liau’s synthesis of fastigiatine (37), which would 
subsequently be applied to a successful synthesis of the proposed structure of (–)-himeradine A (38), 
include a highly convergent fragment coupling via a nucleophilic cyclopropane opening, a 
diastereoselective formal [3+3]-cycloaddition reaction, and a transannular Mannich reaction to 
construct the pentacyclic core common to both 37 and 38. However, the ultimate goal we hoped to 
achieve in a total synthesis of himeradine A (38), which was not realized in our synthesis of 
fastigiatine (37), was a one-pot cascade reaction to construct the strained core system that would 
obviate the need to formally exchange the C13-hydroxyl with Nβ. Furthermore, we envisioned we 
could program the new cascade sequence order such that we could potentially access all 7-membered 
ring-containing Lycopodium alkaloids via a unified, biomimetic, convergent strategy. 
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Total Synthesis of the Proposed Structure of (–)-Himeradine A 
 (–)-Himeradine A (38) is arguably the most synthetically challenging Lycopodium alkaloid 
and contains, in addition to the aforementioned unprecedented pentacyclic core with a C3–C14 
linkage, seven rings, three potentially basic nitrogens, ten stereocenters, and a quinolizidine subunit 
appended to the core via a methylene linker. A synthesis of himeradine A (38) has not yet been 
reported in the literature. Our retrosynthetic analysis of 38 is outlined in Scheme 4.11. Analogous to 
our synthesis of fastigiatine (37), we envisioned constructing the C6–C14 bond in 38 from 
hexacyclic intermediate 97 via a biomimetic transannular Mannich reaction to afford the strained 
core skeleton. Intermediate 97 (redrawn in 2D as 98) could arise from a 7-endo-trig intramolecular 
1,4-conjugate addition of the β-keto ester to the cyclohexenone in 99, and condensation of Nα and 
Nβ with the C13- and C6-carbonyls, respectively. As discussed previously, the ultimate objective 
was to accomplish a one-pot cascade reaction to construct the strained core in 38 from β-keto ester 
99 in a single operation, a goal not realized in our synthesis of fastigiatine (37). 99 could be 
synthesized in a highly convergent fashion from three building blocks via alkylation of β-
carboxyimide 100 with quinolizidine iodide 101 or related derivatives, followed by subsequent 
addition of the lithium enolate of t-butylacetate 102 to the C13-carbonyl.  
 
  
 Scheme 4.11. Retrosynthetic analysis of (–)-himeradine A (38). 
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 Our first-generation retrosynthesis of the quinolizidine subunit is outlined in Scheme 4.12. 
The desired carboxyimide alkylation electrophile 101 could potentially be synthesized from 
quinolizidine 103 via a few straightforward manipulations, including a Mitsunobu displacement of 
the C17-hydroxyl group by azide. Quinolizidine 103 could be constructed from allyl N-Boc-
piperidine 104. The C6'-stereocenter in 104 could be installed via a diastereotopic deprotonation at 
C6' in N-Boc piperidine 105, followed by alkylation. Furthermore, we envisioned installing the C10'- 
and C17-stereocenters by relaying the stereochemical information of the single C8'-stereocenter in 
N,O-methoxyacetal 106 to first introduce the C10'- followed by the C17-stereocenter. 
 
Scheme 4.12. First-generation retrosynthesis of the quinolizidine subunit. 
 The synthesis commenced with the lipase-mediated desymmetrization of 3-methylglutaric 
anhydride with n-PrOH to afford carboxylic acid 107 (93% ee) (Scheme 4.13).110 Chemoselective 
reduction of the carboxylic acid with BH3•SMe2 occurred smoothly to provide the corresponding 
carbinol, which underwent Parikh-Doering oxidation to yield aldehyde 108. Heating 108 in 
NH3/MeOH afforded a mixture of N,O-hydroxy- and N,O-methoxyacetals. Exposure of this crude 
product mixture to p-TsOH in MeOH111 at 50 °C resulted in complete conversion to the desired N,O-
methoxyacetal 106 as a mixture of diastereomers. 
                                                                                                                                                 
110 Marcoux, D.; Bindschädler, P.; Speed, A. W. H.; Chiu, A.; Pero, J. E.; Borg, G. A.; Evans, D. A. Org. Lett. 
2011, 13, 3758–3761. 
 
111 Han, M. J.; Yoo, K. S.; Kim, Y. H.; Chang, J. Y. Org. Biomol. Chem. 2003, 1, 2276–2282. 
 
N
Me
101
N3
X N
Me
103
PO
PO
BocN
Me
H H
PO
PO
104
BocN
Me
H H
PO
PO
105
HN
O
MeMeO
H
106
17 10!
6!
8
12!
17 10!
6!
8
12!
17 10!
6!
8! 10! 8! 10! 8!
6!
17
 119 
 
Scheme 4.13. Synthesis of N,O-methoxyacetal 106. 
 Exposure of N,O-methoxyacetal 106 to BF3•OEt2 in the presence of silyl enol ether 109 
afforded lactam 110 as a single diastereomer via an N-acyliminium ion Mannich reaction (Scheme 
4.14).112 The diastereoselectivity of this reaction was controlled through stereoelectronically favored 
axial attack by silyl enol ether 109 at C10' of the intermediate N-acyliminium ion anti to the C12'-
methyl group. Chelate-controlled 1,3-syn reduction113 of the ketone in 110 with DIBAL-H afforded 
alcohol 111 as a single diastereomer. TBS-protection of the C17-hydroxyl, followed by N-Boc 
protection of the lactam, provided imide 112. Next, reduction of the carbonyl in 112 with DIBAL-H 
and subsequent exposure to BF3•OEt2 in the presence of Et3SiH,114 delivered N-Boc-piperidine 114. 
With 114 in hand, we could next investigate the introduction of the C6'-stereocenter. 
 
                                                                                                                                                 
112 (a) Vink, M. K. S.; Schortinghuis, C. A.; Luten, J.; Maarseveen, J. H.; Schoemaker, H. E.; Hiemstra, H.; 
Rutjes, F. P. J. T. J. Org. Chem. 2002, 67, 7869–7871. (b) Suzuki, H.; Aoyagi, S.; Kibayashi, C. Tetrahedron 
Lett. 1995, 36, 935–936. 
 
113 Josephsohn, N. S.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2004, 126, 3734–3735. 
 
114 Liang, N.; Datta, A. J. Org. Chem. 2005, 70, 10182–10185. 
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Scheme 4.14. Synthesis of N-Boc piperidine 114 as a single diastereomer. 
 We envisioned installing the C6'-stereocenter via a diastereotopic deprotonation at C6', 
followed by addition of a suitable electrophile.115 A diastereotopic deprotonation of 114 at C6' was 
performed with sec-BuLi in the presence of TMEDA (Scheme 4.15). The conformation of lithiated 
N-Boc piperidine 115 is rigidly locked due to 1,3-allylic strain minimization between the N-Boc 
group and the C10'-stereocenter, which is further reinforced by equatorial positioning of the C12'-
methyl group. Equatorial organolithium 115 was favored due to chelation with the N-Boc group. 
Transmetallation with Cu(I), followed by alkylation with allyl bromide, furnished the desired 
allylated piperidine 116 (redrawn as 117) as a single diastereomer in 50% yield (97% brsm). 
 
Scheme 4.15. Successful introduction of the C6'-stereocenter. 
 Attempts to improve the yield of the allylated product 116 beyond 50% proved challenging. 
Transmetallation with Cu(I) was essential or else only trace quantities of 116 were obtained. Varying 
                                                                                                                                                 
115 (a) Beak, P.; Lee, W. K. J. Org. Chem. 1990, 55, 2578–2580. (b) Beak, P.; Lee, W. K. J. Org. Chem. 1993, 
58, 1109–1117. (c) Guerrero, C. A.; Sorensen, E. J. Org. Lett. 2011, 13, 5164–5167. 
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the temperature, concentration, and time allotted for deprotonation, as well as the amount of sec-
BuLi (from 1.3 to 3.0 equiv), TMEDA (from 1.3 to 3.0 equiv), CuCN•2LiCl (from 0.6 to 1.8 equiv), 
and AllylBr (from 1.5 to 3.6 equiv) used all resulted in similar or diminished yields. We suspected 
that complete deprotonation of sterically encumbered C6' was challenging. However, warming of the 
deprotonation with sec-BuLi (up to 0 °C) resulted in partial cleavage of the N-Boc protecting group. 
Alkylation with various electrophiles, which could potentially result in fewer downstream step 
manipulations, was also explored (Figure 4.3). However, in all cases, either trace quantities of the 
corresponding product or complete recovery of starting material 114 was observed. 
  
Figure 4.3. Attempted introduction of other electrophiles to the C6' position. 
 Next, allyl N-Boc-piperidine 117 was converted to the desired quinolizidine 127 (Scheme 
4.16). Exposure of 117 to TMSOTf in the presence of 2,6-lutidine afforded the corresponding Boc-
cleaved piperidine, which underwent subsequent allylation with AllylBr and K2CO3 to provide 
tertiary amine 123. A Grubbs II-catalyzed ring-closing metathesis116 with p-TsOH protonation of the 
tertiary amine cleanly delivered cyclized product 124. Hydrogenation of the alkene in 124 in the 
presence of AcOH furnished quinolizidine 125. Global silyl deprotection upon heating with HCl in 
MeOH, followed by selective monosilylation of the primary hydroxyl group, afforded TBS-ether 
126. Finally, Mitsunobu displacement of the secondary hydroxyl group in 126 with azide, followed 
by cleavage of the primary TBS ether, occurred smoothly to yield alcohol 127. 
                                                                                                                                                 
116 (a) Compain, P. Adv. Synth. Catal. 2007, 349, 1829–1846. (b) Srivastava, A. K.; Das, S. K.; Panda, G. 
Tetrahedron 2009, 65, 5322–5327.  
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Scheme 4.16. Synthesis of quinolizidine 127. 
 Unfortunately, efforts to synthesize a suitable alkylation electrophile for carboxyimide 66 
from alcohol 127 were unsuccessful. Attempted synthesis of the corresponding mesylate, tosylate, 
and iodide from 127 resulted in decomposition in all cases. We speculate that the observed 
decomposition could be attributed to facile intra- and intermolecular alkylation of the desired product 
by the tertiary amine. Nonetheless, we demonstrated, as a proof-of-principle, that successful 
construction of the quinolizidine subunit from N-Boc-piperidine 117 was possible. In the global 
scheme, the quinolizidine would either have to be constructed after alkylation with imide 66 or 
introduced in a protected form.  
 To this end, we decided to synthesize the quinolizidone, a protected form of the 
quinolizidine (Scheme 4.17). Cleavage of the N-Boc protecting group, followed by condensation of 
the resultant secondary amine with acryloyl choride, yielded amide 129. A Grubbs II-catalyzed ring-
closing metathesis cleanly provided cyclized amide 130. Hydrogenation of the alkene in 130 yielded 
quinolizidone 131, which was converted in six steps to the desired alkylation electrophile, iodide 
132. 
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Scheme 4.17. Synthesis of quinolizidone iodide 132. 
 
Imide 66 underwent efficient alkylation with iodide 132 to furnish the desired alkylated 
product 133 in excellent yield (Scheme 4.18). 133 was converted to vinylogous urethane 134 in five 
steps, analogous to the sequence used in our synthesis of fastigiatine (37). At the outset, as a proof-
of-concept, we decided to replicate the cascade utilized in our synthesis of fastigiatine (37) to 
construct the strained pentacyclic core of himeradine A (38). To this end, exposure of 134 to aqueous 
HCl resulted in a formal [3+3]-cycloaddition to afford hexacycle 136 as a single diastereomer. Next, 
in order to conduct a formal exchange between the C6-hydroxyl group with Nβ, the N-Ns protecting 
group must be cleaved. Surprisingly, attempted cleavage of the Ns group of 136, or alkylated 
derivatives 137 and 138, by treatment with PhSH in the presence of K2CO3 resulted in 
decomposition. We rationalized that milder deprotection conditions could be employed if a more 
readily cleaved Nβ-protecting group was utilized. Instead of a 2-nitrobenzenesulfonyl group, we 
were able to protect Nβ with a 2,4-dinitrobenzenesulfonyl group, which, unfortunately, was 
immediately cleaved upon addition of lithiated t-butylacetate during attempted formation of the 
desired β-ketoester analogue precursor to 134. 
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Scheme 4.18. Successful formal [3+3]-cycloaddition to afford hexacycle 136. 
A new cascade order was subsequently developed in order to circumvent the need for the 
C6-hydroxyl and Nβ exchange as well as to potentially permit the one-pot construction of the 
strained core structure in a single operation, which was not realized in our synthesis of fastigiatine 
(37) (Scheme 4.19). To this end, our strategy was revised and instead of forming vinylogous 
urethane 134, 140 was directly exposed to aqueous HCl, which resulted in facile cleavage of the C6-
dioxolane, affording enone 141. Treatment of 141 with Barton’s base cleanly delivered ketone 143 
via: (1) a 7-endo-trig intramolecular 1,4-conjugate addition to form the C10−C11 bond via 
stereoelectronically favored axial attack anti to the C12-methyl group, and (2) tautomerization of the 
ensuing C5−C6 enol to secure the C5-stereocenter through stereoelectronically favored axial 
protonation. Next, cleavage of the N-Ns protecting group by treatment with PhSH in the presence of 
K2CO3 cleanly provided the tricyclic core of imine 144. By forming the C10–C11 bond in 143 prior 
to Ns deprotection, we avoided problems associated with C13–Nβ bond formation and 5-endo-trig 
cyclizations that plagued our first-generation synthesis of fastigiatine (37). Furthermore, we believed 
that under the appropriate conditions, we could perform all of the aforementioned events in a single 
one-pot operation (141 → 144). 
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Scheme 4.19. Successful execution of a new sequence to construct tricyclic imine 144. 
While developing this novel, revised cascade sequence, we also concurrently investigated 
conversion of the quinolizidone moiety to the corresponding quinolizidine on a model system. Due 
to sensitive functionalities present in the molecule, only limited methods for converting the 
quinolizidone to the desired quinolizidine subunit were available. These methods include treatment 
of the amide with Meerwein’s salt (Me3OBF4)117 and subsequent reduction (NaBH4), triflation of the 
tertiary amide followed by reduction, and formation of the corresponding thioamide and subsequent 
reduction.118 Unfortunately, however, all of these methods failed to provide any desired product on 
our simpler model systems. Hence, another revision in our strategy was necessary. 
Instead of preforming the quinolizidine or quinolizidone from 116, we decided to carry the 
N-Boc allyl piperidine 116 forward and construct the quinolizidine bicyclic structure at a later stage 
(Scheme 4.20). Global silyl deprotection of N-Boc-piperidine 116, followed by selective protection 
of the resultant primary hydroxyl, afforded TBS ether 145. Following the same reaction sequence 
                                                                                                                                                 
117 (a) Ishikawa, H.; Elliott, G. I.; Velcicky, J.; Choi, Y.; Boger, D. L. J. Am. Chem. Soc. 2006, 128, 
10596−10612. (b) Martin, S. F.; Clark, C. W.; Ito, M.; Mortimore, M. J. Am. Chem. Soc. 1996, 118, 
9804−9805. (c) Bonazzi, S.; Cheng, B.; Wzorek, J. S.; Evans, D. A. J. Am. Chem. Soc. 2013, 135, 9338−9341. 
 
118 (a) Kurasaki, H.; Okamoto, I.; Morita, N.; Tamura, O. Org. Lett. 2009, 11, 1179−1181. (b) Sirasani, G.; 
Paul, T.; Dougherty, W.; Kassel, S.; Andrade, R. B. J. Org. Chem. 2010, 75, 3529−3532. (c) Campbell, E. L.; 
Zuhl, A. M.; Liu, C. M.; Boger, D. L. J. Am. Chem. Soc. 2010, 132, 3009−3012. 
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utilized previously, Mitsunobu displacement of the secondary hydroxyl group in 145 with azide, 
followed by cleavage of the TBS ether, and formation of the corresponding iodide, occurred 
smoothly to yield the desired alkylation partner, iodide 147. 
 
 
Scheme 4.20. Synthesis of N-Boc-piperidine iodide 147. 
 Imide 66 underwent efficient alkylation with iodide 147 to provide the desired alkylated 
product 148 in excellent yield (94%) (Scheme 4.21). Cleavage of the TMSE ester with concomitant 
decarboxylation upon treatment with TBAF, followed by chemoselective cleavage of the N-Boc 
group of 149 with Mg(ClO4)2, occurred smoothly to afford pyrrolidinone 150. Protection of 150 with 
a Ns group then delivered N-Ns-2-pyrrolidinone 151.119 Next, addition of the lithium enolate of t- 
butylacetate to the C13-carbonyl of 151 furnished β-ketoester 152. 
 
                                                                                                                                                 
119 Unfortunately, performing an exchange of protecting groups from Boc to Ns was necessary because 
attempted nucleophilic cyclopropane opening of the corresponding Ns-protected derivative of cyclopropane 64 
did not yield any desired product. The Ns group appeared to have been compromised. 
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Scheme 4.21. Successful imide alkylation and synthesis of β-ketoester 152.  
Next, the C6-dioxolane of 152 was directly cleaved upon treatment with p-TsOH to provide 
enone 153 (Scheme 4.22). Next, we discovered that in a one-pot sequence involving initial exposure 
of 153 to Barton’s base in MeCN, followed by subsequent addition of PhSH in the presence of 
K2CO3, 153 was converted to imine 156 (84%, 3 steps) via: (1) 7-endo-trig intramolecular conjugate 
addition to form the C10−C11 bond, (2) tautomerization of the ensuing C5−C6 enol to secure the C5 
stereocenter, (3) cleavage of the N-Ns protecting group upon addition of PhSH in the presence of 
K2CO3, and (4) in situ condensation of Nβ with the C6-ketone to form the corresponding imine. 
Isolation of imine 156 was exciting; we believe 156 lends credence to our biosynthetic hypothesis 
(Figure 4.2), and this type of intermediate could potentially allow us to access other 7-membered 
ring-containing Lycopodium alkaloids, including lyconadins A-C, nankakurines A-B, 120  and 
lucidines A-B, 121  via reduction of the imine. Alternatively, if imine 156 undergoes the key 
                                                                                                                                                 
120 For isolation and revised structural assignment, see: (a) Hirasawa, Y.; Morita, H.; Kobayashi, J. Org. Lett. 
2004, 6, 3389−3391. (b) Ayer, W. A.; Ball, L. F.; Browne, L. M.; Tori, M.; Delbaere, L. T. J.; Silverberg, A. 
Can. J. Chem. 1984, 62, 298−302. (c) Hirasawa, Y.; Kobayashi, J.; Obara, Y.; Nakahata, N.; Kawahara, N.; 
Goda, Y.; Morita, H. Heterocycles 2006, 68, 2357−2364. 
 
121 Tori, M.; Shimoji, T.; Shimura, E.; Takaoka, S.; Nakashima, K.; Sono, M.; Ayer, W. A. Phytochemistry 
2000, 53, 503−509. 
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biomimetic transannular Mannich reaction, not only could himeradine A (38) be accessed, but also 
lycopecurine (39) and inundatine (40). In accord with our proposed biosynthetic hypothesis, a 
diverse set of Lycopodium alkaloids could arise from a common precursor derivative such as 156. 
 
 
Scheme 4.22. Successful one-pot sequence to construct imine 156, containing the strained core of 
himeradine A (38). 
 
Next, exposure of azide 156 to PPh3 in the presence of water afforded hexacyclic vinylogous 
urethane 157 in 75% yield via: (1) Staudinger reduction of the azide to the corresponding amine, (2) 
condensation of the resultant amine with the neighboring β-ketoester to form the vinylogous 
urethane, and (3) the key pivotal transannular Mannich reaction to construct the C6−C14 bond. 
Acetylation of the secondary amine in 157 with Ac2O and Et3N provided hexacycle 158 in 83% 
yield.  
With 158 in hand, all that remained in order to complete a total synthesis of himeradine A 
(38) was to convert the N-Boc allyl piperidine moiety in 158 to the corresponding quinolizidine and 
cleave the t-butyl ester. As described previously (Scheme 4.16), a reaction sequence had already 
been developed for the construction of the quinolizidine subunit. To this end, formation of the 
corresponding silyloxy carbamate from N-Boc piperidine 158 occurred smoothly upon exposure to 
TBSOTf and 2,6-lutidine (Scheme 4.23). Treatment with TBAF resulted in cleavage of the silyloxy 
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carbamate with concomitant decarboxylation, furnishing piperidine 159. Alkylation of 159 with 
AllylBr in the presence of K2CO3 afforded allylated product 160. However, increasing the scale of 
this allylation reaction resulted in a complex product mixture, including byproducts in which the 
vinylogous urethane nitrogen was allylated. A new strategy for installing the quinolizidine subunit 
was necessary. 
 
Scheme 4.23. Attempted construction of the quinolizidine subunit. 
 To this end, cross-metathesis122 of the allyl group in 158 with acrolein was accomplished 
with Hoveyda−Grubbs catalyst II, which furnished enal 161 (Scheme 4.24). Hydrogenation of 161, 
followed by reduction of the resultant aldehyde and tosylation of the corresponding hydroxyl group, 
afforded tosylate 162 (70%, 3 steps). Exposure of 162 to TBSOTf resulted in formation of the 
silyloxy carbamate, which was cleaved upon treatment with TBAF. In situ cyclization via SN2 
displacement of the tosylate group with the resultant secondary amine delivered heptacycle 163 
(48%, 2 steps), which now contains the quinolizidine subunit.  
                                                                                                                                                 
122  (a) Chatterjee, A. K.; Choi, T. L.; Sanders, D. P.; Grubbs, R. H. J. Am. Chem. Soc. 2003, 125, 
11360−11370. (b) Movassaghi, M; Tjandra, M.; Qi, J. J. Am. Chem. Soc. 2009, 131, 9648−9650. 
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Scheme 4.24. Synthesis of the proposed structure of (−)-himeradine A (38). 
 Finally, treatment of 163 with TFA resulted in facile removal of the t-butyloxycarbonyl 
group to yield the proposed structure of (−)-himeradine A (38) as the double TFA salt (quant., [α]D24 
= −19 (c 0.3, MeOH)). Except for the chemical shift of H10', which is shifted upfield by Δδ = 0.14 
ppm (Figure 4.4), the 1H NMR, 13C NMR, COSY, NOESY, HSQC, and HMBC spectra for synthetic 
(−)-himeradine A (38) are in good agreement with the values reported for the natural product ([α]D25 
= −23 (c 0.3, MeOH)).  
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Figure 4.4. Comparison of 1H NMR spectra of synthetic (38) and natural (−)-himeradine A as the 
double TFA salt in CD3OD. 
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Because the protonation state of basic nitrogen atoms can have a significant impact on 
proton chemical shifts,123 we carefully titrated the double TFA salt of himeradine A (38) with a 
solution of NaOCD3 in CD3OD until the free base was obtained, and then incrementally titrated 
known aliquots of TFA in CD3OD until the double TFA salt was reisolated. At no point during the 
titration experiments were we able to identically replicate the 1H NMR spectrum of natural 
himeradine A (38). Variable concentration and temperature effects were also investigated and found 
not to have an effect on H10' proton chemical shift.  
We were able to obtain the 1H NMR spectrum of the free base of natural himeradine A in 
CD3OD via private communication with Professor Hiroshi Morita (Figure 4.5). While the 1H NMR 
spectra of the free base of natural and synthetic himeradine A (38) appeared to correspond, we 
suspected that a structural misassignment of natural himeradine A in the original isolation report may 
have occurred. Several misassignment possibilities existed (Figure 4.6), including (1) the C10'-
stereocenter, (2) the C6'-stereocenter, (3) the C17-stereocenter, (4) the absolute stereochemistry of 
the quinolizidine subunit, and (5) permutations thereof.  
 
                                                                                                                                                 
123 (a) Altman, R. A.; Nilsson, B. K.; Overman, L. E.; Alaniz, J. R.; Rohde, J. M.; Taupin, V. J. Org. Chem. 
2010, 75, 7519−7534. (b) Martin, C. L.; Overman, L. E.; Rohde, J. M. J. Am. Chem. Soc. 2008, 130, 
7568−7569. 
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Figure 4.5. Comparison of 1H NMR spectra of synthetic (38) and natural (−)-himeradine A as the 
free base in CD3OD. 
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Synthesis of Quinolizidine Models for the Structural Reassignment of Himeradine A 
 
 
Figure 4.6. Possible candidates for the structural misassignment of himeradine A (38). 
Since other related Lycopodium alkaloids124 containing a quinolizidine subunit all possess 
the same absolute stereochemistry at the C12'-methyl group position, we believed it was unlikely 
that the absolute stereochemistry of the quinolizidine was misassigned (Figure 4.7). Additionally, we 
hypothesized that the stereochemical assignment of the C17-stereocenter was correct since the 
chemical shift of H17 for synthetic (38) and natural himeradine A are in good agreement. 
Furthermore, we believed at the time that if H17 was equatorial instead of axial, there would be a 
significant perturbation to the chemical shift, especially due to the adjacent imine π-system. 
 
 
 
Figure 4.7. Examples of Lycopodium alkaloids possessing a quinolizidine subunit with the same 
absolute stereochemistry (denoted by *) as the C12'-methyl group in himeradine A (38). 
 
 Due to the aforementioned discussion, we suspected that a stereochemical misassignment of 
the quinolizidine subunit (C10' or C6') may have occurred, resulting in four possible stereoisomers. 
In the original isolation report by Kobayashi and coworkers, the stereochemical assignment of the 
quinolizidine subunit was made based on the putative observation of several key NOESY 
                                                                                                                                                 
124 (a) Morita, H; Hirasawa, Y.; Shinzato, T.; Kobayashi, J. Tetrahedron 2004, 60, 7015−7023. (b) Ayer, W. 
A.; Jenkins, J. K.; Valverde-Lopez, S. Can. J. Chem. 1967, 45, 433−443. (c) Ayer, W. A.; Jenkins, J. K.; Piers, 
K.; Valverde-Lopez, S. Can. J. Chem. 1967, 45, 445−450. (d) Ayer, W. A.; Piers, K. Can. J. Chem. 1967, 45, 
451−459. 
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correlations (Figure 4.8). However, in the 2D NOESY spectrum provided in the isolation report, 
NOESY correlations between H6' and H8', and H6' and H2' are not readily apparent. Furthermore, 
we were skeptical of the assignment of H8' to δ = 1.92 ppm in CD3OD, since in the published 1H 
NMR spectrum, this region encompassed one broad nondescript and undefined cluster of twelve 
protons.  
 
Figure 4.8. Putative NOESY correlations observed in the original isolation report of himeradine A 
(38). 
 
Based on 1H NMR spectra comparisons between the TFA salts of natural himeradine A (38) 
and cermizine D, 125  a Lycopodium alkaloid in which both C10' and C6' have the opposite 
configuration to the proposed structure (see Figure 4.7), we ruled out the possibility that both C10' 
and C6' in the proposed structure of himeradine A were misassigned. Hence, we embarked on a new 
synthetic effort to independently invert the C10'- and C6'-stereocenters.  
Since the quinolizidine is relatively remote from the pentacyclic core of himeradine A (38), 
we believed that we could synthesize only the quinolizidine subunit with either C10' or C6' inverted 
as a model to predict the 1H NMR chemical shifts of the final natural product. As a control, we 
synthesized the TFA salt of only the quinolizidine subunit of the proposed structure of himeradine A 
(38) and were pleased to discover that the 1H NMR chemical shifts of H10', H6', and H2' were in 
excellent agreement with synthetic himeradine A (38) (Figure 4.9). 
                                                                                                                                                 
125 Veerasamy, N.; Carlson, E. C.; Carter, R. G. Org. Lett. 2012, 14, 1596−1599. 
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Figure 4.9. Comparison of 1H NMR spectra of quinolizidine subunit model 164 and synthetic 
himeradine A (38) as the TFA salts in CD3OD. 
 
We decided to first embark on a synthesis of a quinolizidine subunit model in which the C6'-
stereocenter is inverted relative to the proposed structure of himeradine A (38). This can be readily 
accomplished with the synthetic route we have previously developed and discussed, with minor 
modifications (Scheme 4.25). The C6'-stereocenter was introduced via exposure of intermediate 113 
to AllylSnBu3 in the presence of BF3•OEt2, delivering allyl N-Boc piperidine 165 as a single 
diastereomer. The diastereoselectivity of this reaction is controlled through stereoelectronically 
favored axial attack of the corresponding N-acyliminium ion intermediate by AllylSnBu3 anti to the 
C12'-methyl group. Cleavage of the N-Boc protecting group in 165, followed by allylation of the 
resultant piperidine, occurred smoothly to afford tertiary amine 166. 166 was transformed to 
quinolizidine 168 in four steps via: (1) ring-closing metathesis to provide alkene 167, (2) 
 137 
hydrogenation of the resultant alkene, (3) global silyl deprotection, and (4) selective protection of the 
resultant primary hydroxyl group. Finally, Mitsunobu displacement of the secondary hydroxyl group 
in 168 with azide, followed by cleavage of the primary TBS ether, yielded quinolizidine 169, our 
desired model substrate. 
 
Scheme 4.25. Synthesis of a model of the quinolizidine subunit 169 in which the C6'-stereocenter is 
inverted relative to the proposed structure of himeradine A (38). 
 
Treatment of 169 with TFA cleanly provided the corresponding TFA salt, the 1H NMR 
spectrum of which was directly compared with that of natural himeradine A (Figure 4.10). As is 
readily apparent, the 1H NMR spectrum of the TFA salt of 169 is noticeably different from natural 
himeradine A. We were originally concerned about the accuracy of our quinolizidine model system 
in which C17 is connected to an azide (169), versus an imine functionality in himeradine A, in 
predicting the chemical shift of the H10'-proton. However, it is evident that the chemical shifts of the 
H2'-protons in 169 (δ = 3.82 and 2.89 ppm (the latter is not shown in Figure 4.10)) were remarkably 
different from that in natural himeradine A (δ = 3.33 and 3.19 ppm). Hence, we concluded that it was 
unlikely that the C6'-stereocenter in the proposed structure of himeradine A (38) was misassigned. 
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Figure 4.10. Comparison of 1H NMR spectra of quinolizidine subunit model 169, in which the C6'-
stereocenter has been inverted, and natural himeradine A as the TFA salts in CD3OD. 
 
Next, we turned our focus to inverting the C10'-stereocenter, which unfortunately could not 
be accomplished with the previously developed synthetic route. A new strategy was devised 
(Scheme 4.26). Utilizing the enantioselective transfer aminoallylation reaction developed by 
Kobayashi et al,126 aldehyde 108 and α-aminoketone 170, derived from (1R)-(−)-camphorquinone, 
were stirred together in the presence of catalytic CSA, furnishing lactam 171 as a single diastereomer 
via: (1) condensation of aldehyde 108 with the amine in 170, (2) a 2-aza-Cope rearrangement of the 
resultant imine, (3) cleavage of the newly formed imine under acidic conditions with the use of 
HONH2•AcOH to reveal the homoallylamine product, and (4) in situ lactam formation. 
                                                                                                                                                 
126 (a) Sugiura, M.; Mori, C.; Kobayashi, S. J. Am. Chem. Soc. 2006, 128, 11038−11039. For an example of the 
use of 170 in a synthesis, see: (b) Nishikawa, Y.; Kitajima, M.; Kogure, N.; Takayama, H. Tetrahedron 2009, 
65, 1608−1617. 
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Scheme 4.26. Synthesis of a model of the quinolizidine subunit 176 in which the C10'-stereocenter is 
inverted relative to the proposed structure of himeradine A (38). 
 
Protection of lactam 171 as the corresponding Boc-imide, followed by exposure to OsO4 and 
NaIO4 in the presence of 2,6-lutidine,127 yielded aldehyde 172 via oxidative cleavage of the terminal 
olefin. An asymmetric allylboration of 172 with Brown’s chiral (+)-Ipc2B(allyl) allylborane 
reagent128 provided alcohol 173 as a single diastereomer. Mitsunobu displacement of the secondary 
hydroxyl group in 173 with azide occurred smoothly to afford azide 174. 174 was converted to 
amine 175 as a single diastereomer via a three-step protocol involving: (1) addition of Grignard 
reagent TIPSO(CH2)4MgI to the imide functionality, (2) subsequent exposure to TFA to cleave the 
N-Boc group and form the corresponding imine with concomitant cleavage of the TIPS ether group, 
and (3) reductive amination with NaBH(OAc)3 in the presence of AcOH. Finally, 175 underwent an 
Appel reaction with CBr4 and PPh3 in the presence of Et3N, resulting in the formation of the 
corresponding bromide and in situ intramolecular SN2 cyclization to deliver quinolizidine 176, the 
desired model.  
Treatment of 176 with TFA cleanly provided the corresponding TFA salt, the 1H NMR 
                                                                                                                                                 
127 Yu, W.; Mei, Y.; Kang, Y.; Hua, Z.; Jin, Z. Org. Lett. 2004, 6, 3217−3219. 
 
128 (a) Racherla, U. S.; Brown, H. C. J. Org. Chem. 1991, 56, 401−404. (b) Jadhav, P. K.; Bhat, K. S.; Perumal, 
P. T.; Brown, H. C. J. Org. Chem. 1967, 32, 404−407. (c) Nicolaou, K. C.; Ninkovic, S.; Sarabia, F.; 
Vourloumis, D.; He, Y.; Vallberg, H.; Finlay, M. R. V.; Yang, Z. J. Am. Chem. Soc. 1997, 119, 7974−7991. 
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spectrum of which was directly compared with that of natural himeradine A (Figure 4.11). Once 
again, the 1H NMR spectrum of the TFA salt of 176 was distinctively different from natural 
himeradine A. Not only was the chemical shift of H10' considerably different (δ = 3.22 ppm versus 
3.77 ppm in natural himeradine A), but also the chemical shifts of the H2'-protons in 176 (δ = 3.86 
and 2.75 ppm (the latter is not shown in Figure 4.11) versus 3.33 and 3.19 ppm in natural himeradine 
A). Hence, we concluded that it was unlikely that the C10'-stereocenter in the proposed structure of 
himeradine A (38) was misassigned. 
 
Figure 4.11. Comparison of 1H NMR spectra of quinolizidine subunit model 176, in which the C10'-
stereocenter has been inverted, and natural himeradine A as the TFA salts in CD3OD. 
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Figure 4.12. Selected NOESY correlations observed for the proposed structure of himeradine A 
(38). 
 
Although these results were discouraging, we turned our attention to the most probable 
remaining candidate for stereochemical misassignment—the C17-stereocenter. In the original 
isolation report by Kobayashi and coworkers, the stereochemical assignment of H17 as the axial 
configuration was based on observed NOESY correlations (Figure 4.12) between H17 and H10', 11'a 
and H8', H11'a and H6', and H11'b and H2'. However, both the axial and equatorial configurations of 
H17 would result in these observed NOESY correlations. Hence, we believed the proposed C17 
stereochemical assignment was ambiguous. Furthermore, both epimers of C17 exist in related 
Lycopodium alkaloids, lucidines A and B,121 suggesting that the opposite C17 configuration to the 
proposed structure of himeradine A (38) was plausible (Figure 4.13). 
 
Figure 4.13. Lucidine A and B are epimeric at the C17-stereocenter. 
  
Me
N
H
N
Me
N
O
Me 10!
6!
17
H
HH
11!a 11!b
H
H
8!
2!
H17 ↔ H10!
H11!a ↔ H8!
H11!a ↔ H6!
H11!b ↔ H2!
NOESY correlations
Proposed Himeradine A (38)
Me
N
H
N
Me
N
O
Me
17
(–)-Himeradine A (38) Lucidine B
Me
N
N
H
H
Me
H
H
R
Lucidine A
Me
N
N
H
H
Me
H
H
R
17 17
 142 
Candidate for the Structural Reassignment of (–)-Himeradine A 
 As discussed in the previous section, we next embarked on a synthesis of the C17-epimer of 
the proposed structure of himeradine A (38). This could readily be accomplished with the synthetic 
route we originally developed with minor modifications (Scheme 4.27). In order to introduce the 
C17-stereocenter, a double inversion of the secondary hydroxyl group in intermediate 145 is 
required. Mitsunobu displacement of the C17-hydroxyl with p-nitrobenzoic acid,129 followed by 
cleavage of the resultant ester, afforded inverted alcohol 177. A second Mitsunobu displacement 
with azide then yielded azide 178. Cleavage of the TBS-ether, followed by iodide formation, 
furnished alkyl iodide 179, the desired alkylation electrophile. β-carboxyimide 66 underwent 
efficient alkylation with 179 in the presence of Cs2CO3 to provide alkylated product 180 in 77% 
yield. 
 
 
Scheme 4.27. Double inversion of the C17-stereocenter. 
Following the same reaction sequence utilized in the synthesis of the proposed structure of 
himeradine A (38), 180 was converted to N-Ns-2-pyrrolidinone 181 in three steps via: (1) cleavage 
of the TMSE ester with concomitant decarboxylation, (2) cleavage of the N-Boc group with 
                                                                                                                                                 
129 Martin, S. F.; Dodge, J. A. Tetrahedron Lett. 1991, 32, 3017−3020. 
BocN
Me
H H
HO
RO
145
DPPA, PPh3
DEAD
THF, RT
(88%)
BocN
Me
H H
RO
177
1. TBAF, THF
    0 °C → RT
  2. I2, PPh3, Imid
      CH2Cl2, RT
   (88%, 2 steps)
BocN
Me
H H
N3
I
179
R = TBS R = TBS
O
OH
O2N
HO
1.
DEAD, PPh3
PhH, RT
2. LiOH
    THF/H2O, RT
     (69%, 2 steps)
BocN
Me
H H
RO
178
R = TBS
N3
17 17 17
O O
Me
NBoc
O
O
O
TMSE
66
O O
Me
NBoc
O
O
O
N3
Cs2CO3, DMF, RT
(77%)
180
BocN
MeTMSE
 143 
Mg(ClO4)2, and (3) protection of the resultant pyrrolidinone with a Ns group (Scheme 4.28). 
Addition of the lithium enolate of t-butylacetate to C13 of 181 and subsequent cleavage of the C6-
dioxolane yielded enone 182. Utilizing our optimized one-pot protocol, exposure of 182 to Barton’s 
base, followed by addition of PhSH in the presence of K2CO3, furnished imine 183. Next, a 
Staudinger reduction of the azide in 183 and condensation of the resultant amine with the 
neighboring β-ketoester, provided the corresponding vinylogous urethane product, which underwent 
subsequent acetylation to afford amide 184 (50%, 2 steps). Next, a cross-metathesis of the allyl 
group in 184 with acrolein in the presence of Hoveyda–Grubbs II catalyst occurred smoothly to yield 
enal 185 (88%). 
 
Scheme 4.28. Successful application of our one-pot sequence protocol toward the synthesis of 
himeradine A candidate structure 188. 
 
Hydrogenation of 185, reduction of the corresponding aldehyde with NaBH4, and tosylation 
of the resultant hydroxyl group provided tosylate 186 (73%, 3 steps) (Scheme 4.29). 186 was 
converted to quinolizidine 187 (59%, 2 steps) via: (1) initial formation of the silyloxy carbamate by 
exposure to TBSOTf and 2,6-lutidine, (2) subsequent cleavage of the carbamate with concomitant 
decarboxylation upon treatment with TBAF, and (3) in situ cyclization via SN2 displacement of the 
tosylate group with the resultant secondary amine. Exposure of 187 to TFA then yielded our 
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candidate structure for (−)-himeradine A (188) as the double TFA salt ([α]D22 = −56 (c 0.3, MeOH)).  
 
Scheme 4.29. Synthesis of our candidate structure for himeradine A (188). 
We were excited to discover that the chemical shift of H10' (δ = 3.79–3.74 ppm) in our 
candidate structure for himeradine A (188) was in excellent agreement with that for natural 
himeradine A (δ = 3.77 ppm) (Figure 4.14). In fact, the chemical shifts of the key protons of the 
quinolizidine subunit (H6', H10', and H2') are all in good agreement with the values reported for 
natural himeradine A. Unfortunately, however, several protons corresponding to the pentacyclic core 
of 188 (boxed in red) no longer match the reported values. Additionally, as expected, H17 is shifted 
upfield relative to the chemical shift in natural himeradine A.  
Based on the combined results of our quinolizidine model systems (169 and 176) and our 
candidate structure for himeradine A (188), we speculated that it could indeed be the absolute 
stereochemistry of the quinolizidine subunit, and not the relative configuration of the C17-, C6'-, or 
C10'-stereocenters, of himeradine A (38) that may have been misassigned. The synthesis of the 
opposite absolute stereochemistry of the quinolizidine subunit of 38 should be readily feasible with 
our developed route due to the latent C2-symmetry of starting material 107. However, embarking on 
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be impractical. Despite our educated hypothesis based on our model studies, there are still 
theoretically a total of sixteen possible stereoisomers. Furthermore, we cannot definitively rule out 
the possibility that we have successfully synthesized the correct structure of himeradine A (38) 
without an authentic sample of the natural product. Nonetheless, we have demonstrated that all 
sixteen possible stereoisomers could theoretically be accessed from the chemistry that we have 
developed.  
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Figure 4.14. Comparison of 1H NMR spectra of candidate (188) and natural (−)-himeradine A as the 
double TFA salt in CD3OD. 
 
In summary, this constitutes the first reported total synthesis of the proposed structure of (−)-
himeradine A (38). Noteworthy transformations include a biosynthetically inspired, 
diastereoselective, one-pot sequence for constructing the strained core common to himeradine A (38) 
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and other Lycopodium alkaloids, and a key biomimetic transannular Mannich reaction. This highly 
convergent and unifying strategy can now be applied towards the streamlined synthesis of other 7-
membered ring-containing Lycopodium alkaloids, which will be the subject of the next chapter. 
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II. A Biomimetic Unified Strategy for the Synthesis of 7-Membered Ring-Containing 
Lycopodium Alkaloids 
 
 
 
 
 
 
Chapter 5 
Total Syntheses of 7-Membered Ring-Containing Lycopodium Alkaloids 
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Introduction 
 In the previous chapter, we presented the development of a biosynthetically inspired one-pot 
cascade sequence for the construction of the strained core system common to a variety of 7-
membered ring-containing Lycopodium alkaloids, including himeradine A (38) and fastigiatine (37). 
This unifying and highly convergent strategy supports our biosynthetic hypothesis (Figure 4.2) and 
can be applied towards the synthesis of a diverse set of Lycopodium alkaloids (Scheme 5.1). 
 
 
Scheme 5.1. A biomimetic and unified strategy for the total syntheses of structurally diverse 
Lycopodium alkaloids. 
 
As illustrated in Scheme 5.2, a variety of structurally diverse Lycopodium alkaloids can be 
accessed with our strategy by varying the alkylation electrophile partner of carboxyimide 66. 
Examples of such alkaloids include not only himeradine A (38) and fastigiatine (37), but also 
lycopecurine (39), lyconadins A (31), B (32), and C (189), and nankakurine (48). General precursor 
imine 190 can be accessed from the one-pot reaction sequence that we have developed. A subsequent 
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biomimetic transannular Mannich reaction would deliver himeradine A (38), fastigiatine (37), and 
lycopecurine (39). Alternatively, reduction of 190 by hydride could give rise to the lyconadin group 
of alkaloids, such as lyconadin B (32) and lyconadin C (189), or nankakurine A (48), which has 
undergone a subsequent rearrangement. 
 
Scheme 5.2. Proposed unified strategy for the synthesis of a variety of Lycopodium alkaloids. 
Highlighted in red is the common 7-membered ring structural motif. Highlighted in gray is the 
variable alkyl chain. 
 
A structurally diverse set of Lycopodium alkaloids could potentially be accessed from our 
biosynthetically inspired unifying strategy. The successful application of our unifying approach to 
the total syntheses of other Lycopodium alkaloids would lend credence to our biosynthetic hypothesis 
and showcase the utility of the one-pot reaction sequence that we have developed. 
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Total Synthesis of Dehydrolycopecurine and Lycopecurine 
 Lycopecurine (39), isolated in 1969 from Lycopodium alopecuroides,130 contains the strained 
tetracyclic core common to himeradine A (38) and fastigiatine (37). Although no NMR spectra were 
provided, the structure was unambiguously determined by single crystal X-ray crystallography of the 
hydrobromide salt of lycopecurine (39). To date, a synthesis of lycopecurine has not yet been 
achieved. We envisioned that we could achieve the first total synthesis of lycopecurine with our 
biosynthetically inspired, unifying strategy to construct the strained core system. 
To this end, alkylation of β-carboxyimide 66 with benzyl 3-bromopropylether occurred 
smoothly to provide alkylated product 191 (Scheme 5.3). Employing the same reaction sequence 
used in the synthesis of himeradine A (38), 191 was converted in five steps to enone 194. In a one-
pot reaction sequence involving initial exposure to K2CO3 and subsequent addition of PhSH, 194 
underwent a cascade reaction to afford imine 195 (84%, 3 steps) via: (1) 7-endo-trig intramolecular 
conjugate addition and (2) in situ condensation of Nβ with the C13-ketone.  
 
Scheme 5.3. Synthesis of imine 195. 
                                                                                                                                                 
130 (a) Ayer, W. A.; Altenkirk, B.; Masaki, N.; Valverde-Lopez, S. Can. J. Chem. 1969, 47, 2449−2455. (b) 
Ayer, W. A.; Masaki, N. Can. J. Chem. 1971, 49, 524−527. 
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Next, treatment of 195 with TFA resulted in loss of the t-butyloxycarbonyl group to afford 
the corresponding ketone, which then underwent the key biomimetic transannular Mannich reaction 
upon heating with HCl in MeOH87 to construct the C4−C13 bond in tetracycle 197 (95%, 2 steps) 
(Scheme 5.4). Hydrogenolysis of the benzyl group in 197, followed by exposure of the resultant 
alcohol 198 to 25% HBr in glacial AcOH87 resulted in bromination of the hydroxyl group and 
formation of the ammonium bromide salt. Upon treatment with K2CO3, this intermediate underwent 
cyclization to yield dehydrolycopecurine131 (199) in 59% yield over 2 steps ([α]D22 = −69 (c 0.34, 
MeOH)). Finally, reduction of the ketone with LiEt3BH delivered lycopecurine (39) in 66% yield 
([α]D22 = −19 (c 0.14, MeOH)), constituting the first total syntheses of Lycopodium alkaloids 39 and 
199. The structure of 39 was unambiguously established via single crystal X-ray diffraction analysis 
of the hydrobromide salt of 39. 
 
 
Scheme 5.4. Total synthesis of dehydrolycopecurine (199) and lycopecurine (39). 
By varying the alkylation electrophile partner with carboxyimide 66, we were able to 
accomplish the first total syntheses of dehydrolycopecurine (199) and lycopecurine (39) using our 
biosynthetically inspired, unifying strategy. Our one-pot cascade sequence was employed in the 
construction of the tricyclic core of 199 and 39. A key biomimetic transannular Mannich reaction 
                                                                                                                                                 
131 Braekman, J. C.; Hootele, C.; Ayer, W. A. Bull. Soc. Chim. Belges 1971, 80, 83−90. 
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then established the C4−C13 bond, furnishing the tetracyclic core common to himeradine A (38) and 
fastigiatine (37).  
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Total Synthesis of (+)-Lyconadin A and (−)-Lyconadin B  
 In 2001, Kobayashi and coworkers isolated (+)-lyconadin A (31) from the club moss 
Lycopodium complanatum.132 a The structure of lyconadin A (31) was revealed to contain a 
pentacyclic core, including a 2-pyridone ring, six stereocenters, and a tertiary amine. 31 exhibits 
modest cytotoxicity against murine lymphoma L1210 cells (IC50 = 0.46 µg/mL) and human 
epidermoid carcinoma KB cells (IC50 = 1.7 µg/mL). Four syntheses of 31 have been accomplished to 
date.88,90,133 (–)-Lyconadin B (32),132b which differs from 31 in that it contains a dihydropyridone 
instead of a pyridone moiety, was isolated in 2006. To date, two total syntheses88,134 of lyconadin B 
(32) have been achieved. Both 31 and 32 demonstrate enhanced mRNA expression for nerve growth 
factor in 1321N1 human astrocytoma cells. We envisioned that a synthesis of lyconadin A (31) and 
B (32) could be realized by utilizing our unifying strategy to construct the core system via our one-
pot reaction sequence. 
 To this end, alkylation of β-carboxyimide 66 with acrylonitrile proceeded smoothly to afford 
alkylated product 200 (Scheme 5.5). Utilizing the same reaction sequence employed in the synthesis 
of himeradine A (38) and lycopecurine (39), 200 was converted to enone 203 in five steps. A one-pot 
reaction sequence involving initial exposure to K2CO3 followed by addition of PhSH then delivered 
tricyclic imine 204 (63%, 3 steps).  
 
                                                                                                                                                 
132 (a) Kobayashi, J.; Hirasawa, Y.; Yoshida, N.; Morita, H. J. Org. Chem. 2001, 66, 5901–5904. (b) Ishiuchi, 
K.; Kubota, T.; Hoshino, T.; Obara, Y.; Nakahata, N.; Kobayashi, J. Bioorg. Med. Chem. 2006, 14, 5996–6000. 
 
133 (a) Nishimura, T.; Unni, A. K.; Yokoshima, S.; Fukuyama, T. J. Am. Chem. Soc. 2011, 133, 418–419. (b) 
Yang, Y.; Haskins, C. W.; Zhang, W.; Low, P. L.; Dai, M. Angew. Chem. Int. Ed. 2014, 53, 3922–3925. 
 
134 Nishimura, T.; Unni, A. K.; Yokoshima, S.; Fukuyama, T. J. Am. Chem. Soc. 2013, 135, 3243−3247. 
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Scheme 5.5. Synthesis of imine 204. 
 Unlike himeradine A (38) and lycopecurine (39), which underwent a subsequent 
transannular Mannich reaction, a synthesis of the lyconadins would require reduction of the imine 
functionality (Scheme 5.6). Treatment of 204 (redrawn as 205) with NaBH(OAc)3 and AcOH 
resulted in chemoselective reduction of the imine to furnish amine 206. Next, treatment of 206 with 
TFA resulted in removal of the t-butyloxycarbonyl group to afford ketone 207 (59%, 2 steps).  
 
 
Scheme 5.6. Total synthesis of (+)-lyconadin A (31) and (−)-lyconadin B (32). 
 
 Deprotonation of 207 with LiHMDS, followed by trapping with I2,90 directly delivered 
amine 208 (73%); this presumably occurred via one of two possible mechanisms, including: (1) 
initial α-iodination of the ketone from the convex face, followed by intramolecular SN2 displacement 
of the iodide by the secondary amine, or (2) oxidative enolate amination via a radical pathway. 
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Finally, heating nitrile 208 in a 7.0 M NH3/MeOH135 solution in a sealed vessel at 120 °C furnished 
(−)-lyconadin B (32) in 57% yield ([α]D21 = −102 (c 0.5, MeOH)). The 1H NMR (Figure 5.1) and 13C 
NMR spectra for synthetic (−)-lyconadin B (32) are in good agreement with the spectra reported for 
the natural product. During our studies to convert 208 to lyconadin B (32), we discovered a trace 
byproduct in the crude 1H NMR corresponding to lyconadin A (31) after heating the reaction in 
NH3/MeOH for two days.136 Lyconadin A (31) presumably formed by autoxidation in the presence of 
trace oxygen. Gratifyingly, heating lyconadin B (32) neat at 160 °C under an atmosphere of air 
afforded lyconadin A (31) in 57% yield ([α]D22 = +37 (c 0.12, MeOH)). The 1H NMR and 13C NMR 
spectra for synthetic and natural (+)-lyconadin A (31) are in good agreement (Figure 5.2) 
 
                                                                                                                                                 
135 Högenauer, K.; Baumann, K.; Mulzer, J. Tetrahedron Lett. 2000, 41, 9229−9232. 
 
136 A similar observation was made by Fukuyama and coworkers: See ref. 134. 
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Figure 5.1. Comparison of 1H NMR spectra of natural and synthetic (−)-lyconadin B (32) in 
CD3OD. 
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Figure 5.2. Comparison of 1H NMR spectra of natural and synthetic (+)-lyconadin A (31) in 
CD3OD. 
 
 
 The successful total syntheses of lyconadin A (31) and lyconadin B (32) further lend support 
to our biosynthetic hypothesis that 7-membered ring-containing Lycopodium alkaloids arise from a 
common imine precursor, which can then undergo either a transannular Mannich reaction or imine 
reduction to generate a large diverse group of alkaloid natural products. Our biomimetic and unifying 
strategy has allowed us to readily and efficiently access a variety of structurally diverse Lycopodium 
alkaloids by simply varying the carboxyimide alkylation electrophile partner. The application of our 
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strategy enabled the successful total syntheses of himeradine A (38), lycopecurine (39), 
dehydrolycopecurine (199), lyconadin A (31), and lyconadin B (32), and can potentially be used to 
synthesize all other 7-membered ring-containing Lycopodium alkaloids. 
 
 
  
 160 
Concluding Remarks 
 In conclusion, the first total synthesis of the proposed structure of himeradine A (38), 
arguably the most complex and synthetically challenging Lycopodium alkaloid, was achieved. A 
biosynthetically inspired, diastereoselective, one-pot reaction sequence for constructing the strained 
core common to 7-membered ring-containing Lycopodium alkaloids was developed. A key 
biomimetic transannular Mannich reaction was successfully executed in the synthesis of the 
pentacyclic core of 38. 
This biosynthetically inspired reaction sequence was further applied towards the first total 
syntheses of lycopecurine (39) and dehydrolycopecurine (199), which also featured a key biomimetic 
intramolecular Mannich reaction. Our one-pot cascade sequence was also successfully utilized in a 
concise and streamlined synthesis of (+)-lyconadin A (31) and (–)-lyconadin B (32), which involved 
reduction of an imine intermediate instead of a transannular Mannich reaction to construct the core 
system. Our results constitute a unified strategy towards the synthesis of a structurally diverse set of 
7-membered ring-containing Lycopodium alkaloids, lending support to our proposed revised 
biosynthetic hypothesis of these natural products. 
 
 
Scheme 5.7. Successful synthesis of a diverse set of 7-membered ring-containing Lycopodium 
alkaloids by employing our biomimetic unifying strategy. 
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Experimental Section 
 General Procedures. All reactions were performed in flame-dried glassware under a 
positive pressure of argon unless otherwise noted. Flash column chromatography was performed as 
described by Still et al. employing silica gel 60 (40-63 µm, Whatman).72 Where necessary (so 
specified), silica gel was neutralized by treatment of the silica gel prior to chromatography with the 
eluent containing triethylamine or 5 M aqueous NH4OH. Analytical thin-layer chromatography 
(TLC) was performed using 0.25 mm silica gel 60 F254 plates purchased from EMD Chemicals. TLC 
plates were visualized by exposure to ultraviolet light (UV) and/or exposure to an acidic solution of 
p-anisaldehyde (Anis) or an aqueous solution of potassium permanganate (KMnO4), followed by 
heating on a hot plate.  
 
Materials. Commercial reagents and solvents were used as received with the following 
exceptions: tetrahydrofuran (THF), diethyl ether (Et2O), dichloromethane (CH2Cl2), acetonitrile 
(MeCN), hexamethyldisilazane (HMDS), benzene (PhH), and N,N-dimethylformamide (DMF) were 
degassed with argon and passed through a solvent purification system (designed by J. C. Meyer of 
Glass Contour) utilizing alumina columns as described by Grubbs et al.73 Triethylamine, 
diisopropylamine, and pyridine were distilled over calcium hydride before use. TMSOTf was 
distilled before use. N,N,Nʹ′Nʹ′-Tetramethylethylenediamine was distilled over potassium hydroxide 
immediately before use. The celite used was Celite® 545, purchased from J.T. Baker. The molarities 
of n-butyllithium and sec-butyllithium solutions were determined by titration using 1,10-
phenanthroline as an indicator (average of three determinations). 
 
Instrumentation. 1H NMR spectra were recorded with a Varian INOVA-600 or Varian 
INOVA-500 spectrometer. Proton chemical shifts are reported in parts per million (δ scale) and are 
calibrated using residual undeuterated solvent as an internal reference (CDCl3: δ 7.26 (CHCl3), 
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CD3OD: δ 3.31 (CD2HOD), C6D6: δ 7.15 (C6D5H)). Data for 1H NMR spectra are reported as 
follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = 
apparent, or combinations thereof. 13C NMR spectra were recorded with a Varian INOVA-500 
spectrometer. Carbon chemical shifts are reported in parts per million (δ scale) and are referenced 
from the carbon resonances of the solvent (CDCl3: δ 77.00, CD3OD: δ 49.00, C6D6: δ 128.39). 
Infrared (FTIR) spectra were recorded on a Bruker Alpha FT-IR spectrophotometer referenced to a 
polystyrene standard. FTIR data is reported in frequency of absorption (cm-1). High-resolution mass 
spectra (HRMS) were obtained from the Harvard University Mass Spectrometry Laboratory where 
electrospray ionization (ESI) mass spectroscopy (MS) experiments were performed on an Agilent 
6210 TOF LC/MS instrument. Optical rotations were measured on a Jasco P-2000 digital polarimeter 
with a sodium lamp. Reported readings are the average of five measurements for each sample. The 
structure of (–)-lycopecurine (39) was obtained with the assistance of Dr. Shao-Liang Zheng at the 
X-ray diffraction facility of the Department of Chemistry and Chemical Biology, Harvard 
University. 
 
 (For clarity, intermediates that have not been assigned numbers in the text are numbered 
sequentially in the experimental section beginning with S1). 
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(R)-Propyl 3-methyl-5-oxopentanoate (108):  
Borane dimethyl sulfide complex (4.54 mL, 46.3 mmol, 1.20 equiv) was added dropwise via 
syringe to a stirred solution of (R)-3-methyl-5-oxo-5-propoxypentanoic acid (107)110,137 (7.26 g, 38.6 
mmol, 1.00 equiv), which was azeotropically dried with benzene (5 × 10 mL), in THF (103 mL) at 0 
°C, which was subsequently allowed to warm naturally to room temperature. After stirring for an 
additional 21 h, the reaction mixture was recooled to 0 °C and water (40 mL) was added. The 
resultant mixture was stirred vigorously and allowed to warm to room temperature. All volatiles 
were subsequently removed in vacuo and the resultant solution was partitioned between Et2O (150 
mL) and water (60 mL). The layers were separated and the aqueous layers were further extracted 
with Et2O (3 × 50 mL). The organic layers were combined, washed with saturated aqueous NaHCO3 
solution (100 mL) and brine (100 mL), then dried over anhydrous MgSO4, filtered, and concentrated 
under reduced pressure to afford the corresponding alcohol S1 as a colorless oil, which was carried 
forward to the next step without further purification. 
A solution of alcohol S1, which was azeotropically dried with benzene (5 × 50 mL), in 
CH2Cl2 (193 mL) was cooled to 0 °C. DMSO (27.4 mL, 386 mmol, 10.0 equiv), i-Pr2NEt (33.6 mL, 
193 mmol, 5.00 equiv), and SO3•Py (18.4 g, 116 mmol, 3.00 equiv) were then added sequentially to 
the solution, which was then allowed to warm to room temperature. After stirring for 1 h, water (200 
mL) and Et2O (400 mL) were added to the reaction mixture. The layers were separated and the 
aqueous layer was extracted with Et2O (3 × 150 mL). The organic layers were combined and washed 
with 10% aqueous HCl solution (3 × 150 mL), saturated aqueous NaHCO3 solution (200 mL), and 
                                                                                                                                                 
137 Synthesized in one step from 3-methylglutaric anhydride. The enantiopurity of 107 was determined to be 
93% ee by chiral HPLC using authentic (±)-107.  
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brine (200 mL). The organic layers were dried over anhydrous MgSO4 and concentrated under 
reduced pressure to afford crude (R)-propyl 3-methyl-5-oxopentanoate 108 as a pale yellow oil, 
which was carried forward to the next step without further purification. 
 
1H NMR (500 MHz, CDCl3) δ: 9.76 (t, J = 2.2 Hz, 1H), 4.04 (t, J = 6.7 Hz, 2H), 2.64–2.48 (m, 2H), 
2.39–2.32 (m, 2H), 2.28 (dd, J = 7.1, 15.1 Hz, 1H), 1.65 (sxt, J = 7.1 Hz, 2H), 1.04 (d, J = 6.6 Hz, 
3H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 201.5, 172.3, 66.0, 50.1, 40.9, 25.2, 
21.9, 20.1, 10.4. FTIR (thin film) cm-1: 2966, 2880, 1724, 1460, 1263, 1213, 1170, 1088. HRMS 
(ESI) (m/z) calc’d for C9H16NaO3 [M+Na]+: 195.0992, found 195.0995. TLC (1:1 hexanes:EtOAc), 
Rf : 0.84 (KMnO4). 
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4-((Triisopropylsilyl)oxy)butan-2-one (S3):  
Imidazole (39.5 g, 581 mmol, 2.50 equiv) and TIPSCl (55.0 mL, 279 mmol, 1.10 equiv) 
were added successively to a solution of 4-hydroxy-2-butanone (S2) (20.0 mL, 232 mmol, 1.00 
equiv) in DMF (42 mL) at room temperature. The resultant solution was allowed to stir for 19.5 h, at 
which point water (150 mL), Et2O (100 mL), and EtOAc (100 mL) were added. The layers were 
separated and the aqueous layer was extracted with Et2O (3 × 200 mL). The organic layers were 
combined, washed with brine (300 mL), dried over anhydrous MgSO4, filtered, and concentrated 
under reduced pressure. The resulting oil was then purified by flash column chromatography (silica 
gel, eluent: 12:1 hexanes:EtOAc) to afford 4-(triisopropylsilyl)oxy)butan-2-one (S3) (56.8 g, quant.) 
as a clear colorless oil. 
 
1H NMR (500 MHz, CDCl3) δ: 3.98 (t, J = 6.3 Hz, 2H), 2.64 (t, J = 6.3 Hz, 2H), 2.20 (s, 3H), 1.12–
1.02 (m, 21 H). 13C NMR (126 MHz, CDCl3) δ: 208.3, 59.3, 46.7, 30.9, 17.9, 11.9. FTIR (thin film) 
cm-1: 2942, 2866, 1716, 1463, 1356, 1105, 882, 680. HRMS (ESI) (m/z) calc’d for C13H28NaO2Si 
[M+Na]+: 267.1751, found 267.1755. TLC (4:1 hexanes:EtOAc), Rf : 0.62 (KMnO4). 
  
O
MeHO
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Silyl enol ether 109:  
 To a solution of diisopropylamine (21.5 mL, 153 mmol, 1.50 equiv) in THF (255 mL) at 0 
°C was added dropwise a solution of n-butyllithium in hexanes (2.60 M, 57.0 mL, 148 mmol, 1.45 
equiv). After 10 min, the reaction was recooled to −78 °C and TMSCl (65.0 mL, 511 mmol, 5.00 
equiv) was added dropwise via syringe. After stirring the resultant mixture for 20 min, a solution of 
4-(triisopropylsilyl)oxy)butan-2-one (S3) (25.0 g, 102 mmol, 1.00 equiv) in THF (255 mL), which 
was azeotropically dried with benzene (5 × 50 mL), was added dropwise via cannula to the stirred 
reaction at –78 °C. After 15 min, Et3N (47.0 mL, 338 mmol, 3.30 equiv) was added dropwise via 
syringe to the reaction. The reaction was stirred for an additional 1.5 h at −78 °C, at which point a 
saturated aqueous NaHCO3 solution (400 mL) was added. The resultant mixture was allowed to 
warm to room temperature and Et2O (200 mL), EtOAc (200 mL), and water (100 mL) were 
subsequently added. The layers were separated and the aqueous layer was extracted with Et2O (3 × 
300 mL). The organic layers were combined, washed with brine (300 mL), dried over anhydrous 
MgSO4, filtered, and concentrated under reduced pressure to afford crude silyl enol ether 109 as a 
pale yellow oil and as a 2:1 mixture of regioisomers, favoring the indicated 109. The crude silyl enol 
ether was carried forward to the next step without further purification. 
  
O
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Lactam 110:  
Aldehyde 108 (800 mg, 4.65 mmol, 1.00 equiv), which was azeotropically dried with 
benzene (3 × 5 mL), was dissolved in a solution of NH3 in MeOH (2.00 M, 24.0 mL) and heated at 
50 °C for 8 h. The reaction mixture was subsequently concentrated under reduced pressure to afford 
a mixture of N,O-hydroxy- and N,O-methoxyacetals, and uncyclized (3R)-propyl 5-amino-5-
hydroxy-3-methylpentanoate. The crude product mixture was carried forward to the next step 
without further purification. 
p-TsOH•H2O (177 mg, 0.930 mmol, 0.20 equiv) was added as a single portion to a stirred 
solution of the crude product mixture in MeOH (46.5 mL), which was subsequently heated at 50 °C 
for 2 days, during which additional p-TsOH•H2O (40.0 mg, 0.210 mmol, 0.05 equiv) was added.  
The reaction was then allowed to cool to room temperature and a saturated aqueous NaHCO3 
solution (50 mL) was added. The mixture was subsequently concentrated under reduced pressure to 
remove all volatiles. The resultant aqueous layer was diluted with CHCl3 (100 mL), water (50 mL), 
and brine (50 mL), and the layers were separated. The aqueous layer was further extracted with 
CHCl3 (5 × 50 mL) and the organic layers were combined, washed with brine (100 mL), dried over 
anhydrous MgSO4, and concentrated under reduced pressure to afford a diastereomeric mixture of 
N,O-methoxyacetals 106 as a crude white solid, which was carried forward to the next step without 
further purification. 
BF3•OEt2 (922 µL, 7.47 mmol, 2.00 equiv) was added dropwise to a solution of crude 106 
and silyl enol ether 109 (7.10 g, 22.4 mmol, 6.00 equiv), which were azeotropically dried with 
benzene (5 × 15 mL), in MeCN (37.5 mL) at −40 °C. The reaction was allowed to warm gradually to 
room temperature. After 2.5 h, water (100 mL), Et2O (50 mL), and EtOAc (50 mL) were added to 
Me O
OnPr
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O
H
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O
MeMeO
1. NH3, MeOH
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the reaction mixture. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 
50 mL). The organic layers were combined, washed with brine (200 mL), dried over anhydrous 
MgSO4, and concentrated under reduced pressure. The resulting oil was then purified by flash 
column chromatography (silica gel, eluent: gradient: EtOAc → 15:1 EtOAc:MeOH) to afford lactam 
110 (709 mg, 43% over 3 steps) as a single diastereomer and as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 6.26 (s, 1H), 4.06–3.89 (m, 3H), 2.78 (dd, J = 9.5, 18.3 Hz, 1H), 
2.69 (dd, J = 3.2, 18.3 Hz, 1H), 2.66–2.51 (m, 2H), 2.41 (dd, J = 4.2, 17.8 Hz, 1H), 1.98 (dd, J = 8.3, 
16.8 Hz, 1H), 1.68–1.60 (m, 1H), 1.15–0.97 (m, 23H). 13C NMR (126 MHz, CDCl3) δ: 208.9, 171.3, 
59.3, 50.8, 46.1, 45.8, 39.3, 34.8, 24.3, 20.4, 17.9, 11.8. FTIR (thin film) cm-1: 2942, 2866, 1712, 
1662, 1462, 1364, 1101, 882, 681. HRMS (ESI) (m/z) calc’d for C19H37NNaO3Si [M+Na]+: 
378.2435, found 378.2448. [α]D22: –52 (c = 0.94, CH2Cl2). TLC (9:1 EtOAc:MeOH), Rf : 0.50 
(KMnO4,UV). 
1D NOESY (500 MHz, CDCl3): 
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O
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10! 8!
0.4% nOe
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Alcohol 111:  
Diisobutylaluminum hydride (3.80 mL, 21.3 mmol, 8.00 equiv) was added to a stirred 
solution of lactam 110 (945 mg, 2.66 mmol, 1.00 equiv), which was azeotropically dried with 
benzene (5 × 5 mL), in THF (53 mL) at −78 °C. After stirring the resultant reaction for 4 h at −78 °C, 
a saturated aqueous solution of Rochelle’s salt (200 mL) was carefully added at a slow rate. The 
resultant mixture was allowed to warm to room temperature and was subsequently diluted with Et2O 
(150 mL) and EtOAc (150 mL), and stirred vigorously for 12 h. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 150 mL). The organic layers were combined, washed 
with brine (200 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure to 
afford crude alcohol 111 as a single diastereomer and as a pale yellow oil, which was carried forward 
to the next step without further purification. 
 
1H NMR (600 MHz, CDCl3) δ: 76.83 (br. s, 1H), 4.10–3.97 (m, 3H), 3.93 (dt, J = 2.7, 10.3 Hz, 1H), 
3.77–3.68 (m, 1H), 2.43 (dd, J = 5.5, 17.2 Hz, 1H), 2.18–2.09 (m, 1H), 2.04 (dd, J = 5.5, 17.2 Hz, 
1H), 1.81–1.71 (m, 1H), 1.71–1.57 (m, 4H), 1.49 (d, J = 13.7 Hz, 1H), 1.17–1.01 (m, 24H). 13C 
NMR (126 MHz, CDCl3) δ: 171.2, 73.0, 63.6, 49.2, 44.0, 38.7, 38.6, 35.4, 24.6, 19.8, 17.9, 11.7. 
FTIR (thin film) cm-1: 2941, 2865, 1650, 1462, 1316, 1095, 882, 679. HRMS (ESI) (m/z) calc’d for 
C19H39NNaO3Si [M+Na]+: 380.2591, found 380.2588. TLC (9:1 EtOAc:MeOH), Rf : 0.42 (KMnO4). 
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Cyclic imide S5:  
A solution of n-butyllithium in hexanes (2.56 M, 15.5 µL, 0.0396 mmol, 2.50 equiv) was 
added to a stirred solution of alcohol S4 138  (5.0 mg, 0.016 mmol, 1.0 equiv), which was 
azeotropically dried with benzene (5 × 1 mL), in THF (200 µL) at −78 °C. After 20 min, the reaction 
was allowed to warm to 0 °C and stirred for an additional 10 min, at which point the solution was 
recooled to −78 °C. A solution of 1,1'-carbonyldiimidazole (9.0 mg, 0.055 mmol, 3.5 equiv) in THF 
(200 µL) was added to the stirred reaction mixture, which was subsequently allowed to warm 
gradually to room temperature over 30 min. A solution of saturated aqueous NH4Cl (1 mL) and 
EtOAc (1 mL) were added sequentially to the reaction mixture. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 1 mL). The organic layers were combined, washed 
with brine (2 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure. The 
resultant residue was purified by flash column chromatography (silica gel, eluent: 2:1 
EtOAc:hexanes) to afford cyclic imide S5 as a white solid. 
 
1H NMR (600 MHz, CDCl3) δ: 4.54–4.47 (m, 1H), 3.99 (tt, J = 4.4, 11.4 Hz, 1H), 3.85–3.78 (m, 
1H), 3.73 (td, J = 5.2, 10.3 Hz, 1H), 2.64 (dd, J = 5.1, 15.4 Hz, 1H), 2.34–2.26 (m, 1H), 2.19 (ddd, J 
= 2.0, 4.8, 14.0 Hz, 1H), 1.94–1.84 (m, 2H), 1.82–1.63 (m, 4H), 1.10 (d, J = 6.6 Hz, 3H), 0.88 (s, 
9H), 0.05 (s, 6H). 13C NMR (126 MHz, CDCl3) δ: 171.9, 148.1, 74.1, 58.2, 52.7, 42.1, 37.9, 37.3, 
35.1, 25.9, 24.3, 21.6, 18.2, –5.4, –5.4. FTIR (thin film) cm-1: 2957, 2927, 2855, 1762, 1313, 1101, 
837, 773. HRMS (ESI) (m/z) calc’d for C17H31NNaO4Si [M+Na]+: 364.1915, found 364.1931. TLC 
(9:1 EtOAc:MeOH), Rf : 0.68 (KMnO4, UV). 
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1D NOESY (500 MHz, CDCl3): 
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Silyl ether S6:  
Imidazole (905 mg, 13.3 mmol, 5.00 equiv) and TBSCl (962 mg, 6.38 mmol, 2.40 equiv) 
were added successively to a stirred solution of crude alcohol 111, which was azeotropically dried 
with benzene (3 × 3 mL), in DMF (26 mL) at room temperature. After 15.5 h, water (50 mL), Et2O 
(30 mL), and EtOAc (30 mL) were added. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine (100 mL), 
dried over anhydrous MgSO4, and concentrated under reduced pressure. The resulting oil was then 
purified by flash column chromatography (silica gel, eluent: EtOAc) to afford silyl ether S6 (1.23 g, 
98%) as a clear colorless oil. 
 
1H NMR (500 MHz, CDCl3) δ: 5.94 (br. s., 1H), 4.04–3.97 (m, 1H), 3.76–3.70 (m, 2H), 3.67–3.61 
(m, 1H), 2.42 (dd, J = 5.5, 17.2 Hz, 1H), 2.15–2.05 (m, 1H), 2.00 (dd, J = 7.1, 17.3 Hz, 1H), 1.86–
1.78 (m, 1H), 1.77–1.71 (m, 1H), 1.68–1.57 (m, 4H), 1.13–1.01 (m, 24H), 0.90 (s, 9H), 0.09 (s, 3H), 
0.08 (s, 3H). 13C NMR (126 MHz, C6D6) δ: 171.3, 68.4, 60.8, 47.8, 44.9, 41.6, 39.9, 35.5, 26.5, 24.9, 
20.6, 18.7, 18.6, 12.7, –3.7, –3.9. FTIR (thin film) cm-1: 3202, 3090, 2941, 2928, 2864, 1663, 1462, 
1252, 1100, 1070, 835, 774. HRMS (ESI) (m/z) calc’d for C25H53NNaO3Si2 [M+Na]+: 494.3456, 
found 494.3465. [α]D22: –4.2 (c = 1.4, CH2Cl2). TLC (EtOAc), Rf : 0.45 (KMnO4). 
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Imide 112:  
Boc2O (5.82 g, 25.9 mmol, 2.00 equiv) and 4-DMAP (1.90 g, 15.5 mmol, 1.20 equiv) were 
added successively to a solution of silyl ether S6 (6.10 g, 12.9 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (5 × 10 mL), in MeCN (120 mL) at room temperature. The 
resultant solution was stirred for 96 h, during which additional Boc2O (23.3 g, 103 mmol, 8.00 
equiv) and 4-DMAP (7.60 g, 62.0 mmol, 4.80 equiv) were added in four portions. Water (100 mL), 
Et2O (150 mL), and EtOAc (100 mL) were added to the reaction mixture. The layers were separated 
and the aqueous layer was extracted with EtOAc (3 × 100 mL). The organic layers were combined, 
washed with brine (200 mL), dried over anhydrous MgSO4, and concentrated under reduced 
pressure. The resulting oil was then purified by flash column chromatography (silica gel, eluent: 
gradient: 12:1 → 7:1 hexanes:EtOAc) to afford imide 112 (6.24 g, 84%) as a pale yellow oil. 
 
1H NMR (600 MHz, CDCl3) δ: 4.44–4.37 (m, 1H), 4.04–3.95 (m, 1H), 3.80–3.68 (m, 2H), 2.59 (dd, 
J = 3.9, 17.3 Hz, 1H), 2.17–2.09 (m, 1H), 2.08–1.97 (m, 2H), 1.87–1.72 (m, 3H), 1.64 (dt, J = 5.7, 
13.0 Hz, 1H), 1.53–1.49 (m, 10H), 1.14–1.01 (m, 21H), 0.98 (d, J = 6.3 Hz, 3H), 0.89 (s, 9H), 0.08 
(s, 3H), 0.06 (s, 3H). 13C NMR (126 MHz, C6D6) δ: 170.9, 154.9, 82.3, 67.9, 60.8, 52.9, 43.5, 41.3, 
41.1, 34.7, 28.5, 26.5, 24.6, 21.9, 18.7, 12.7, –3.8, –3.9. FTIR (thin film) cm-1: 2941, 2929, 2865, 
1715, 1367, 1291, 1249, 1158, 1100, 836, 775. HRMS (ESI) (m/z) calc’d for C30H61NNaO5Si2 
[M+Na]+: 594.3971, found 594.3980. TLC (12:1 hexanes:EtOAc), Rf : 0.58 (KMnO4). 
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N-Boc piperidine 114:  
Diisobutylaluminum hydride (887 µL, 4.97 mmol, 4.00 equiv) was added to a stirred 
solution of imide 112 (711 mg, 1.24 mmol, 1.00 equiv), which was azeotropically dried with 
benzene (5 × 5 mL), in THF (12.4 mL) at −78 °C. The reaction was allowed to warm gradually to 
room temperature over 2 h, at which point a saturated aqueous solution of Rochelle’s salt (50 mL) 
was carefully added at a slow rate. The resultant mixture was subsequently diluted with Et2O (50 
mL) and EtOAc (50 mL), and stirred vigorously for 5 h. The layers were separated and the aqueous 
layer was extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine 
(100 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure to afford crude 
N,O-hemiaminal 113 as a pale yellow flocculent solid and as a 1:1 mixture of diastereomers, which 
was carried forward to the next step without further purification. 
BF3•OEt2 (1.53 mL, 12.4 mmol, 10.0 equiv) was added dropwise to a solution of crude 113, 
which was azeotropically dried with benzene (5 × 5 mL), and Et3SiH (1.99 mL, 12.4 mmol, 10.0 
equiv) in CH2Cl2 (62 mL) at −78 °C. After 2 h, saturated aqueous NaHCO3 solution (50 mL), Et2O 
(50 mL), and EtOAc (50 mL) were added successively to the reaction. The resultant mixture was 
allowed to warm to room temperature. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine (100 mL), 
dried over anhydrous MgSO4, and concentrated under reduced pressure. The resulting oil was then 
purified by flash column chromatography (silica gel, eluent: gradient: 20:1 → 7:1 hexanes:EtOAc) to 
afford N-Boc piperidine 114 (522 mg, 75% over 2 steps) as a clear colorless oil. 
 
1H NMR (600 MHz, CDCl3, 50 °C) δ: 4.45–4.31 (m, 1H), 4.17–3.93 (m, 1H), 3.86–3.78 (m, 2H), 
3.77–3.70 (m, 1H), 2.78 (t, J = 13.6 Hz, 1H), 1.85–1.76 (m, 3H), 1.76–1.65 (m, 3H), 1.63–1.54 (m, 
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2H), 1.46 (s, 9H), 1.24–1.16 (m, 1H), 1.12–1.02 (m, 24H), 0.89 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 
13C NMR (126 MHz, C6D6, 70 °C) δ: 155.1, 79.3, 68.8, 61.5, 48.4, 41.0, 40.1, 39.1, 38.4, 35.0, 29.1, 
26.6, 26.2, 22.7, 18.7, 13.0, –3.7, –3.9. FTIR (thin film) cm-1: 2946, 2927, 2865, 1693, 1413, 1364, 
1251, 1164, 1095, 1070, 836, 773. HRMS (ESI) (m/z) calc’d for C30H63NNaO4Si2 [M+Na]+: 
580.4188, found 580.4165. [α]D22: –5.6 (c = 0.67, CH2Cl2). TLC (6:1 hexanes:EtOAc), Rf : 0.45 
(KMnO4). 
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Allyl N-Boc piperidine 116: 
A solution of sec-butyllithium in cyclohexane (1.45 M, 968 µL, 1.40 mmol, 1.50 equiv) was 
added to a stirred solution of N-Boc piperidine 114 (522 mg, 0.935 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (5 × 5 mL), and TMEDA (210 µL, 1.40 mmol 1.50 equiv) in Et2O 
(11 mL) at −78 °C. The reaction was stirred for 7 h at −78 °C.  
During this period, a separate 0.10 M stock solution of CuCN•2LiCl in THF was prepared 
according to the following protocol: CuCN (100 mg, 1.12 mmol, 1.00 equiv) and LiCl (94.6 mg, 
2.24 mmol, 2.00 equiv) in THF (11.1 mL) were stirred vigorously for 20 min at room temperature 
prior to use. 
After the 7 h deprotonation period of 114, a solution of CuCN•2LiCl in THF (0.10 M, 5.60 
mL, 0.60 equiv) was added slowly via syringe down the walls of the reaction vessel. The resultant 
reaction was stirred vigorously for 1 h, at which point allyl bromide (151 µL, 1.68 mmol, 1.80 equiv) 
was added dropwise via syringe to the reaction mixture, which immediately turned bright yellow. 
After stirring for 1 h at −78 °C, the reaction was gradually allowed to warm to room temperature 
over 3 h. After stirring for an additional 1 h at room temperature, the reaction was cooled to 0 °C and 
an aqueous solution of 5 M NH4OH (3 mL) was added. The resultant mixture was allowed to warm 
to room temperature and was stirred vigorously for 30 min, at which point the mixture was filtered 
through Celite. The Celite filter cake was washed with Et2O (50 mL) and water (10 mL). The layers 
were separated and the aqueous layer was extracted with Et2O (3 × 50 mL). The organic layers were 
combined, washed with water (100 mL), then brine (100 mL), and dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The resulting oil was then purified by flash column 
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chromatography (silica gel, eluent: gradient: 30:1 → 7:1 → 4:1 hexanes:EtOAc) to afford allyl N-
Boc piperidine 116 (277 mg, 50%, 97% brsm) as a single diastereomer as a clear colorless oil.  
 
1H NMR (600 MHz, C6D6) δ: 6.00–5.91 (m, 1H), 5.17 (d, J = 17.1 Hz, 1H), 5.09 (d, J = 10.3 Hz, 
1H), 4.51–4.42 (m, 1H), 4.08–4.02 (m, 1H), 3.98–3.92 (m, 1H), 3.87 (td, J = 6.5, 9.6 Hz, 1H), 3.43–
3.31 (m, 1H), 3.09–2.96 (m, 1H), 2.53–2.39 (m, 1H), 2.13 (ddd, J = 5.4, 8.3, 13.9 Hz, 1H), 2.04–1.88 
(m, 2H), 1.75–1.63 (m, 2H), 1.61–1.52 (m, 1H), 1.49 (s, 9H), 1.31–1.22 (m, 2H), 1.19 (d, J = 13.2 
Hz, 1H), 1.17–1.09 (m, 21H), 1.04 (s, 9H), 0.79 (d, J = 6.6 Hz, 3H), 0.18 (s, 3H), 0.18 (s, 3H). 13C 
NMR (126 MHz, C6D6) δ: 156.1, 137.6, 116.86, 79.3, 68.1, 61.2, 54.3, 51.0, 40.5, 40.3, 39.5, 37.1, 
36.9, 28.9, 26.6, 26.5, 23.0, 18.7, 18.6, 12.7, –3.6, –4.0. FTIR (thin film) cm-1: 2927, 2865, 1702, 
1365, 1251, 1171, 1097, 836, 774. HRMS (ESI) (m/z) calc’d for C33H67NNaO4Si2 [M+Na]+: 
620.4501, found 620.4526. TLC (6:1 hexanes:EtOAc), Rf : 0.71 (KMnO4). 
1D NOESY (500 MHz, C6D6): 
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Diol S7: 
A solution of TBAF in THF (1.00 M, 8.10 mL, 8.06 mmol, 6.00 equiv) was added to a 
solution of allyl N-Boc piperidine 116 (803 mg, 1.34 mmol, 1.00 equiv) in THF (13.4 mL) at 0 °C. 
After 5 min, the reaction was allowed to warm to room temperature and was stirred for an additional 
3.5 h, at which point saturated aqueous NH4Cl solution (25 mL), water (10 mL), Et2O (20 mL), and 
EtOAc (20 mL) were added successively. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 20 mL). The organic layers were combined, washed with brine (50 mL), 
then dried over anhydrous MgSO4 and concentrated under reduced pressure. The resultant oil was 
purified by flash column chromatography (silica gel, eluent: gradient: 2:1 EtOAc:hexanes → EtOAc) 
to afford diol S7 (439 mg, quant.) as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 5.80–5.70 (m, 1H), 5.12–5.02 (m, 2H), 4.16–4.09 (m, 1H), 4.07 (br. 
s., 1H), 3.92 (tt, J = 3.8, 8.2 Hz, 2H), 3.83 (t, J = 5.5 Hz, 2H), 3.56 (dt, J = 5.9, 9.9 Hz, 1H), 3.00 (br. 
s., 1H), 2.59 (td, J = 6.0, 13.5 Hz, 1H), 2.30 (td, J = 8.5, 13.7 Hz, 1H), 1.90 (td, J = 6.4, 12.4 Hz, 
1H), 1.87–1.77 (m, 2H), 1.73–1.63 (m, 4H), 1.51–1.43 (m, 10H), 1.33 (td, J = 6.1, 13.9 Hz, 1H), 
1.01 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 156.3, 135.8, 117.1, 110.7, 80.2, 71.4, 
61.8, 52.8, 51.2, 41.9, 40.2, 38.7, 35.8, 33.0, 28.5, 23.2. FTIR (thin film) cm-1: 3401, 2950, 2928, 
2871, 1661, 1399, 1365, 1168, 1115, 1069. HRMS (ESI) (m/z) calc’d for C18H33KNO4 [M+K]+: 
366.2041, found 366.2056. [α]D22: –4.4 (c = 0.50, CH2Cl2). TLC (2:1 EtOAc:hexanes), Rf : 0.14 
(KMnO4). 
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Silyl ether 145: 
Et3N (220 µL, 1.57 mmol, 1.20 equiv), TBSCl (217 mg, 1.44 mmol, 1.10 equiv), and 4-
DMAP (16.0 mg, 0.131 mmol, 0.10 equiv) were added sequentially to a stirred solution of diol S7 
(428 mg, 1.31 mmol, 1.00 equiv), which was azeotropically dried with benzene (5 × 1.5 mL), in 
CH2Cl2 (13 mL) at room temperature. After 17 h, saturated aqueous NH4Cl solution (15 mL) was 
added and the resultant mixture was diluted with EtOAc (15 mL), Et2O (20 mL), and water (10 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (3 × 20 mL). The organic 
layers were combined, washed with brine (50 mL), dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The resulting crude residue was then purified by flash column 
chromatography (silica gel, eluent: gradient: 12:1 → 6:1 hexanes:EtOAc) to afford silyl ether 145 
(560 mg, 97%) as a clear colorless oil. 
 
1H NMR (500 MHz, CDCl3) δ: 5.82–5.71 (m, 1H), 5.07 (d, J = 16.8 Hz, 1H), 5.02 (d, J = 10.0 Hz, 
1H), 4.23–4.16 (m, 1H), 3.91–3.75 (m, 3H), 3.64 (br. s., 1H), 3.50–3.42 (m, 1H), 2.70–2.60 (m, 1H), 
2.37–2.27 (m, 1H), 1.95–1.88 (m, 1H), 1.88–1.81 (m, 1H), 1.78–1.55 (m, 5H), 1.49–1.41 (m, 9H), 
1.39–1.31 (m, 1H), 1.24 (td, J = 7.7, 13.9 Hz, 1H), 0.96 (d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 
6H). 13C NMR (126 MHz, CDCl3) δ: 155.9, 136.3, 116.7, 79.5, 69.4, 62.1, 52.9, 50.6, 39.9, 39.9, 
38.5, 35.9, 34.5, 28.5, 25.9, 24.5, 22.9, 18.2, –5.5, –5.5. FTIR (thin film) cm-1: 3419, 2952, 2928, 
2857, 1686, 1662, 1392, 1365, 1251, 1171, 1090, 836, 775. HRMS (ESI) (m/z) calc’d for 
C24H47NNaO4Si [M+Na]+: 464.3167, found 464.3195. [α]D23: –2.2 (c = 0.72, CH2Cl2). TLC (2:1 
EtOAc: hexanes), Rf : 0.82 (KMnO4). 
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Azide 146: 
Triphenylphosphine (1.32 g, 5.02 mmol, 4.00 equiv), diethyl azodicarboxylate (806 µL, 5.02 
mmol, 4.00 equiv), and diphenyl phosphoryl azide (1.11 mL, 5.02 mmol, 4.00 equiv) were added 
sequentially to a stirred solution of silyl ether 145 (554 mg, 1.25 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (5 × 1 mL), in THF (20 mL) at room temperature. After 1 h, the 
reaction was concentrated under reduced pressure. The resultant residue was then purified by flash 
column chromatography (silica gel, eluent: 16:1 hexanes:EtOAc) to afford alkyl azide 146 (479 mg, 
82%) as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 5.82–5.72 (m, 1H), 5.08 (qd, J = 1.6, 17.1 Hz, 1H), 5.02 (td, J = 1.0, 
10.2 Hz, 1H), 4.26–4.15 (m, 1H), 3.79–3.69 (m, 2H), 3.59–3.51 (m, 1H), 3.38–3.31 (m, 1H), 2.71 
(td, J = 6.6, 13.5 Hz, 1H), 2.39–2.29 (m, 1H), 2.03 (ddd, J = 3.8, 9.8, 14.0 Hz, 1H), 1.82–1.73 (m, 
2H), 1.72–1.61 (m, 3H), 1.52–1.43 (m, 10H), 1.34–1.15 (m, 2H), 0.94 (d, J = 6.6 Hz, 3H), 0.89 (s, 
9H), 0.06 (s, 3H), 0.06 (s, 3H). 13C NMR (126 MHz, CDCl3) δ: 155.9, 136.4, 116.5, 79.5, 59.5, 57.7, 
53.5, 50.8, 39.4, 38.2, 36.8, 36.2, 35.7, 28.5, 25.9, 25.8, 22.5, 18.3, –5.4, –5.5. FTIR (thin film) cm-1: 
2953, 2928, 2857, 2104, 1694, 1365, 1322, 1252, 1167, 1109, 835, 776. HRMS (ESI) (m/z) calc’d 
for C24H47N4O3Si [M+H]+: 467.3412, found 467.3417. [α]D23: –13 (c = 0.39, CH2Cl2). TLC (12:1 
hexanes:EtOAc), Rf : 0.69 (KMnO4). 
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Alcohol S8: 
A solution of TBAF in THF (1.00 M, 2.00 mL, 2.02 mmol, 2.00 equiv) was added to a 
solution of alkyl azide 146 (472 mg, 1.01 mmol, 1.00 equiv) in THF (20 mL) at 0 °C. After 5 min, 
the reaction was allowed to warm to room temperature and was stirred for an additional 1 h, at which 
point saturated aqueous NH4Cl solution (10 mL), water (10 mL), Et2O (15 mL), and EtOAc (15 mL) 
were added successively. The layers were separated and the aqueous layer was extracted with EtOAc 
(3 × 15 mL). The organic layers were combined, washed with brine (30 mL), then dried over 
anhydrous MgSO4 and concentrated under reduced pressure. The resultant oil was purified by flash 
column chromatography (silica gel, eluent: gradient: 4:1 → 2:1 hexanes:EtOAc) to afford alcohol S8 
(340 mg, 96%) as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 5.79 (tdd, J = 7.1, 10.1, 17.2 Hz, 1H), 5.08 (dd, J = 1.3, 17.2 Hz, 
1H), 5.03 (td, J = 1.0, 10.3 Hz, 1H), 3.97 (dd, J = 4.9, 8.8 Hz, 1H), 3.84–3.73 (m, 2H), 3.62–3.50 (m, 
2H), 2.61 (td, J = 6.8, 13.5 Hz, 1H), 2.32–2.22 (m, 2H), 1.93–1.84 (m, 1H), 1.79–1.66 (m, 4H), 
1.48–1.39 (m, 10H), 1.31–1.22 (m, 1H), 1.19 (td, J = 9.4, 13.2 Hz, 1H), 0.95 (d, J = 6.1 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ: 156.1, 136.2, 116.6, 79.7, 59.4, 57.8, 54.1, 50.0, 39.3, 37.1, 36.5, 36.1, 
35.5, 28.5, 25.7, 22.3. FTIR (thin film) cm-1: 3432, 2951, 2929, 2873, 2102, 1685, 1366, 1323, 1253, 
1166, 1117. HRMS (ESI) (m/z) calc’d for C18H33N4O3 [M+H]+: 353.2547, found 353.2549. [α]D23: –
2.0 (c = 0.59, CH2Cl2). TLC (2:1 hexanes:EtOAc), Rf : 0.22 (KMnO4). 
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Alkyl iodide 147: 
Triphenylphosphine (671 mg, 2.56 mmol, 2.70 equiv) and iodine (722 mg, 2.84 mmol, 3.00 
equiv) were added sequentially as single portions to a stirred solution of imidazole (387 mg, 5.69 
mmol, 6.00 equiv) in CH2Cl2 (9.5 mL). After 20 min, a solution of alcohol S8 (334 mg, 0.948 mmol, 
1.00 equiv), which was azeotropically dried with benzene (5 × 1 mL), in CH2Cl2 (9.5 mL) was added 
dropwise via syringe to the reaction mixture. After 30 min, saturated aqueous Na2S2O3 solution (20 
mL), EtOAc (15 mL), and Et2O (15 mL) were added sequentially to the reaction. The layers were 
separated and the aqueous layer was extracted with EtOAc (3 × 15 mL). The organic layers were 
combined, washed with brine (50 mL), dried over anhydrous MgSO4, and concentrated under 
reduced pressure. The resulting residue was then purified by flash column chromatography (silica 
gel, eluent: 12:1 hexanes:EtOAc) to afford alkyl iodide 147 (419 mg, 96%) as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 5.81 (dddd, J = 6.2, 8.0, 10.3, 16.9 Hz, 1H), 5.10 (qd, J = 1.5, 17.2 
Hz, 1H), 5.05 (td, J = 1.1, 10.1 Hz, 1H), 4.24–4.16 (m, 1H), 3.51 (tt, J = 4.2, 9.1 Hz, 1H), 3.38–3.32 
(m, 1H), 3.32–3.19 (m, 2H), 2.74 (td, J = 6.5, 13.6 Hz, 1H), 2.37–2.26 (m, 1H), 2.09–1.92 (m, 3H), 
1.82–1.73 (m, 1H), 1.72–1.67 (m, 1H), 1.63 (td, J = 4.5, 13.6 Hz, 1H), 1.55–1.49 (m, 1H), 1.47 (s, 
9H), 1.31 (ddd, J = 5.5, 11.7, 13.6 Hz, 1H), 1.26–1.17 (m, 1H), 0.95 (d, J = 6.6 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ: 155.9, 136.4, 116.8, 79.7, 60.8, 53.7, 50.5, 39.4, 39.0, 36.2, 36.0, 35.7, 28.5, 
25.8, 22.5, 1.7. FTIR (thin film) cm-1: 2952, 2927, 2118, 2100, 1690, 1365, 1322, 1252, 1167, 1111. 
HRMS (ESI) (m/z) calc’d for C18H31IN4NaO2 [M+Na]+: 485.1384, found 485.1388. TLC (1:1 
hexanes:EtOAc), Rf : 0.68 (KMnO4, UV). 
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Alkylated imide 148: 
A solution of alkyl iodide 147 (419 mg, 0.906 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (5 × 1 mL), in DMF (5 mL) was added dropwise to a stirred solution of β-
carboxyimide 6693 (584 mg, 1.18 mmol, 1.30 equiv) and Cs2CO3 (886 mg, 2.72 mmol, 3.00 equiv) in 
DMF (4 mL). After 12.5 h, Et2O (20 mL) and saturated aqueous NH4Cl solution (15 mL) were added 
sequentially to the reaction mixture. The layers were separated and the aqueous layer was extracted 
with EtOAc (3 × 10 mL). The organic layers were combined and washed with brine (20 mL), dried 
over anhydrous MgSO4, and concentrated under reduced pressure. The resultant residue was purified 
by flash column chromatography (silica gel, eluent: gradient: 9:1 → 7:1 → 4:1 hexanes:EtOAc, 1% 
Et3N) to afford alkylated imide 148 (708 mg, 94%) as a white flocculent solid. 
 
1H NMR (500 MHz, C6D6) δ: 6.05–5.93 (m, 1H), 5.60 (d, J = 3.9 Hz, 1H), 5.23 (d, J = 18.3 Hz, 1H), 
5.14 (d, J = 10.3 Hz, 1H), 4.44–4.36 (m, 1H), 4.28–4.19 (m, 1H), 4.18–4.09 (m, 1H), 4.09–4.01 (m, 
1H), 3.84–3.74 (m, 3H), 3.73–3.68 (m, 1H), 3.57–3.48 (m, 2H), 3.06 (br. s., 2H), 2.89–2.76 (m, 2H), 
2.51–2.41 (m, 1H), 2.32 (dt, J = 4.4, 13.2 Hz, 1H), 2.26–2.18 (m, 1H), 2.06–1.88 (m, 4H), 1.84–1.72 
(m, 3H), 1.49 (s, 9H), 1.44 (s, 9H), 1.40–1.25 (m, 5H), 1.24–1.04 (m, 3H), 0.89–0.84 (m, 2H), 0.80 
(d, J = 6.6 Hz, 3H), 0.71 (d, J = 6.3 Hz, 3H), –0.17 (s, 9H). 13C NMR (126 MHz, C6D6) δ: 171.4, 
170.5, 156.3, 151.6, 137.7, 134.9, 132.3, 117.1, 108.8, 83.1, 79.5, 65.8, 64.5, 64.2, 62.2, 61.4, 54.5, 
51.6, 50.6, 42.5, 39.8, 38.4, 37.3, 37.1, 36.6, 34.6, 31.2, 30.8, 29.8, 28.9, 28.4, 28.1, 26.8, 22.8, 21.9, 
18.1, –1.4. FTIR (thin film) cm-1: 2952, 2106, 1719, 1701, 1367, 1314, 1251, 1171, 839. HRMS 
(ESI) (m/z) calc’d for C43H71N5NaO9Si [M+Na]+: 852.4918, found 852.4913. TLC (4:1 
hexanes:EtOAc), Rf : 0.65 (Anis, KMnO4, UV).  
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N-Boc-2-pyrrolidinone 149: 
A solution of TBAF in THF (1.00 M, 843 µL, 0.843 mmol, 1.00 equiv) was added to a 
solution of alkylated imide 148 (700 mg, 0.843 mmol, 1.00 equiv) and DBU (32.0 µL, 0.211 mmol, 
0.25 equiv) in THF (17 mL) at room temperature. After 5 min, the reaction was heated to 50 °C and 
was stirred for 16 h, at which point water (20 mL), Et2O (15 mL), and EtOAc (15 mL) were added 
successively. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 15 
mL). The organic layers were combined, washed with brine (30 mL), then dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The resultant residue was purified by flash column 
chromatography (silica gel, eluent: gradient: 8:1 → 6:1 → 4:1 → 2:1 hexanes:EtOAc, 1% Et3N) to 
afford N-Boc-2-pyrrolidinone 149 (562 mg, 97%) as a white flocculent solid. 
 
1H NMR (500 MHz, C6D6) δ: 6.05–5.88 (m, 1H), 5.44 (d, J = 3.4 Hz, 1H), 5.20 (d, J = 17.1 Hz, 1H), 
5.12 (dd, J = 2.0, 10.3 Hz, 1H), 4.42–4.36 (m, J = 4.6 Hz, 1H), 3.97–3.88 (m, 1H), 3.68–3.53 (m, 
4H), 3.51–3.39 (m, 3H), 3.05 (dd, J = 8.8, 10.7 Hz, 3H), 2.36 (dd, J = 4.5, 13.8 Hz, 1H), 2.29–2.22 
(m, 1H), 2.20–2.12 (m, 1H), 1.98–1.89 (m, 2H), 1.88–1.81 (m, 1H), 1.81–1.68 (m, 5H), 1.49 (s, 9H), 
1.47 (s, 9H), 1.45–1.27 (m, 5H), 1.27–1.04 (m, 3H), 0.82 (d, J = 6.6 Hz, 3H), 0.73 (d, J = 6.3 Hz, 
3H). 13C NMR (126 MHz, C6D6) δ: 174.2, 156.3, 151.6, 137.8, 135.7, 131.3, 117.0, 108.7, 82.4, 
79.5, 65.8, 64.4, 61.5, 54.4, 51.6, 50.7, 49.5, 42.6, 39.9, 37.2, 37.2, 36.6, 35.8, 35.0, 34.6, 32.6, 28.9, 
28.5, 28.1, 26.8, 26.1, 22.8, 22.0. FTIR (thin film) cm-1: 2950, 2925, 2074, 1784, 1712, 1367, 1316, 
1160. HRMS (ESI) (m/z) calc’d for C37H59N5NaO7 [M+Na]+: 708.4307, found 708.4306. TLC (1:1 
hexanes:EtOAc), Rf : 0.61 (Anis, KMnO4, UV). 
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N-2-Nitrobenzenesulfonyl-2-pyrrolidinone 151: 
Mg(ClO4)2 (36.5 mg, 0.164 mmol, 0.20 equiv) was added as a single portion to a stirred 
solution of N-Boc-2-pyrrolidinone 149 (561 mg, 0.818 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (5 × 1 mL), in MeCN (13.6 mL) at room temperature. The resultant mixture was 
heated to 60 °C and stirred for 2 h, at which point it was cooled to room temperature and Et2O (25 
mL) and saturated aqueous NH4Cl solution (15 mL) were added sequentially. The layers were 
separated and the aqueous layer was extracted with EtOAc (3 × 15 mL). The organic layers were 
combined, washed with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under 
reduced pressure to afford crude 2-pyrrolidinone 150 as a white flocculent solid, which was carried 
forward to the next step without further purification. 
A freshly prepared solution of LiHMDS in THF (1.00 M, 982 µL, 0.982 mmol, 1.20 equiv) 
was added dropwise to a solution of 150, which was azeotropically dried with benzene (5 × 1 mL), in 
THF (4.25 mL) at room temperature. After 1 h, the reaction was cooled to 0 °C and a solution of 
NsCl in THF (1.00 M, 1.06 mL, 1.06 mmol, 1.30 equiv) was added. After 5 min, the reaction was 
warmed to room temperature and stirred for 1 h. Saturated aqueous NH4Cl solution (10 mL), and 
then Et2O (10 mL), were added. The layers were separated and the aqueous layer was extracted with 
EtOAc (3 × 10 mL). The organic layers were combined, washed with brine (20 mL), dried over 
anhydrous MgSO4, and concentrated in vacuo. The residue was purified by flash column 
chromatography (silica gel, eluent: gradient: 7:1 → 4:1 → 2:1 hexanes:EtOAc, 1% Et3N) to afford 
N-2-nitrobenzenesulfonyl-2-pyrrolidinone 151 (566 mg, 90% over 2 steps) as a white flocculent 
solid. 
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1H NMR (500 MHz, C6D6) δ: 8.45 (dd, J = 1.3, 7.9 Hz, 1H), 6.76–6.71 (m, 1H), 6.66–6.60 (m, 1H), 
6.49–6.41 (m, 1H), 5.99–5.84 (m, 1H), 5.52 (d, J = 3.7 Hz, 1H), 5.14 (d, J = 17.1 Hz, 1H), 5.07 (dd, 
J = 2.0, 10.0 Hz, 1H), 4.33–4.23 (m, 2H), 3.69 (dd, J = 4.5, 7.4 Hz, 1H), 3.66 (d, J = 6.8 Hz, 2H), 
3.56–3.46 (m, 2H), 3.40–3.31 (m, 1H), 3.07–2.96 (m, 1H), 2.55–2.43 (m, 1H), 2.36 (dd, J = 5.7, 14.0 
Hz, 1H), 2.25–2.14 (m, 1H), 1.98–1.79 (m, 4H), 1.78–1.63 (m, 3H), 1.60–1.50 (m, 1H), 1.47–1.42 
(m, 11H), 1.40–1.23 (m, 6H), 1.18–1.02 (m, 3H), 0.82 (d, J = 6.6 Hz, 3H), 0.71 (d, J = 6.3 Hz, 3H). 
13C NMR (126 MHz, C6D6) δ: 175.6, 156.3, 148.7, 137.7, 135.2, 135.0, 134.6, 132.5, 132.1, 131.7, 
124.1, 116.9, 108.7, 79.6, 65.7, 64.5, 61.2, 54.4, 51.6, 51.5, 48.9, 42.5, 39.9, 37.8, 37.1, 36.5, 34.9, 
34.5, 32.5, 29.0, 28.0, 26.7, 25.8, 22.7, 21.9. FTIR (thin film) cm-1: 2952, 2926, 2102, 1737, 1691, 
1545, 1366, 1174, 1128, 594. HRMS (ESI) (m/z) calc’d for C38H55N6O9S [M+H]+: 771.3746, found 
771.3738. TLC (2:1 hexanes:EtOAc), Rf : 0.39 (Anis, KMnO4, UV). 
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Enone 153: 
A solution of n-butyllithium in hexanes (2.53 M, 869 µL, 2.20 mmol, 3.00 equiv) was added 
dropwise to a stirred solution of diisopropylamine (339 µL, 2.42 mmol, 3.30 equiv) in THF (4.2 mL) 
at −78 °C. The reaction was stirred for 10 min, at which point it was warmed to 0 °C. After 10 min, 
the reaction was warmed to room temperature. The solution was recooled to −78 °C after 5 min. t-
Butylacetate (295 µL, 2.20 mmol, 3.00 equiv) was then added dropwise to the reaction mixture. 
After 1 h, a solution of 151 (565 mg, 0.733 mmol, 1.00 equiv), which was azeotropically dried with 
benzene (5 × 2 mL), in THF (9.3 mL) was added dropwise down the walls of the reaction vessel. 
After stirring at −78 °C for 1.5 h, saturated aqueous NH4Cl solution (15 mL) was added to the deep 
red reaction mixture at −78 °C. The resultant mixture was then allowed to warm to room 
temperature. Et2O (15 mL) and EtOAc (15 mL) were added and the layers were separated. The 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed 
with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford crude β-ketoester 152 as a white flocculent solid, which was carried forward to the next step 
without further purification. 
p-TsOH•H2O (70.0 mg, 0.366 mmol, 0.50 equiv) was added as a single portion to a stirred 
solution of crude 152 in THF (13 mL) and water (1.6 mL) at room temperature. After 3 h, a saturated 
aqueous NaHCO3 solution (20 mL) was added, followed by Et2O (10 mL), EtOAc (10 mL), and 
water (5 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 × 10 
mL). The organic layers were combined, washed with brine (30 mL), then dried over anhydrous 
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MgSO4 and concentrated under reduced pressure to afford crude enone 153 as a white flocculent 
solid, which was carried forward to the next step without further purification. 
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Imine 156: 
2-t-Butyl-1,1,3,3-tetramethylguanidine (591 µL, 2.90 mmol, 5.00 equiv) was added 
dropwise to a solution of crude enone 153, which was azeotropically dried with benzene (5 × 2 mL), 
in MeCN (29 mL) at 0 °C. After 15 min, the reaction mixture was warmed to room temperature and 
stirred for 18 h, at which point K2CO3 (401 mg, 2.90 mmol, 5.00 equiv) was added as a single 
portion. The suspension was then cooled to 0 °C and PhSH (298 µL, 2.90 mmol, 5.00 equiv) was 
added dropwise via syringe. After 10 min, the reaction was warmed to room temperature and stirred 
for an additional 4.5 h, at which point water (100 mL), Et2O (100 mL), and EtOAc (100 mL) were 
added sequentially. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 
50 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous 
MgSO4, and concentrated under reduced pressure. The crude residue was then purified by flash 
column chromatography (silica gel, eluent: gradient: 2:1 → 1:1 → 0:1 hexanes:EtOAc, 1% Et3N) to 
afford imine 156 (312 mg, 84% over 3 steps) as a pale yellow flocculent solid. 
 
1H NMR (500 MHz, C6D6) δ: 6.06–5.89 (m, 1H), 5.17 (d, J = 16.6 Hz, 1H), 5.08 (d, J = 9.8 Hz, 1H), 
4.37–4.25 (m, 1H), 4.03 (d, J = 18.3 Hz, 1H), 3.57–3.52 (m, J = 7.8 Hz, 1H), 3.49 (d, J = 3.2 Hz, 
1H), 3.23 (d, J = 19.5 Hz, 1H), 3.20–3.14 (m, 1H), 3.09–2.97 (m, J = 5.9 Hz, 1H), 2.87 (br. s., 1H), 
2.64–2.56 (m, 1H), 2.51 (d, J = 12.0 Hz, 1H), 2.34–2.20 (m, 2H), 2.05 (t, J = 11.8 Hz, 1H), 1.95 (br. 
s., 1H), 1.86 (br. s., 1H), 1.82–1.71 (m, 2H), 1.66 (br. s., 1H), 1.58–1.50 (m, 4H), 1.48 (s, 9H), 1.46–
1.40 (m, J = 12.2 Hz, 2H), 1.37 (s, 9H), 1.36–1.32 (m, 3H), 1.19–1.02 (m, 3H), 0.73 (d, J = 6.1 Hz, 
3H), 0.62 (d, J = 6.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 205.1, 170.5, 169.0, 156.3, 137.7, 
116.9, 82.2, 79.5, 66.2, 61.4, 55.3, 54.6, 51.5, 49.2, 48.4, 43.4, 39.9, 39.0, 38.3, 37.3, 37.1, 36.1, 
153
Me
NHNs
O
O
tBuO
N3BocN
Me
H H
O
Me
N
CO2tBu
O N3 BocN
H
Me
H
N
NMe2Me2N
t-Bu
MeCN
0 °C → RT;
K2CO3, PhSH
0 °C → RT
(84%, 3 steps)
156
 190 
34.4, 33.1, 30.2, 29.8, 28.9, 28.3, 26.9, 26.7, 22.7, 22.6. FTIR (thin film) cm-1: 2951, 2926, 2101, 
1699, 1455, 1366, 1253, 1154. HRMS (ESI) (m/z) calc’d for C36H58N5O5 [M+H]+: 640.4432, found 
640.4418. TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.38 (KMnO4, UV). 
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Vinylogous Urethane 157: 
 Triphenylphosphine (84.0 mg, 0.321 mmol, 1.50 equiv) was added as a single portion to a 
stirred solution of imine 156 (137 mg, 0.214 mmol, 1.00 equiv) in THF (6.2 mL) and water (780 µL) 
at room temperature. The reaction was heated to 70 °C and stirred for 23 h, at which point the 
reaction was cooled to room temperature and concentrated. The resultant residue was azeotropically 
dried with MeOH (5 × 3 mL), then benzene (3 × 3 mL), and stirred with silica gel (200 mg) in 
CH2Cl2 (5 mL) for 2 h. The slurry was subsequently filtered and washed with 90:9:1 
CHCl3:MeOH:NH4OH (10 × 5 mL) and concentrated in vacuo. The crude residue was then purified 
by flash column chromatography (silica gel, eluent: gradient: 1:1 → 0:1 hexanes:EtOAc, 1% Et3N → 
90:9:1 CHCl3:MeOH:NH4OH) to afford vinylogous urethane 157 (95.4 mg, 75%) as a pale yellow 
flocculent solid. 
 
1H NMR (500 MHz, C6D6) δ: 9.73 (s, 1 H), 6.03–5.83 (m, 1H), 5.17 (d, J = 16.1 Hz, 1H), 5.07 (d, J 
= 12.5 Hz, 1H), 4.21–4.07 (m, 1H), 3.59–3.48 (m, 1H), 3.31–3.22 (m, J = 6.2, 11.8 Hz, 1H), 2.95 (d, 
J = 3.7 Hz, 1H), 2.90 (dd, J = 6.6, 12.5 Hz, 1H), 2.76 (d, J = 7.8 Hz, 1H), 2.48–2.36 (m, 1H), 2.17 
(br. s., 1H), 2.08–2.01 (m, 2H), 2.01–1.90 (m, 1H), 1.88–1.81 (m, J = 6.1 Hz, 1H), 1.80–1.73 (m, 
1H), 1.71–1.61 (m, J = 8.5 Hz, 2H), 1.57–1.52 (m, J = 6.3 Hz, 2H), 1.51 (s, 9H), 1.47 (s, 9H), 1.40–
1.29 (m, 4H), 1.21 (t, J = 13.9 Hz, 1H), 1.16–1.07 (m, J = 10.3 Hz, 3H), 1.07–0.98 (m, 2H), 0.95 (d, 
J = 6.1 Hz, 3H), 0.79 (d, J = 5.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 170.9, 162.8, 156.2, 
137.6, 116.7, 90.5, 79.3, 78.0, 63.9, 54.2, 51.7, 51.3, 50.4, 50.3, 47.6, 47.0, 41.4, 40.5, 40.5, 39.9, 
38.1, 36.3, 35.7, 34.0, 29.2, 29.0, 27.9, 25.6, 25.5, 23.1, 23.1, 21.5. FTIR (thin film) cm-1: 2948, 
2926, 2868, 1686, 1635, 1594, 1453, 1364, 1249, 1155, 1114. HRMS (ESI) (m/z) calc’d for 
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C36H58N3O4 [M+H]+: 596.4422, found 596.4416. [α]D23: –69 (c = 0.55, CH2Cl2). TLC (90:9:1 
CHCl3:MeOH:NH4OH), Rf : 0.20 (KMnO4, UV). 
  
 193 
 
Amide 158: 
Acetic anhydride (562 µL, 5.95 mmol, 20.0 equiv) was added dropwise to a stirred solution 
of vinylogous urethane 157 (177 mg, 0.297 mmol, 1.00 equiv), which was azeotropically dried with 
benzene (5 × 3 mL), and Et3N (830 µL, 5.95 mmol, 20.0 equiv) in CH2Cl2 (6 mL) at room 
temperature. After stirring for 30 h, the reaction was concentrated under reduced pressure. The 
resultant residue was then directly purified by flash column chromatography (silica gel, eluent: 
gradient: 2:1 → 1:1 → 0:1 hexanes:EtOAc) to afford amide 158 (158 mg, 83%) as a white flocculent 
solid. 
 
1H NMR (600 MHz, C6D6) δ: 9.58 (s, 1H), 5.97–5.86 (m, 1H), 5.17 (d, J = 17.0 Hz, 1H), 5.08 (d, J 
= 10.3 Hz, 1H), 4.21–4.09 (m, J = 5.0 Hz, 1H), 3.66 (t, J = 13.1 Hz, 1H), 3.60–3.49 (m, 1H), 3.28–
3.16 (m, 1H), 3.00 (br. s., 1H), 2.93–2.81 (m, 2H), 2.70–2.59 (m, 1H), 2.46–2.32 (m, 2H), 2.08 (dd, J 
= 6.9, 13.1 Hz, 1H), 2.02 (br. s., 1H), 1.95 (d, J = 11.2 Hz, 1H), 1.80–1.73 (m, 2H), 1.73–1.71 (m, 
1H), 1.70 (s, 3H), 1.67–1.60 (m, 1H), 1.59–1.51 (m, 2H), 1.50–1.45 (m, 18H), 1.42–1.25 (m, 5H), 
1.18–1.09 (m, 2H), 1.08–1.05 (m, 1H), 1.03 (d, J = 6.2 Hz, 3H), 0.80 (d, J = 6.2 Hz, 3H). 13C NMR 
(126 MHz, C6D6) δ: 170.8, 170.7, 161.2, 156.1, 137.5, 116.8, 90.9, 79.4, 78.4, 70.5, 54.5, 54.1, 52.7, 
51.8, 50.3, 43.3, 42.9, 41.2, 40.7, 40.0, 39.2, 36.1, 35.5, 34.5, 33.8, 29.1, 29.0, 27.5, 25.6, 25.3, 24.9, 
23.1, 23.0, 22.1. FTIR (thin film) cm-1: 2972, 2948, 2928, 2870, 1686, 1655, 1641, 1596, 1389, 
1365, 1251, 1166, 1155. HRMS (ESI) (m/z) calc’d for C38H59N3NaO5 [M+Na]+: 660.4347, found 
660.4374. [α]D23: –156 (c = 0.23, CH2Cl2). TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.79 (KMnO4, 
UV). 
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Enal 161: 
Hoveyda-Grubbs 2nd generation catalyst (20.0 mg, 0.0322 mmol, 0.50 equiv) was added as a 
single portion to a solution of amide 158 (41.4 mg, 0.0644 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (5 × 1 mL), and acrolein (50.0 µL, 0.644 mmol, 10.0 equiv) in 
CH2Cl2 (1.8 mL) at room temperature. The reaction was stirred for 21 h, at which point additional 
acrolein (25.0 µL, 0.322 mmol, 5.00 equiv) and Hoveyda-Grubbs catalyst (10.0 mg, 0.0161 mmol, 
0.25 equiv) were added. After stirring for a further 12 h, the reaction was concentrated under reduced 
pressure. The resultant residue was then directly purified by flash column chromatography (silica 
gel, eluent: gradient: 4:1 → 2:1 → 1:1 hexanes:EtOAc) to afford enal 161 (43.0 mg, quant.) as a 
yellow solid. 
 
1H NMR (500 MHz, C6D6) δ: 9.56 (s, 1H), 9.42 (d, J = 7.8 Hz, 1H), 6.53–6.44 (m, 1H), 6.14 (dd, J 
= 7.7, 15.7 Hz, 1H), 4.01 (br. s., 1H), 3.66 (t, J = 13.5 Hz, 1H), 3.43 (br. s., 1H), 3.25–3.12 (m, 1H), 
3.03–2.85 (m, 3H), 2.64 (br. s., 1H), 2.43 (d, J = 8.8 Hz, 1H), 2.26 (td, J = 7.0, 14.6 Hz, 1H), 2.04 
(br. s., 1H), 2.02–1.90 (m, 3H), 1.80 (d, J = 12.4 Hz, 1H), 1.75–1.68 (m, 4H), 1.65–1.59 (m, 1H), 
1.53–1.48 (m, J = 5.9 Hz, 1H), 1.45 (s, 9H), 1.42 (s, 9H), 1.37–1.23 (m, 6H), 1.06 (d, J = 6.3 Hz, 
4H), 1.04–0.97 (m, 1H), 0.97–0.93 (m, 1H), 0.89–0.86 (m, 1H), 0.73 (d, J = 6.3 Hz, 3H). 13C NMR 
(126 MHz, C6D6) δ: 193.3, 171.1, 161.2, 156.1, 155.3, 134.9, 128.9, 91.4, 79.9, 78.3, 70.3, 54.5, 
53.5, 52.6, 51.7, 50.4, 43.4, 42.8, 41.1, 40.0, 39.2, 38.6, 36.8, 36.5, 34.5, 33.7, 29.1, 28.9, 27.7, 25.8, 
25.5, 24.9, 23.0, 22.8, 22.1. FTIR (thin film) cm-1: 2949, 2927, 2869, 1691, 1653, 1639, 1596, 1390, 
1365, 1166, 1154. HRMS (ESI) (m/z) calc’d for C39H59N3NaO6 [M+Na]+: 688.4296, found 
688.4289. [α]D23: –86 (c = 0.35, CH2Cl2). TLC (EtOAc), Rf : 0.43 (KMnO4, UV). 
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Tosylate 162: 
 Palladium on carbon (10 wt%, 14.0 mg, 0.0130 mmol, 0.20 equiv) was added as a single 
portion to a stirred solution of enal 161 (43.0 mg, 0.0650 mmol, 1.00 equiv) in EtOAc (3.2 mL). The 
reaction vessel was purged with H2 and placed under an atmosphere of H2. After 2 h, Celite was 
poured into the stirred reaction mixture and the resultant slurry was then filtered through a pad of 
Celite. The solution was concentrated under reduced pressure to afford the corresponding aldehyde, 
which was carried forward to the next step without further purification. 
NaBH4 (5.0 mg, 0.13 mmol, 2.0 equiv) was added as a single portion to a stirred solution of 
the crude aldehyde, which was azeotropically dried with benzene (5 × 1 mL), in EtOH (1.5 mL) at 0 
°C. The reaction was stirred for 40 min, at which point saturated aqueous NH4Cl solution (0.5 mL) 
was added and all volatiles were removed in vacuo. Water (2 mL), Et2O (2 mL), and EtOAc (2 mL) 
were added sequentially to the crude residue. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 2 mL). The organic layers were combined, washed with brine (5 mL), 
dried over anhydrous MgSO4, and concentrated under reduced pressure to provide alcohol S9, which 
was carried forward to the next step without further purification. 
Next, Et3N (75.0 µL, 0.520 mmol, 8.00 equiv), 4-DMAP (8.0 mg, 0.065 mmol, 1.0 equiv), 
and p-TsCl (50.0 mg, 0.260 mmol, 4.00 equiv) were added sequentially to a stirred solution of crude 
alcohol S9, which was azeotropically dried with benzene (5 × 1 mL), in CH2Cl2 (1.3 mL) at room 
temperature. After stirring for 12 h, a saturated aqueous NaHCO3 solution (2 mL) and brine (2 mL) 
were added sequentially, followed by Et2O (2 mL), and EtOAc (2 mL). The layers were separated 
and the aqueous layer was extracted with EtOAc (3 × 2 mL). The organic layers were combined, 
dried over anhydrous MgSO4, and concentrated under reduced pressure. The residue was purified by 
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flash column chromatography (silica gel, eluent: gradient: 2:1 → 1:1 → 0:1 hexanes:EtOAc) to 
afford tosylate 162 (37.5 mg, 70% over 3 steps) as a yellow solid. 
 
1H NMR (500 MHz, C6D6) δ: 9.57 (s, 1H), 7.77 (d, J = 7.8 Hz, 2H), 6.73 (d, J = 8.1 Hz, 2H), 4.13 
(br. s., 1H), 3.97–3.84 (m, 2H), 3.66 (t, J = 12.9 Hz, 1H), 3.27 (br. s., 1H), 3.25–3.19 (m, 1H), 2.98 
(d, J = 2.9 Hz, 1H), 2.93 (d, J = 8.1 Hz, 1H), 2.64 (t, J = 5.4 Hz, 1H), 2.44 (d, J = 8.5 Hz, 1H), 2.07 
(dd, J = 3.0, 4.3 Hz, 1H), 2.05–2.00 (m, 2H), 1.93 (d, J = 11.5 Hz, 2H), 1.84 (s, 3H), 1.82–1.76 (m, 
2H), 1.73 (s, 3H), 1.68–1.62 (m, 1H), 1.58–1.51 (m, 3H), 1.48 (s, 9H), 1.46 (s, 9H), 1.41–1.32 (m, 
7H), 1.31–1.24 (m, 3H), 1.18–1.05 (m, 3H), 1.01 (d, J = 5.6 Hz, 3H), 0.79 (d, J = 6.1 Hz, 3H). 13C 
NMR (126 MHz, C6D6) δ: 170.8, 170.7, 161.2, 156.3, 144.4, 135.0, 130.2, 128.0, 90.9, 79.5, 78.4, 
70.7, 70.5, 54.5, 54.3, 52.7, 51.9, 50.6, 43.3, 42.9, 41.3, 40.0, 39.2, 36.9, 36.7, 35.0, 34.4, 33.8, 29.7, 
29.1, 29.0, 27.7, 26.0, 25.6, 24.9, 23.7, 23.0, 23.0, 22.1, 21.5. FTIR (thin film) cm-1: 2946, 2928, 
1685, 1654, 1638, 1595, 1389, 1364, 1175, 1166, 1154. HRMS (ESI) (m/z) calc’d for 
C46H69N3NaO8S [M+Na]+: 846.4698, found 846.4716. TLC (EtOAc), Rf : 0.56 (KMnO4, UV). 
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Quinolizidine 163: 
2,6-Lutidine (13.5 µL, 0.115 mmol, 10.0 equiv) was added dropwise to a stirred solution of 
tosylate 162 (9.5 mg, 0.012 mmol, 1.0 equiv), which was azeotropically dried with benzene (5 × 0.5 
mL) in CH2Cl2 (1 mL) at 0 °C, followed by TBSOTf (21.0 µL, 0.0922 mmol, 8.00 equiv). After 
stirring for 5 min at 0 °C, the reaction mixture was allowed to warm to room temperature and was 
stirred for an additional 16.5 h, at which point a saturated aqueous NaHCO3 solution (0.5 mL) was 
added, followed by Et2O (1 mL) and EtOAc (1 mL). The layers were separated and the aqueous layer 
was extracted with EtOAc (3 × 1 mL). The organic layers were combined, washed with brine (2 
mL), dried over anhydrous MgSO4, and concentrated under reduced pressure to afford the 
corresponding silyloxy carbamate S10, which was carried forward to the next step without further 
purification. 
A solution of TBAF in THF (1.00 M, 23.0 µL, 0.0230 mmol, 2.00 equiv) was added to a 
solution of crude silyloxy carbamate S10 in THF (1 mL) at 0 °C. After stirring for 0.5 h at 0 °C, 8 
drops of AcOH were added and the reaction was concentrated under reduced pressure. The resultant 
residue was then directly purified by flash column chromatography (silica gel, eluent, gradient: 2:1 
→ 1:1 → 0:1 hexanes:EtOAc, 1% Et3N → 9:1 CH2Cl2:MeOH, 1% Et3N) to afford quinolizidine 163. 
163 was further purified by preparatory thin-layer chromatography (PTLC) using 90:9:1 
CHCl3:MeOH:NH4OH, furnishing quinolizidine 163 (4.2 mg, 66% over 2 steps) as a white solid. 
 
1H NMR (600 MHz, C6D6) δ: 9.57 (br. s., 1H), 3.67 (t, J = 13.2 Hz, 1H), 3.11 (dt, J = 5.4, 11.6 Hz, 
1H), 3.01 (br. s., 1H), 2.92 (d, J = 5.1 Hz, 1H), 2.88 (d, J = 6.8 Hz, 1H), 2.70–2.63 (m, 1H), 2.58 (d, 
J = 10.8 Hz, 1H), 2.41 (d, J = 8.3 Hz, 2H), 2.15–2.06 (m, 1H), 2.05–1.92 (m, 3H), 1.80 (d, J = 13.4 
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Hz, 1H), 1.72 (s, 3H), 1.70–1.62 (m, 3H), 1.61–1.50 (m, 6H), 1.46 (s, 9H), 1.38 (d, J = 14.2 Hz, 1H), 
1.34–1.19 (m, 6H), 1.18–1.06 (m, 2H), 1.03 (d, J = 6.1 Hz, 3H), 1.00–0.94 (m, 1H), 0.93–0.87 (m, 
1H), 0.84 (d, J = 5.6 Hz, 3H). 13C NMR (126 MHz, C6D6) δ: 170.7, 170.6, 161.1, 90.9, 78.4, 70.4, 
57.3, 54.4, 53.2, 52.7, 52.3, 52.0, 43.3, 42.9, 42.0, 40.0, 39.2, 37.5, 34.8, 34.5, 33.8, 33.3, 29.1, 27.5, 
27.4, 25.6, 25.6, 24.9, 24.7, 23.2, 23.1, 22.1. FTIR (thin film) cm-1: 2926, 2866, 1655, 1641, 1596, 
1388, 1154. HRMS (ESI) (m/z) calc’d for C34H54N3O3 [M+H]+: 552.4160, found 552.4173. [α]D23: –
91 (c = 0.22, CH2Cl2). TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.16 (KMnO4, UV). 
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Proposed structure of (–)-himeradine A (38): 
Trifluoroacetic acid (500 µL) was added to a stirred solution of quinolizidine 163 (9.4 mg, 
0.017 mmol, 1.0 equiv) in CH2Cl2 (500 µL) at room temperature. After stirring for 13 h, the reaction 
was concentrated in vacuo to afford (–)-himeradine A (38) as the double TFA salt (11.6 mg, quant.) 
and as a white solid. 
 
1H NMR (600 MHz, CD3OD) δ: 4.08 (tt, J = 5.0, 9.9 Hz, 1H), 3.81 (d, J = 9.4 Hz, 1H), 3.63 (d, J = 
11.7 Hz, 1H), 3.36 (d, J = 9.4 Hz, 1H), 3.28 (d, J = 11.2 Hz, 1H), 3.26–3.21 (m, 1H), 3.17 (dt, J = 
2.3, 12.5 Hz, 1H), 3.03 (dd, J = 12.6, 14.1 Hz, 1H), 2.69 (dd, J = 2.9, 4.7 Hz, 1H), 2.62–2.56 (m, 
1H), 2.53–2.46 (m, 1H), 2.38 (d, J = 4.4 Hz, 1H), 2.32–2.26 (m, 1H), 2.16–2.09 (m, 1H), 2.03 (s, 
3H), 2.01–1.93 (m, 7H), 1.87–1.75 (m, 5H), 1.74–1.64 (m, 3H), 1.64–1.58 (m, 1H), 1.55 (t, J = 11.2 
Hz, 2H), 1.37–1.26 (m, 3H), 1.22 (q, J = 12.3 Hz, 1H), 1.00 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 5.9 Hz, 
3H). 13C NMR (126 MHz, C6D6) δ: 196.5, 174.3, 75.9, 59.7, 58.7, 57.4, 57.1, 55.9, 53.1, 45.1, 43.0, 
40.7, 40.6, 40.5, 35.4, 35.3, 35.0, 32.6, 31.5, 29.6, 27.7, 24.6, 24.6, 24.4, 24.1, 23.0, 22.8, 21.4, 20.3. 
FTIR (thin film) cm-1: 3430, 2955, 2931, 2875, 1667, 1400, 1199, 1132. HRMS (ESI) (m/z) calc’d 
for C29H46N3O [M+H]+: 452.3635, found 452.3637. [α]D23: –19 (c = 0.3, MeOH).139 TLC (80:18:2 
CHCl3:MeOH:NH4OH), Rf : 0.62 (KMnO4). 
 
  
                                                                                                                                                 
139 The reported specific rotation for (–)-himeradine A (38) is [α]D25: –23 (c = 0.3, MeOH). 
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Table S1. 1H NMR Data Comparison Between Natural and Synthetic Proposed Structure of (−)-
Himeradine A (38) as the Double TFA Salt in CD3OD. 
 
Isolation Report92 (1H, 600 MHz,  
CD3OD) 
Synthetic (−)-Himeradine A (38)  
(1H, 600 MHz, CD3OD) 
0.96 (d, J = 4.6 Hz, 3H) 0.98 (d, J = 5.9 Hz, 3H) 
0.98 (d, J = 5.9 Hz, 3H) 1.00 (d, J = 6.2 Hz, 3H) 
1.19 (br. q, J = 13.2 Hz, 1H) 1.22 (q, J = 12.3 Hz, 1H) 
1.23−1.32 (m, 3H) 1.37–1.26 (m, 3H) 
1.54−1.58 (m, 3H) 1.55 (t, J = 11.2 Hz, 2H) 
 1.64–1.58 (m, 1H) 
1.64−1.66 (m, 3H) 1.74–1.64 (m, 3H) 
1.73−1.82 (m, 5H) 1.87–1.75 (m, 5H) 
1.90−1.95 (m, 7H) 2.01–1.93 (m, 7H) 
2.02 (s, 3H) 2.03 (s, 3H) 
2.10 (m, 1H) 2.16–2.09 (m, 1H) 
2.29 (m, 1H) 2.32–2.26 (m, 1H) 
2.35 (br. s, 1H) 2.38 (d, J = 4.4 Hz, 1H) 
2.49 (br. d, J = 11.8 Hz, 1H) 2.53–2.46 (m, 1H) 
2.57 (br. s, 1H) 2.62–2.56 (m, 1H) 
2.70 (br. s, 1H) 2.69 (dd, J = 2.9, 4.7 Hz, 1H) 
3.01 (br. t, J = 12.9 Hz, 1H) 3.03 (dd, J = 12.6, 14.1 Hz, 1H) 
3.19 (m, 1H) 3.17 (dt, J = 2.3, 12.5 Hz, 1H) 
3.24 (m, 1H) 3.26–3.21 (m, 1H) 
3.33 (m, 1H) 3.28 (d, J = 11.2 Hz, 1H) 
3.34 (m, 1H) 3.36 (d, J = 9.4 Hz, 1H) 
3.77 (m, 1H)* 3.63 (d, J = 11.7 Hz, 1H)* 
3.80 (m, 1H) 3.81 (d, J = 9.4 Hz, 1H) 
4.09 (m, 1H) 4.08 (tt, J = 5.0, 9.9 Hz, 1H) 
 
*The chemical shift of H10' in the synthetic proposed structure of himeradine A (38) was shifted 
upfield by Δδ = 0.14 ppm relative to natural himeradine A. 
  
 201 
 
Figure S1. Comparison of 1H NMR Spectra of Natural and Synthetic Proposed Structure of (−)-
Himeradine A (38) as the Double TFA Salt in CD3OD. 
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Figure S2. Comparison of 1H NMR Spectra of Natural and Synthetic Proposed Structure of (−)-
Himeradine A (38) as the Free Base in CD3OD.140 
  
                                                                                                                                                 
140 The free base 1H NMR spectrum of natural himeradine A (38) in CD3OD was kindly provided by Professor 
Hiroshi Morita via private communication. 
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Table S2. 13C NMR Data Comparison Between Natural and Synthetic Proposed Structure of (−)-
Himeradine A (38) as the Double TFA Salt in CD3OD. 
 
Isolation Report92 (13C, 150 MHz,  
CD3OD) 
Synthetic (−)-Himeradine A (38)  
(13C, 126 MHz, CD3OD) 
20.6 20.3 
21.5 21.4 
22.8 22.8 
22.9 23.0 
24.2 24.1 
24.4 24.4 
24.6 24.6 
26.0 24.6 
27.7 27.7 
31.1 29.6 
31.6 31.5 
32.5 32.6 
35.0 35.0 
35.5 35.3 
37.0 35.4 
39.0141 40.5 
40.5 40.6 
40.7 40.7 
43.0 43.0 
45.4 45.1 
52.9 53.1 
56.6 55.9 
57.1 57.1 
57.5 57.4 
58.4 58.7 
60.0 59.7 
76.1 75.9 
174.3 174.3 
196.7 196.5 
 
  
                                                                                                                                                 
141 In pyridine-d5. 
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Figure S3. Comparison of 13C NMR Spectra of Synthetic Proposed Structure and Natural (−)-
Himeradine A (38) as the Double TFA Salt in CD3OD.  
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Candidate amide 184: 
Triphenylphosphine (31.0 mg, 0.118 mmol, 1.50 equiv) was added as a single portion to a 
stirred solution of imine 183 (50.2 mg, 0.0785 mmol, 1.00 equiv) in THF (1.4 mL) and water (180 
µL) at room temperature. The reaction was heated to 70 °C and stirred for 15.5 h, at which point the 
reaction was cooled to room temperature and concentrated. The resultant residue was azeotroped 
with MeOH (5 × 1 mL), followed by benzene (3 × 1 mL), then stirred with silica gel (100 mg) in 
CH2Cl2 (5 mL) for 4 h. The slurry was subsequently filtered and washed with a solution of 80:18:2 
CHCl3:MeOH:NH4OH (10 × 1 mL) and concentrated in vacuo. The crude residue was then purified 
by flash column chromatography (silica gel, eluent: gradient: 1:1 → 0:1 hexanes:EtOAc, 1% Et3N → 
90:9:1 CHCl3:MeOH:NH4OH) to afford vinylogous urethane S11 as a pale white flocculent solid. 
S11 was contaminated with inseparable Ph3PO byproduct and was carried forward to the next step 
without further purification.  
Acetic anhydride (150 µL, 1.58 mmol, 20.0 equiv) was added dropwise to a stirred solution 
of vinylogous urethane S11, which was azeotropically dried with benzene (5 × 1 mL), and Et3N (331 
µL, 1.58 mmol, 20.0 equiv) in CH2Cl2 (1.6 mL) at room temperature. After stirring for 10 h, the 
reaction was concentrated under reduced pressure. The resultant residue was then directly purified by 
flash column chromatography (silica gel, eluent, gradient: 2:1 → 1:1 hexanes:EtOAc) to afford 
amide 184 (25.0 mg, 50% over 2 steps) as a white flocculent solid. 
 
1H NMR (500 MHz, C6D6) δ: 9.60 (s, 1H), 5.92–5.82 (m, 1H), 5.15 (dd, J = 1.7, 17.1 Hz, 1H), 5.06 
(dd, J = 1.8, 10.1 Hz, 1H), 4.32 (br. s., 1H), 3.68 (t, J = 12.8 Hz, 1H), 3.39 (br. s., 1H), 3.13 (dd, J = 
7.8, 17.3 Hz, 1H), 3.04 –2.93 (m, 2H), 2.87 (d, J = 9.3 Hz, 1H), 2.65 (br. s., 1H), 2.41 (d, J = 8.5 Hz, 
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1H), 2.27–2.13 (m, 1H), 2.03–1.90 (m, 3H), 1.83 (dd, J = 5.4, 15.1 Hz, 1H), 1.80–1.74 (m, 1H), 1.71 
(s, 3H), 1.69– 1.63 (m, 1H), 1.61–1.51 (m, 2H), 1.48 (s, 9H), 1.46 (s, 9H), 1.40–1.31 (m, 5H), 1.31–
1.24 (m, 2H), 1.18 (dd, J = 5.2, 11.8 Hz, 1H), 1.11–1.07 (m, 2H), 1.03 (d, J = 6.6 Hz, 3H), 0.74 (d, J 
= 6.3 Hz, 3H). 13C NMR (126 MHz, C6D6) δ: 171.1, 170.6, 161.5, 156.4, 137.5, 116.8, 91.2, 79.6, 
78.3, 70.8, 54.8, 54.0, 52.5, 50.9, 47.8, 43.2, 43.0, 39.9, 39.8, 39.5, 39.1, 37.1, 37.1, 34.5, 33.5, 29.2, 
28.9, 26.4, 25.8, 24.9, 24.9, 23.1, 22.9, 19.2. FTIR (thin film) cm-1: 2949, 2925, 2870, 1686, 1654, 
1641, 1597, 1390, 1348, 1250, 1232, 1166, 1153. HRMS (ESI) (m/z) calc’d for C38H60N3O5 [M+H]+: 
638.4527, found 638.4548. TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.68 (KMnO4, UV). 
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Candidate enal 185: 
Hoveyda-Grubbs 2nd generation catalyst (12.3 mg, 0.0200 mmol, 0.50 equiv) was added as a 
single portion to a solution of amide 184 (25.0 mg, 0.0390 mmol, 1.00 equiv), which was 
azeotropically dried with benzene (5 × 1 mL), and acrolein (30.0 µL, 0.390 mmol, 10.0 equiv) in 
CH2Cl2 (800 µL) at room temperature. The reaction was stirred for 32.5 h, at which point the 
reaction was concentrated under reduced pressure. The resultant residue was then directly purified by 
flash column chromatography (silica gel, eluent: gradient: 4:1 → 2:1 → 1:1 → 1:2 hexanes:EtOAc) 
to afford enal 185 (22.8 mg, 88%) as a yellow flocculent solid. 
 
1H NMR (500 MHz, C6D6) δ: 9.57 (s, 1H), 9.41 (d, J = 7.6 Hz, 1H), 6.47–6.33 (m, 1H), 6.13 (dd, J 
= 7.7, 15.5 Hz, 1H), 4.21 (br. s., 1H), 3.67 (t, J = 13.2 Hz, 1H), 3.25–3.15 (m, 1H), 3.04–2.93 (m, 
3H), 2.64 (t, J = 5.4 Hz, 1H), 2.51 (d, J = 8.8 Hz, 1H), 2.13–2.02 (m, 1H), 2.01–1.88 (m, 4H), 1.82 
(d, J = 14.9 Hz, 1H), 1.79–1.74 (m, 1H), 1.73 (s, 3H), 1.68 (d, J = 14.4 Hz, 1H), 1.59 (td, J = 4.4, 
13.7 Hz, 1H), 1.47 (s, 9H), 1.40 (s, 9H), 1.36–1.27 (m, 4H), 1.25–1.15 (m, 2H), 1.14–1.05 (m, 2H), 
1.02 (d, J = 6.4 Hz, 3H), 0.99–0.82 (m, 3H), 0.69 (d, J = 6.4 Hz, 3H). 13C NMR (126 MHz, C6D6) δ: 
192.9, 170.9, 170.7, 161.6, 156.2, 155.4, 135.0, 91.7, 80.0, 78.4, 70.8, 55.0, 52.9, 52.4, 51.1, 47.8, 
43.6, 43.0, 39.8, 39.5, 38.9, 38.1, 37.7, 37.1, 34.5, 33.5, 29.1, 28.8, 26.4, 25.9, 25.5, 24.9, 23.1, 22.7, 
19.8. FTIR (thin film) cm-1: 2951, 2907, 2869, 1691, 1637, 1597, 1390, 1167, 1154. HRMS (ESI) 
(m/z) calc’d for C39H59N3NaO6 [M+Na]+: 688.4296, found 688.4314. TLC (EtOAc), Rf : 0.58 
(KMnO4, UV). 
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Candidate tosylate 186: 
 Palladium on carbon (10 wt%, 7.3 mg, 0.0069 mmol, 0.20 equiv) was added as a single 
portion to a stirred solution of enal 185 (22.8 mg, 0.0342 mmol, 1.00 equiv) in EtOAc (1.7 mL). The 
reaction vessel was purged with H2 and placed under an atmosphere of H2. After 1 h, Celite was 
poured into the stirred reaction mixture and the resultant slurry was then filtered through a pad of 
Celite. The solution was concentrated under reduced pressure to afford the corresponding aldehyde, 
which was carried forward to the next step without further purification. 
NaBH4 (2.6 mg, 0.069 mmol, 2.0 equiv) was added as a single portion to a stirred solution of 
the crude aldehyde, which was azeotropically dried with benzene (5 × 1 mL), in EtOH (850 µL) at 0 
°C. The reaction was stirred for 50 min, at which point saturated aqueous NH4Cl solution (0.5 mL) 
was added and all volatiles were removed in vacuo. Water (1 mL), Et2O (1 mL), and EtOAc (1 mL) 
were added sequentially to the crude residue. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 1 mL). The organic layers were combined, washed with brine (4 mL), 
dried over anhydrous MgSO4, and concentrated under reduced pressure to provide alcohol S12, 
which was carried forward to the next step without further purification. 
Next, Et3N (9.5 µL, 0.068 mmol, 2.0 equiv), Me3N•HCl (3.3 mg, 0.034 mmol, 1.0 equiv), 
and p-TsCl (7.8 mg, 0.041 mmol, 1.2 equiv) were added sequentially to a stirred solution of crude 
alcohol S12, which was azeotropically dried with benzene (5 × 1 mL), in MeCN (1.1 mL) at room 
temperature. After stirring for 6.5 h, additional Et3N (4.8 µL, 0.034 mmol, 1.0 equiv), Me3N•HCl 
(1.7 mg, 0.017 mmol, 0.50 equiv), and p-TsCl (3.9 mg, 0.021 mmol, 0.60 equiv) were added 
successively. After stirring for an additional 2 h, water (1 mL), Et2O (1 mL), and EtOAc (1 mL) 
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were added to the reaction mixture. The layers were separated and the aqueous layer was extracted 
with EtOAc (3 × 1 mL). The organic layers were combined, dried over anhydrous MgSO4, and 
concentrated under reduced pressure. The residue was purified by flash column chromatography 
(silica gel, eluent: gradient: 2:1 → 1:1 → 1:2 → 0:1 hexanes:EtOAc) to afford tosylate 186 (20.6 mg, 
73% over 3 steps) as a pale yellow flocculent solid. 
 
1H NMR (600 MHz, C6D6) δ: 9.61 (s, 1H), 7.79 (d, J = 8.2 Hz, 2H), 6.77 (d, J = 8.5 Hz, 2H), 4.26 
(br. s., 1H), 3.94–3.85 (m, 2H), 3.69 (t, J = 13.5 Hz, 1H), 3.37 (dd, J = 4.7, 9.7 Hz, 1H), 3.04–2.97 
(m, 2H), 2.88 (br. s., 1H), 2.66 (t, J = 5.9 Hz, 1H), 2.55 (d, J = 8.8 Hz, 1H), 2.10 (dd, J = 2.6, 4.4 Hz, 
1H), 2.06 (d, J = 9.4 Hz, 1), 2.03–1.94 (m, 3H), 1.86 (s, 3H), 1.85–1.82 (m, 1H), 1.75 (s, 3H), 1.73–
1.69 (m, 1H), 1.63–1.55 (m, 2H), 1.47 (s, 9H), 1.46 (s, 9H), 1.45–1.40 (m, 2H), 1.40–1.29 (m, 5H), 
1.29–1.19 (m, 3H), 1.19–1.07 (m, 4H), 1.03 (d, J = 6.2 Hz, 3H), 0.98 (q, J = 10.6 Hz, 1H), 0.73 (d, J 
= 6.5 Hz, 3H). 13C NMR (126 MHz, C6D6) δ: 170.9, 170.8, 161.9, 156.5, 144.5, 135.0, 130.2, 128.0, 
91.4, 79.6, 78.3, 70.7, 55.0, 53.9, 52.6, 50.7, 47.8, 43.4, 43.0, 39.9, 39.5, 38.8, 38.4, 37.5, 34.6, 34.5, 
33.6, 29.7, 29.2, 29.1, 28.9, 27.0, 25.9, 24.9, 24.7, 23.8, 23.1, 22.8, 21.5, 19.3. FTIR (thin film) cm-1: 
2948, 2927, 2870, 1686, 1648, 1596, 1389, 1364, 1175, 1153. HRMS (ESI) (m/z) calc’d for 
C46H69N3NaO8S [M+Na]+: 846.4698, found 846.4698. TLC (EtOAc), Rf : 0.59 (KMnO4, UV). 
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Candidate quinolizidine 187: 
2,6-Lutidine (18.0 µL, 0.150 mmol, 10.0 equiv), followed by TBSOTf (28.0 µL, 0.120 
mmol, 8.00 equiv), were added dropwise to a stirred solution of tosylate 186 (12.4 mg, 0.0150 mmol, 
1.00 equiv), which was azeotropically dried with benzene (5 × 0.5 mL), in CH2Cl2 (1.5 mL) at 0 °C. 
After stirring for 5 min at 0 °C, the reaction mixture was allowed to room temperature and was 
stirred for an additional 12 h, at which point a saturated aqueous NaHCO3 solution (0.5 mL) was 
added, followed by Et2O (1 mL), and EtOAc (1 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 × 1 mL). The organic layers were combined, washed with brine 
(2 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure to afford the 
corresponding silyloxy carbamate S13, which was carried forward to the next step without further 
purification. 
A solution of TBAF in THF (1.00 M, 30.0 µL, 0.0301 mmol, 2.00 equiv) was added to a 
solution of crude silyloxy carbamate S13 in THF (1.5 mL) at 0 °C. After stirring for 45 min at 0 °C, 
AcOH (13.0 µL, 0.226 mmol, 15.0 equiv) was added and the reaction was concentrated under 
reduced pressure. The resultant residue was then directly purified by flash column chromatography 
(silica gel, eluent: gradient: 2:1 → 1:1 → 0:1 hexanes:EtOAc, 1% Et3N → 9:1 CH2Cl2:MeOH, 1% 
Et3N) to afford quinolizidine 187. 187 was further purified by preparatory thin-layer chromatography 
(PTLC) using 90:9:1 CHCl3:MeOH:NH4OH, furnishing quinolizidine 187 (4.9 mg, 59% over 2 
steps) as a white solid. 
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1H NMR (600 MHz, C6D6) δ: 9.70 (br. s., 1H), 3.66 (t, J = 13.5 Hz, 1H), 3.13 (br. s., 1H), 3.07 (d, J 
= 5.3 Hz, 1H), 2.99 (br. s., 1H), 2.89 (d, J = 7.9 Hz, 1H), 2.70 (d, J = 10.9 Hz, 1H), 2.63 (t, J = 5.6 
Hz, 1H), 2.43 (d, J = 8.8 Hz, 1H), 2.31 (dt, J = 2.1, 11.0 Hz, 1H), 2.06 (t, J = 10.3 Hz, 1H), 2.00–
1.86 (m, 4H), 1.83 (d, J = 11.4 Hz, 1H), 1.73 (s, 3H), 1.66 (td, J = 2.6, 12.8 Hz, 1H), 1.63–1.59 (m, 
2H), 1.58–1.48 (m, 4H), 1.45 (s, 9H), 1.36–1.29 (m, 3H), 1.28–1.21 (m, 3H), 1.21–1.14 (m, 2H), 
1.12–1.05 (m, 2H), 1.01 (d, J = 6.2 Hz, 3H), 0.96–0.88 (m, 2H), 0.83 (d, J = 5.3 Hz, 3H). 13C NMR 
(126 MHz, C6D6) δ: 170.7, 170.5, 161.2, 92.3, 78.4, 70.7, 57.6, 54.9, 53.5, 52.5, 52.1, 49.3, 43.3, 
43.0, 42.6, 40.0, 39.4, 38.3, 35.0, 34.6, 33.6, 32.5, 29.1, 27.3, 27.1, 25.9, 25.8, 24.9, 24.9, 23.1, 22.9, 
19.5. FTIR (thin film) cm-1: 2929, 2896, 1643, 1595, 1388, 1232, 1167, 1152. HRMS (ESI) (m/z) 
calc’d for C34H54N3O3 [M+H]+: 552.4160, found 552.4175. TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf 
: 0.69 (KMnO4, UV). 
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Candidate (–)-himeradine A (188): 
Trifluoroacetic acid (300 µL) was added to a stirred solution of quinolizidine 187 (4.9 mg, 
0.0089 mmol, 1.0 equiv) in CH2Cl2 (300 µL) at room temperature. After stirring for 14 h, the 
reaction was concentrated in vacuo to afford candidate (–)-himeradine A (188) as the double TFA 
salt (6.0 mg, quant.) and as a white solid. 
 
1H NMR (600 MHz, CD3OD) δ: 4.04–3.94 (m, J = 5.0 Hz, 1H), 3.81 (d, J = 9.4 Hz, 1H), 3.79–3.74 
(m, 1H), 3.37 (d, J = 9.4 Hz, 1H), 3.34–3.31 (m, 1H), 3.29–3.22 (m, 2H), 3.04 (t, J = 12.9 Hz, 1H), 
2.79 (br. s., 1H), 2.62 (dd, J = 2.8, 4.8 Hz, 1H), 2.61–2.56 (m, 1H), 2.47 (td, J = 4.7, 10.3 Hz, 1H), 
2.38 (d, J = 3.5 Hz, 1H), 2.23–2.11 (m, 2H), 2.04 (s, 3H), 2.02–1.89 (m, 7H), 1.89–1.74 (m, 5H), 
1.72–1.62 (m, 3H), 1.61 –1.50 (m, 2H), 1.36–1.28 (m, 2H), 1.26–1.16 (m, 2H), 1.00 (d, J = 6.2 Hz, 
3H), 0.98 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ: 197.1, 174.3, 76.4, 60.2, 58.4, 57.7, 
57.2, 54.9, 52.7, 46.2, 43.2, 40.6, 40.5, 37.1, 35.8, 34.8, 32.5, 31.6, 30.4, 28.3, 25.2, 24.6, 24.4, 24.2, 
22.9, 22.7, 21.5, 19.1. FTIR (thin film) cm-1: 3367, 2956, 2929, 2876, 1671, 1404, 1200, 1131, 720. 
HRMS (ESI) (m/z) calc’d for C29H46N3O [M+H]+: 452.3635, found 452.3633. [α]D22: –56 (c = 0.35, 
MeOH). TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.50 (KMnO4). 
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Figure S4. Comparison of 1H NMR Spectra of Natural and Candidate (−)-Himeradine A (188) as the 
Double TFA Salt in CD3OD.  
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Figure S5. Comparison of 13C NMR Spectra of Natural and Candidate (−)-Himeradine A (188) as 
the Double TFA Salt in CD3OD.  
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Alkylated imide 191: 
Benzyl 3-bromopropyl ether (118 µL, 0.656 mmol, 1.30 equiv) was added dropwise to a 
stirred solution of β-carboxyimide 66 (250 mg, 0.504 mmol, 1.00 equiv) and Cs2CO3 (329 mg, 1.01 
mmol, 2.00 equiv) in DMF (3.4 mL). After 17.5 h, Et2O (5 mL) and saturated aqueous NH4Cl 
solution (10 mL) were added sequentially to the reaction mixture. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined and 
washed with brine (20 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure. 
The resultant residue was purified by flash column chromatography (silica gel, eluent: 6:1 
hexanes:EtOAc, 1% Et3N) to afford alkylated imide 191 (325 mg, quant.) as a 9:1 mixture of 
diastereomers at C4 and as a clear colorless oil. 
 
1H NMR (500 MHz, C6D6, major C4-epimer reported) δ: 7.21 (d, J = 7.6 Hz, 2H), 7.12 (d, J = 7.8 
Hz, 2H), 7.06 (t, J = 7.1 Hz, 1H), 5.53 (d, J = 3.7 Hz, 1H), 4.21 (s, 2H), 4.20–4.17 (m, 1H), 4.17–
4.09 (m, 1H), 4.07–3.99 (m, 1H), 3.79 (t, J = 10.3 Hz, 1H), 3.68–3.58 (m, 2H), 3.57–3.49 (m, 1H), 
3.46–3.37 (m, 1H), 3.36–3.22 (m, 2H), 2.81 (d, J = 9.8 Hz, 2H), 2.39 (td, J = 4.9, 12.5 Hz, 1H), 2.27 
(td, J = 4.2, 13.2 Hz, 1H), 2.00 (t, J = 13.2 Hz, 1H), 1.96–1.86 (m, 2H), 1.83–1.73 (m, 2H), 1.71 (d, J 
= 12.9 Hz, 1H), 1.45 (s, 9H), 1.40–1.31 (m, 1H), 1.27 (t, J = 13.2 Hz, 1H), 0.89–0.82 (m, 2H), 0.77 
(d, J = 6.8 Hz, 3H), –0.17 (s, 3H), –0.18 (s, 3H). 13C NMR (126 MHz, C6D6, major C4-epimer 
reported) δ: 171.6, 170.7, 151.7, 139.7, 135.1, 131.8, 128.8, 128.7, 127.9, 108.8, 82.9, 73.3, 71.1, 
65.8, 64.3, 64.0, 61.4, 50.6, 42.6, 38.0, 34.6, 30.8, 29.8, 28.4, 28.1, 25.5, 21.9, 18.1, –1.4. FTIR (thin 
film) cm-1: 2952, 2925, 2871, 1753, 1716, 1313, 1250, 1172, 1156, 839. HRMS (ESI) (m/z) calc’d 
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for C35H53NNaO8Si [M+Na]+: 666.3433, found 666.3438. TLC (3:1 hexanes:EtOAc), Rf : 0.32 
(Anis, UV). 
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N-Boc-2-pyrrolidinone S14: 
A solution of TBAF in THF (1.00 M, 530 µL, 0.530 mmol, 1.00 equiv) was added to a 
solution of alkylated imide 191 (341 mg, 0.530 mmol, 1.00 equiv) and DBU (20.0 µL, 0.133 mmol, 
0.25 equiv) in THF (10 mL) at room temperature. After 5 min, the reaction was heated to 50 °C and 
was stirred for 19 h, at which point water (15 mL), Et2O (10 mL), and EtOAc (10 mL) were added 
successively. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 10 
mL). The organic layers were combined, washed with brine (25 mL), then dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The resultant residue was purified by flash column 
chromatography (silica gel, eluent: 2:1 hexanes:EtOAc, 1% Et3N) to afford N-Boc-2-pyrrolidinone 
S14 (232 mg, 87%) as a >4:1 mixture of diastereomers at C4 and as a clear colorless oil. 
 
1H NMR (500 MHz, C6D6, major C4-epimer reported) δ: 7.27 (d, J = 7.6 Hz, 2H), 7.18 (d, J = 1.7 
Hz, 2H), 7.11–7.05 (m, 1H), 5.45–5.34 (m, 1H), 4.28 (s, 2H), 3.90 (dd, J = 7.8, 11.0 Hz, 1H), 3.57–
3.45 (m, 3H), 3.43–3.35 (m, 1H), 3.32–3.27 (m, 2H), 3.09 (dd, J = 8.3, 10.7 Hz, 1H), 2.41 (dd, J = 
3.4, 14.6 Hz, 1H), 2.18–2.06 (m, 1H), 1.96–1.85 (m, 2H), 1.84–1.60 (m, 6H), 1.48 (s, 9H), 1.42–1.33 
(m, 2H), 1.31–1.23 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, C6D6, major C4-epimer 
reported) δ: 174.6, 151.8, 139.8, 135.8, 131.1, 128.9, 128.1, 127.9, 108.7, 82.2, 73.3, 70.8, 65.7, 
64.3, 50.6, 49.9, 42.7, 36.0, 35.1, 34.5, 28.5, 28.0, 27.6, 26.7, 21.9. FTIR (thin film) cm-1: 2949, 
2925, 2869, 1783, 1747, 1712, 1367, 1314, 1157, 1124. HRMS (ESI) (m/z) calc’d for C29H42NO6 
[M+H]+: 500.3007, found 500.3016. TLC (2:1 hexanes:EtOAc), Rf : 0.34 (Anis, UV). 
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N-2-Nitrobenzenesulfonyl-2-pyrrolidinone 193: 
Mg(ClO4)2 (21.0 mg, 0.0927 mmol, 0.20 equiv) was added as a single portion to a stirred 
solution of N-Boc-2-pyrrolidinone S14 (232 mg, 0.464 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (5 × 1 mL), in MeCN (7.7 mL) at room temperature. The resultant mixture was 
heated to 60 °C and stirred for 5.5 h, at which point it was cooled to room temperature and Et2O (10 
mL) and saturated aqueous NH4Cl solution (10 mL) were added sequentially. The layers were 
separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were 
combined, washed with brine (20 mL), then dried over anhydrous MgSO4 and concentrated under 
reduced pressure to afford crude 2-pyrrolidinone 192 as a white flocculent solid, which was carried 
forward to the next step without further purification. 
A solution of freshly prepared LiHMDS in THF (1.00 M, 478 µL, 0.478 mmol, 1.20 equiv) 
was added to a solution of 192, which was azeotropically dried with benzene (5 × 1 mL), in THF (4 
mL) at room temperature. After 1 h, the reaction was cooled to 0 °C and a solution of NsCl in THF 
(1.00 M, 518 µL, 0.518 mmol, 1.30 equiv) was added dropwise. After 5 min, the reaction was 
allowed to warm to room temperature and stirred for 2 h, at which point saturated aqueous NH4Cl 
solution (5 mL) and Et2O (5 mL) were added sequentially. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 5 mL). The organic layers were combined, washed 
with brine (15 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (silica gel, eluent: gradient: 6:1 → 4:1 → 2:1 
hexanes:EtOAc, 1% Et3N) to afford N-2-nitrobenzenesulfonyl-2-pyrrolidinone 193 (585 mg, 95% 
over 2 steps) as a 5:1 mixture of diastereomers at C4 and as a white flocculent solid. 
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1H NMR (500 MHz, C6D6, major C4-epimer reported) δ: 8.48 (dd, J = 1.3, 7.9 Hz, 1H), 7.22–7.19 
(m, 2H), 7.14–7.11 (m, 2H), 7.10–7.04 (m, 1H), 6.72 (dd, J = 1.2, 7.8 Hz, 1H), 6.64 (dt, J = 1.2, 7.8 
Hz, 1H), 6.44 (dt, J = 1.3, 7.8 Hz, 1H), 5.48 (d, J = 3.4 Hz, 1H), 4.28 (dd, J = 7.7, 9.9 Hz, 1H), 4.20 
(s, 2H), 3.67–3.59 (m, 1H), 3.58–3.54 (m, 2H), 3.51 (dd, J = 8.1, 9.8 Hz, 1H), 3.48–3.40 (m, 1H), 
3.20–3.12 (m, 2H), 2.50–2.35 (m, 2H), 1.98–1.84 (m, 2H), 1.83–1.67 (m, 4H), 1.65–1.52 (m, 2H), 
1.45–1.31 (m, 2H), 1.26 (t, J = 13.2 Hz, 1H), 0.78 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, C6D6, 
major C4-epimer reported) δ: 175.9, 148.6, 139.6, 135.2, 135.0, 134.5, 132.6, 132.3, 131.9, 131.6, 
128.9, 128.1, 124.0, 108.7, 73.2, 70.4, 65.7, 64.3, 51.5, 49.1, 42.5, 37.9, 34.9, 34.5, 28.0, 27.4, 26.4, 
21.9. FTIR (thin film) cm-1: 2951, 2923, 2854, 1735, 1543, 1366, 1173, 1126, 1096, 966, 738, 594. 
HRMS (ESI) (m/z) calc’d for C30H37N2O8S [M+H]+: 585.2265, found 585.2272. TLC (1:1 
hexanes:EtOAc), Rf : 0.72 (Anis, UV). 
  
 220 
 
Enone 194: 
A solution of n-butyllithium in hexanes (2.55 M, 445 µL, 1.14 mmol, 3.00 equiv) was added 
dropwise to a stirred solution of diisopropylamine (175 µL, 1.25 mmol, 3.30 equiv) in THF (2.1 mL) 
at −78 °C. The reaction was allowed to stir for 10 min, at which point it was warmed to 0 °C. After 
10 min, the reaction was warmed to room temperature. The solution was recooled to −78 °C after 10 
min. t-Butylacetate (152 µL, 1.14 mmol, 3.00 equiv) was then added dropwise to the reaction 
mixture. After 1.5 h, a solution of 193 (221 mg, 0.379 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (5 × 1 mL), in THF (4.7 mL) was added dropwise down the walls of the reaction 
vessel. After stirring at −78 °C for 2.5 h, saturated aqueous NH4Cl solution (10 mL) was added to the 
deep red reaction mixture at −78 °C. The resultant mixture was then allowed to warm to room 
temperature. Et2O (10 mL) and EtOAc (10 mL) were added and the layers were separated. The 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed 
with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford crude β-ketoester S15 as a pale yellow flocculent solid, which was carried forward to the next 
step without further purification. 
10% aqueous HCl (680 µL) was added dropwise to a stirred solution of crude S15 in THF 
(5.5 mL) at room temperature. After 4 h, a saturated aqueous NaHCO3 solution (10 mL) was added, 
followed by Et2O (10 mL), EtOAc (10 mL), and water (5 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed 
with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford crude enone 194 as a yellow flocculent solid, which was carried forward to the next step 
without further purification. 
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Imine 195: 
K2CO3 (262 mg, 1.90 mmol, 5.00 equiv) was added in a single portion to a stirred solution of 
crude enone 194, which was azeotropically dried with benzene (5 × 1 mL), in DMF (5.4 mL) at room 
temperature. After 18.5 h, the suspension was cooled to 0 °C and PhSH (97.0 µL, 0.948 mmol, 2.50 
equiv) was added dropwise via syringe. After 5 min, the reaction was warmed to room temperature 
and stirred for an additional 6.5 h, at which point water (10 mL), Et2O (10 mL), and EtOAc (10 mL) 
were added sequentially. The layers were separated and the aqueous layer was extracted with EtOAc 
(3 × 10 mL). The organic layers were combined, washed with brine (30 mL), dried over anhydrous 
MgSO4, and concentrated under reduced pressure. The crude residue was then purified by flash 
column chromatography (silica gel, eluent: gradient: 1:1 → 0:1 hexanes:EtOAc, 1% Et3N → 90:9:1 
CHCl3:MeOH:NH4OH) to afford imine 195 (145 mg, 84% over 3 steps) as a >4:1 mixture of 
diastereomers at C4 and as a pale yellow oil. 
 
1H NMR (500 MHz, C6D6, major C4-epimer reported) δ: 7.30 (d, J = 7.6 Hz, 2H), 7.18 (t, J = 7.6 
Hz, 2H), 7.10 (t, J = 7.1 Hz, 1H), 4.31 (s, 2H), 3.98 (d, J = 18.1 Hz, 1H), 3.47 (d, J = 3.4 Hz, 1H), 
3.32 (dd, J = 6.1, 8.8 Hz, 1H), 3.27 (td, J = 2.9, 9.3 Hz, 1H), 3.21 (d, J = 15.6 Hz, 1H), 2.92–2.86 (m, 
1H), 2.61–2.53 (m, 2H), 2.19–2.07 (m, 1H), 2.01–1.92 (m, 1H), 1.89 (t, J = 6.1 Hz, 1H), 1.79–1.61 
(m, 3H), 1.60–1.46 (m, 3H), 1.38–1.34 (m, 2H), 1.32 (s, 9H), 1.10 (td, J = 3.7, 12.9 Hz, 1H), 0.61 (d, 
J = 6.6 Hz, 3H). 13C NMR (126 MHz, C6D6, major C4-epimer reported) δ: 205.2, 170.5, 169.2, 
139.8, 128.9, 128.1, 127.9, 82.1, 73.4, 71.0, 66.2, 55.2, 49.1, 48.2, 43.4, 38.8, 38.3, 32.9, 30.1, 29.8, 
29.3, 28.3, 27.5, 22.6. FTIR (thin film) cm-1: 2949, 2924, 2862, 1737, 1701, 1668, 1455, 1368, 1154, 
1110, 734. HRMS (ESI) (m/z) calc’d for C28H39NNaO4 [M+Na]+: 476.2781, found 476.2771. TLC 
(90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.40 (KMnO4, UV). 
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Amine 197: 
Trifluoroacetic acid (2.1 mL) was added to a stirred solution of imine 195 (43.4 mg, 0.0957 
mmol, 1.00 equiv) in CH2Cl2 (2.1 mL) at room temperature. After stirring for 19 h, the reaction was 
concentrated in vacuo to afford ketone 196, which was carried forward to the next step without 
further purification. 
A solution of HCl in Et2O (2.00 M, 144 µL, 0.287 mmol, 3.00 equiv) was added to a stirred 
solution of crude ketone 196 in MeOH (1.9 mL). The resultant mixture was heated to 65 °C and 
stirred for 3 d, at which point it was cooled to room temperature and concentrated under reduced 
pressure. The crude residue was then purified by flash column chromatography (silica gel, eluent: 
90:9:1 CHCl3:MeOH:NH4OH) to afford amine 197 (32.3 mg, 95% over 2 steps) as a pale yellow oil. 
 
1H NMR (500 MHz, C6D6) δ: 7.36–7.33 (m, 2H), 7.17 (t, J = 7.6 Hz, 2H), 7.08 (t, J = 7.3 Hz, 1H), 
4.41 (s, 2H), 3.54 (td, J = 5.9, 9.0 Hz, 1H), 3.47 (ddd, J = 6.0, 7.5, 9.1 Hz, 1H), 2.84 (td, J = 2.6, 9.2 
Hz, 1H), 2.36 (d, J = 8.8 Hz, 1H), 2.35–2.31 (m, 1H), 2.29 (dd, J = 8.5, 18.8 Hz, 1H), 1.99 (d, J = 
19.1 Hz, 1H), 1.88 (t, J = 3.8 Hz, 1H), 1.75 (td, J = 4.1, 12.0 Hz, 1H), 1.71 (dd, J = 2.8, 7.5 Hz, 1H), 
1.65 (q, J = 1.0 Hz, 2H), 1.45 (ddd, J = 1.6, 4.0, 13.4 Hz, 1H), 1.40–1.34 (m, 1H), 1.33 (dt, J = 2.3, 
4.8 Hz, 1H), 1.30 (d, J = 7.9 Hz, 1H), 1.29–1.26 (m, 1H), 1.25–1.21 (m, 1H), 0.90 (t, J = 12.6 Hz, 
1H), 0.81 (dt, J = 3.2, 12.6 Hz, 1H), 0.67 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, C6D6) δ: 214.2, 
140.0, 128.9, 128.7, 127.9, 73.3, 72.0, 69.5, 64.8, 53.2, 47.4, 44.8, 43.0, 41.5, 36.9, 33.8, 32.0, 27.4, 
26.2, 23.7, 23.0. FTIR (thin film) cm-1: 3340, 2949, 2909, 2869,1685, 1453, 1099, 735, 698. HRMS 
(ESI) (m/z) calc’d for C23H31NNaO2 [M+Na]+: 376.2247, found 376.2250. [α]D23: –41 (c = 0.56, 
CH2Cl2). TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.58 (KMnO4, UV). 
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Alcohol 198: 
Palladium on carbon (10 wt%, 146 mg, 0.137 mmol, 1.50 equiv) was added as a single 
portion to a stirred solution of amine 197 (32.3 mg, 0.0914 mmol, 1.00 equiv) and aqueous HCl 
(3.00 M, 46.0 µL, 0.137 mmol, 1.50 equiv) in EtOH (3 mL). The reaction vessel was purged with H2 
and placed under an atmosphere of H2. After 1.5 h, Celite was poured into the stirred reaction 
mixture and the resultant slurry was then filtered through a pad of Celite and washed with CHCl3 (10 
mL). The filtrate was concentrated under reduced pressure and the resultant crude residue was then 
purified by flash column chromatography (silica gel, eluent: gradient: 90:9:1 → 80:18:2 
CHCl3:MeOH:NH4OH) to afford alcohol 198 (19.3 mg, 80%) as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ: 3.73–3.61 (m, 2H), 3.09 (td, J = 2.9, 9.4 Hz, 1H), 2.72 (d, J = 9.3 
Hz, 1H), 2.64 (dd, J = 8.6, 19.1 Hz, 1H), 2.26 (t, J = 4.2 Hz, 1H), 2.20–2.11 (m, 3H), 2.07–2.02 (m, 
1H), 1.95–1.85 (m, 1H), 1.79 (tdd, J = 2.4, 4.8, 13.5 Hz, 1H), 1.75–1.65 (m, 3H), 1.63–1.54 (m, 2H), 
1.40–1.30 (m, 2H), 1.21–1.12 (m, 2H), 0.89 (d, J = 6.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 
213.8, 71.4, 64.2, 63.0, 51.7, 44.0, 43.6, 42.1, 40.3, 35.2, 33.0, 30.8, 29.1, 25.6, 22.4, 22.2. FTIR 
(thin film) cm-1: 3341, 2951, 2913, 1687, 1456, 1059, 731. HRMS (ESI) (m/z) calc’d for C16H26NO2 
[M+H]+: 264.1958, found 264.1972. TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.18 (KMnO4). 
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Dehydrolycopecurine (199): 
An aqueous solution of HBr (48 wt%, 800 µL) was added to a stirred solution of alcohol 198 
(19.3 mg, 0.0736 mmol, 1.00 equiv) in AcOH (2.4 mL). After 14 h, all volatiles were removed in 
vacuo and the resultant residue was azeotropically dried with MeOH (5 × 2 mL), then benzene (5 × 2 
mL), and carried forward to the next step without further purification. 
K2CO3 (152 mg, 1.10 mmol, 15.0 equiv) was added as a single portion to a stirred solution 
of the crude product, which was azeotropically dried with benzene (5 × 1 mL), in MeCN (3.6 mL). 
The reaction was heated to 60 °C and stirred for 18.5 h, at which point it was cooled to room 
temperature and diluted with Et2O (1 mL). The resultant slurry was then filtered through a pad of 
Celite and washed with Et2O (6 mL). The filtrate was concentrated under reduced pressure and the 
resultant crude residue was then purified by flash column chromatography (silica gel, eluent: 
gradient: 90:9:1 → 80:18:2 CHCl3:MeOH:NH4OH) to afford dehydrolycopecurine (199) (10.7 mg, 
59% over 2 steps) as a white solid. 
 
1H NMR (600 MHz, CDCl3) δ: 3.18 (td, J = 7.9, 14.4 Hz, 1H), 3.12 (td, J = 4.2, 10.9 Hz, 1H), 2.74 
(d, J = 10.9 Hz, 1H), 2.65 (dd, J = 8.8, 19.7 Hz, 1H), 2.61–2.55 (m, 1H), 2.27 (t, J = 4.5 Hz, 1H), 
2.25–2.22 (m, 1H), 2.17–2.14 (m, 1H), 2.12 (d, J = 20.0 Hz, 1H), 2.04 (br. s., 1H), 1.98–1.86 (m, 
3H), 1.76–1.71 (m, 1H), 1.63–1.59 (m, 1H), 1.57 (dd, J = 8.4, 13.1 Hz, 1H), 1.53–1.46 (m, 1H), 1.42 
(dtd, J = 2.3, 6.2, 10.2 Hz, 1H), 1.30 (t, J = 13.2 Hz, 1H), 1.20 (dt, J = 2.9, 12.6 Hz, 1H), 0.95 (d, J = 
6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 215.2, 68.4, 59.7, 58.8, 47.8, 46.5, 43.7, 42.2, 40.8, 
35.4, 34.9, 34.3, 25.4, 22.8, 19.2, 15.6. FTIR (thin film) cm-1: 3382, 2950, 2912, 1687, 1455, 1216, 
1124, 1099, 830. HRMS (ESI) (m/z) calc’d for C16H23NO [M+H]+: 246.1852, found 246.1863. 
[α]D22: –69 (c = 0.34, MeOH). TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.33 (KMnO4). 
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Lycopecurine (39): 
A solution of LiEt3BH in THF (1.00 M, 21.0 µL, 0.0210 mmol, 2.50 equiv) was added 
dropwise to a stirred solution of dehydrolycopecurine (199) (2.1 mg, 0.0086 mmol, 1.0 equiv) in 
THF (400 µL) at 0 °C. The reaction was allowed to warm naturally to room temperature and was 
stirred for 3 h, at which point saturated aqueous NH4Cl solution (100 µL), followed by a 1 M NaOH 
aqueous solution (until pH>10), were added. CHCl3 (1 mL) was added and the layers were separated. 
The aqueous layer was further extracted with CHCl3 (3 × 1 mL). The organic layers were combined, 
dried over anhydrous MgSO4, and concentrated under reduced pressure. The resultant crude residue 
was then purified by flash column chromatography (silica gel, eluent: gradient: 90:9:1 → 80:18:2 
CHCl3:MeOH:NH4OH) to afford lycopecurine (39) (1.4 mg, 66%) as a white crystalline solid. The 
structure of 39 was unambiguously established via single crystal X-ray diffraction analysis. Crystals 
suitable for X-ray diffraction were obtained by recrystallization of the hydrobromide salt of 39142 
from MeOH and acetone. 
 
1H NMR (600 MHz, CDCl3) δ: 3.99 (dd, J = 1.0, 8.8 Hz, 1H), 3.47 (ddd, J = 7.3, 9.8, 13.6 Hz, 1H), 
3.26 (td, J = 4.1, 11.7 Hz, 1H), 3.09 (d, J = 10.9 Hz, 1H), 2.92 (dd, J = 9.5, 13.1 Hz, 1H), 2.55 (td, J 
= 9.0, 16.4 Hz, 1H), 2.49–2.39 (m, 2H), 2.31 (dq, J = 5.4, 11.8 Hz, 1H), 2.20 (t, J = 4.3 Hz, 1H), 
2.17 (dd, J = 4.4, 12.9 Hz, 1H), 2.14–2.09 (m, 1H), 2.05–1.94 (m, 1H), 1.92–1.83 (m, 1H), 1.70–1.63 
(m, 1H), 1.62–1.50 (m, 4H), 1.31 (d, J = 16.1 Hz, 1H), 1.20 (td, J = 3.2, 13.2 Hz, 1H), 0.99 (d, J = 
                                                                                                                                                 
142 The hydrobromide salt of 39 was prepared from 39 via the following procedure: two drops of HBr (48 wt% 
in water) was added to a solution of 39 (1.4 mg) in CH2Cl2. The resulting suspension was concentrated in 
vacuo and the resultant solid was recrystallized from MeOH (single drop) and acetone (300 µL). This protocol 
provided crystals of the hydrobromide salt of 39 that were suitable for X-ray diffraction analysis. 
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6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 67.8, 56.4, 52.0, 45.4, 45.4, 41.1, 39.9, 36.0, 35.8, 
34.3, 33.2, 29.7, 24.6, 22.6, 19.9, 15.7. FTIR (thin film) cm-1: 3349, 2951, 2924, 2581, 1579, 1456, 
1399, 1062, 1052. HRMS (ESI) (m/z) calc’d for C16H26NO [M+H]+: 248.2009, found 248.2021. 
[α]D22: –19 (c = 0.14, MeOH). M.p.: 236–238 °C.143 TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.18 
(KMnO4). 
  
                                                                                                                                                 
143 The reported melting point for lycopecurine (39) is 239–241 °C. 
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N-Boc-2-pyrrolidinone S16: 
Acrylonitrile (150 µL, 2.27 mmol, 3.00 equiv) and n-Bu4NOH•30H2O (61.0 mg, 0.0757 
mmol, 0.10 equiv) were added sequentially to a stirred solution of β-carboxyimide 66 (375 mg, 
0.757 mmol, 1.00 equiv) in MeCN (19 mL) at 0 °C. After 5 min, the reaction was allowed to warm 
to room temperature and was stirred for 2 h, at which point water (10 mL), Et2O (15 mL), and 
EtOAc (10 mL) were added sequentially. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed with brine (50 mL), 
dried over anhydrous MgSO4, and concentrated under reduced pressure to afford alkylated imide 
200, which was carried forward to the next step without further purification. 
A solution of TBAF in THF (1.00 M, 757 µL, 0.757 mmol, 1.00 equiv) was added to a 
solution of crude 200 and DBU (28.0 µL, 0.189 mmol, 0.25 equiv) in THF (15 mL) at room 
temperature. After 5 min, the reaction was heated to 50 °C and was stirred for 15 h, at which point 
water (10 mL), Et2O (15 mL), and EtOAc (10 mL) were added successively. The layers were 
separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were 
combined, washed with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The resultant residue was purified by flash column chromatography (silica gel, 
eluent: gradient: 2:1 → 1:1 hexanes:EtOAc, 1% Et3N) to afford N-Boc-2-pyrrolidinone S16 (239 mg, 
78% over 2 steps) as a >14:1 mixture of diastereomers at C4 and as a white flocculent solid. 
 
1H NMR (600 MHz, C6D6, major C4-epimer reported) δ: 5.38 (d, J = 4.1 Hz, 1H), 3.74 (dd, J = 7.6, 
10.9 Hz, 1H), 3.56–3.51 (m, 1 H), 3.49–3.45 (m, 1H), 3.44–3.37 (m, 2H), 2.85 (dd, J = 8.8, 10.9 Hz, 
1H), 2.20 (td, J = 8.1, 16.7 Hz, 1H), 2.11 (dd, J = 4.7, 14.1 Hz, 1H), 1.97 (td, J = 6.4, 16.9 Hz, 1H), 
1.92–1.86 (m, 1H), 1.82 (td, J = 5.3, 10.3 Hz, 1H), 1.78–1.63 (m, 4H), 1.47 (s, 9H), 1.46–1.40 (m, 
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1H), 1.39–1.29 (m, 2H), 1.25 (t, J = 12.9 Hz, 1H), 0.79 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, 
C6D6, major C4-epimer reported) δ: 173.7, 151.3, 135.3, 131.6, 119.7, 108.6, 82.5, 65.6, 64.4, 50.4, 
48.0, 42.5, 36.2, 34.5, 34.4, 28.5, 28.0, 26.2, 21.9, 14.9. FTIR (thin film) cm-1: 2951, 2930, 1782, 
1744, 1714, 1368, 1314, 1157, 1125, 967. HRMS (ESI) (m/z) calc’d for C22H32N2NaO5 [M+Na]+: 
427.2203, found 427.2203. TLC (1:1 hexanes:EtOAc), Rf : 0.48 (Anis). 
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N-2-Nitrobenzenesulfonyl-2-pyrrolidinone 202: 
Mg(ClO4)2 (18.5 mg, 0.0830 mmol, 0.20 equiv) was added as a single portion to a stirred 
solution of N-Boc-2-pyrrolidinone S16 (168 mg, 0.415 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (5 × 1 mL), in MeCN (6.9 mL) at room temperature. The resultant mixture was 
heated to 60 °C and stirred for 4 h, at which point it was cooled to room temperature and Et2O (10 
mL) and saturated aqueous NH4Cl solution (10 mL) were added sequentially. The layers were 
separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were 
combined, washed with brine (20 mL), then dried over anhydrous MgSO4 and concentrated under 
reduced pressure to afford crude 2-pyrrolidinone 201 as a white flocculent solid, which was carried 
forward to the next step without further purification. 
A solution of freshly prepared LiHMDS in THF (1.00 M, 610 µL, 0.610 mmol, 1.20 equiv) 
was added to a solution of 201, which was azeotropically dried with benzene (5 × 1 mL), in THF (5 
mL) at room temperature. After 1 h, the reaction was cooled to 0 °C and a solution of NsCl in THF 
(1.00 M, 661 µL, 0.661 mmol, 1.30 equiv) was added dropwise. After 5 min, the reaction was 
allowed to warm to room temperature and stirred for 2 h, at which point saturated aqueous NH4Cl 
solution (5 mL) and Et2O (5 mL) were added sequentially. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 5 mL). The organic layers were combined, washed 
with brine (15 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (silica gel, eluent: gradient: 4:1 → 2:1 → 1:1 
hexanes:EtOAc, 1% Et3N) to afford N-2-nitrobenzenesulfonyl-2-pyrrolidinone 202 (158 mg, 64% 
over 2 steps) as a white flocculent solid. 
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1H NMR (600 MHz, C6D6) δ: 8.41 (dd, J = 1.3, 8.1 Hz, 1H), 6.72 (dd, J = 1.2, 7.9 Hz, 1H), 6.64 (dt, 
J = 1.2, 7.8 Hz, 1H), 6.44 (dt, J = 1.3, 7.7 Hz, 1H), 5.45 (d, J = 3.2 Hz, 1H), 4.16 (dd, J = 7.9, 10.0 
Hz, 1H), 3.63–3.58 (m, 1H), 3.57–3.52 (m, 1H), 3.49–3.43 (m, 2H), 3.32 (dd, J = 8.5, 10.0 Hz, 1H), 
2.20–2.13 (m, 1H), 2.12–2.05 (m, 1H), 1.94–1.87 (m, 2H), 1.85 (dd, J = 5.6, 7.9 Hz, 1H), 1.83–1.78 
(m, 1H), 1.75 (dd, J = 8.7, 13.9 Hz, 1H), 1.73–1.68 (m, 2H), 1.46–1.39 (m, 1H), 1.33–1.26 (m, 1H), 
1.23 (t, J = 12.9 Hz, 1H), 1.20–1.14 (m, 1H), 0.79 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, C6D6) 
δ: 175.0, 134.9, 134.8, 134.7, 132.5, 131.8, 127.9, 127.7, 124.1, 119.2, 108.5, 65.6, 64.4, 51.4, 47.4, 
42.4, 38.0, 34.5, 34.3, 28.0, 25.8, 21.9, 14.6. FTIR (thin film) cm-1: 2952, 2910, 1733, 1543, 1367, 
1174, 1128, 1046, 966, 594. HRMS (ESI) (m/z) calc’d for C23H27N3NaO7S [M+Na]+: 512.1462, 
found 512.1463. TLC (1:1 hexanes:EtOAc), Rf : 0.38 (Anis). 
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Enone 203: 
A solution of n-butyllithium in hexanes (2.53 M, 414 µL, 1.05 mmol, 3.00 equiv) was added 
dropwise to a stirred solution of diisopropylamine (161 µL, 1.15 mmol, 3.30 equiv) in THF (2 mL) 
at −78 °C. The reaction was allowed to stir for 10 min, at which point it was warmed to 0 °C. After 
10 min, the reaction was warmed to room temperature. The solution was recooled to −78 °C after 10 
min. t-Butylacetate (140 µL, 1.05 mmol, 3.00 equiv) was then added dropwise to the reaction 
mixture. After 1 h, a solution of 202 (171 mg, 0.349 mmol, 1.00 equiv), which was azeotropically 
dried with benzene (5 × 1 mL), in THF (4.3 mL) was added dropwise down the walls of the reaction 
vessel. After stirring at −78 °C for 3 h, saturated aqueous NH4Cl solution (10 mL) was added to the 
deep red reaction mixture at −78 °C. The resultant mixture was then allowed to warm to room 
temperature. Et2O (10 mL) and EtOAc (10 mL) were added and the layers were separated. The 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed 
with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford crude β-ketoester S17 as a pale yellow flocculent solid, which was carried forward to the next 
step without further purification. 
10% aqueous HCl (775 µL) was added dropwise to a stirred solution of crude S17 in THF 
(6.2 mL) at room temperature. After 1 h, a saturated aqueous NaHCO3 solution (10 mL) was added, 
followed by Et2O (10 mL), EtOAc (10 mL), and water (5 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed 
with brine (30 mL), then dried over anhydrous MgSO4 and concentrated under reduced pressure to 
afford crude enone 203 as a yellow flocculent solid, which was carried forward to the next step 
without further purification. 
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Imine 204: 
K2CO3 (241 mg, 1.75 mmol, 5.00 equiv) was added as a single portion to a stirred solution 
of crude enone 203, which was azeotropically dried with benzene (5 × 1 mL), in DMF (5.8 mL) at 
room temperature and stirred for 13 h, at which point the suspension was then cooled to 0 °C and 
PhSH (90.0 µL, 0.873 mmol, 2.50 equiv) was added dropwise via syringe. After 5 min, the reaction 
was warmed to room temperature and stirred for an additional 10 h, at which point water (10 mL), 
Et2O (10 mL), and EtOAc (10 mL) were added sequentially. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed 
with brine (30 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure. The 
crude residue was then purified by flash column chromatography (silica gel, eluent: gradient: 2:1 → 
1:1 → 0:1 hexanes:EtOAc, 1% Et3N → 90:9:1 CHCl3:MeOH:NH4OH) to afford imine 204 (79.5 mg, 
63% over 3 steps) as a >3:1 mixture of diastereomers at C4 and as a pale yellow flocculent solid. 
 
1H NMR (600 MHz, C6D6, major C4-epimer reported) δ: 3.62 (dd, J = 2.3, 17.9 Hz, 1H), 3.40 (d, J 
= 3.5 Hz, 1H), 3.06– 3.00 (m, 1H), 2.83 (td, J = 3.8, 8.0 Hz, 1H), 2.61 (td, J = 4.7, 9.2 Hz, 1H), 2.46 
(ddd, J = 2.2, 4.0, 12.8 Hz, 1H), 2.02 (tdd, J = 6.6, 9.2, 13.7 Hz, 1H), 1.92–1.83 (m, 1H), 1.77 (ddd, 
J = 2.1, 5.2, 7.4 Hz, 1H), 1.68–1.63 (m, 2H), 1.61–1.57 (m, 1H), 1.52–1.46 (m, 2H), 1.36 (s, 9H), 
1.35–1.32 (m, 1H), 1.25–1.21 (m, 1H), 1.13–1.04 (m, 2H), 0.60 (d, J = 6.5 Hz, 3H). 13C NMR (126 
MHz, C6D6, major C4-epimer reported) δ: 204.7, 170.1, 169.5, 119.9, 83.0, 66.3, 53.2, 48.8, 48.2, 
43.5, 39.0, 38.0, 32.7, 29.9, 29.7, 28.4, 28.2, 26.4, 22.5, 15.4. FTIR (thin film) cm-1: 2947, 2927, 
2869, 1735, 1670, 1368, 1249, 1152. HRMS (ESI) (m/z) calc’d for C21H30N2NaO3 [M+Na]+: 
381.2149, found 381.2150. TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.45 (KMnO4).  
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Amine 207: 
NaBH(OAc)3 (99.0 mg, 0.444 mmol, 2.00 equiv) was added as a single portion to a stirred 
solution of imine 204, which was azeotropically dried with benzene (5 × 0.5 mL), and AcOH (15.2 
µL, 0.266 mmol, 1.20 equiv) in CH2Cl2 (4.4 mL) at 0 °C. After 5 min, the reaction was warmed to 
room temperature and stirred for 3.5 h. Additional NaBH(OAc)3 (50.0 mg, 0.222 mmol, 1.00 equiv) 
and AcOH (7.6 µL, 0.13 mmol, 0.60 equiv) were added and the reaction was stirred for 5 h, at which 
point a 1 M NaOH aqueous solution (5 mL) and CHCl3 (10 mL) were added sequentially. The layers 
were separated and the aqueous layer was extracted with CHCl3 (3 × 5 mL). The organic layers were 
combined, dried over anhydrous MgSO4, and concentrated under reduced pressure to afford crude 
amine 206, which was carried forward to the next step without further purification. 
Trifluoroacetic acid (3.7 mL) was added to a stirred solution of crude amine 206 in CH2Cl2 
(3.7 mL) at room temperature. After stirring for 17 h, the reaction was concentrated in vacuo. The 
crude residue was then purified by flash column chromatography (silica gel, eluent: 90:9:1 
CHCl3:MeOH:NH4OH) to afford amine 207 (34.1 mg, 59% over 2 steps) as a pale yellow solid. 
 
1H NMR (500 MHz, C6D6) δ: 3.46 (dd, J = 10.0, 12.2 Hz, 1H), 2.47 (d, J = 12.0 Hz, 1H), 2.38–2.30 
(m, 1H), 2.21 (td, J = 5.3, 10.7 Hz, 1H), 2.14 (dd, J = 3.5, 12.1 Hz, 1H), 2.10–2.03 (m, 1H), 1.80–
1.69 (m, 3H), 1.69–1.63 (m, 2H), 1.51 (td, J = 5.9, 14.1 Hz, 1H), 1.40–1.31 (m, 2H), 1.24– 1.18 (m, 
1H), 1.18–1.12 (m, 2H), 1.11–1.02 (m, 1H), 0.91 (dtd, J = 4.1, 12.8, 16.4 Hz, 2H), 0.74 (d, J = 6.6 
Hz, 3H). 13C NMR (126 MHz, C6D6) δ: 211.1, 119.7, 57.6, 56.4, 49.4, 48.4, 48.3, 43.5, 42.7, 37.3, 
35.6, 32.2, 26.5, 23.0, 21.7, 15.8. FTIR (thin film) cm-1: 3335, 2946, 2912, 2870, 1691, 1454, 1445, 
1430, 1085. HRMS (ESI) (m/z) calc’d for C16H25N2O [M+H]+: 261.1961, found 261.1963. TLC 
(80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.70 (KMnO4, UV).  
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Tertiary amine 208: 
A solution of freshly prepared LiHMDS in THF (1.00 M, 170 µL, 0.171 mmol, 3.00 equiv) 
was added to a solution of 207 (14.8 mg, 0.0568 mmol, 1.00 equiv), which was azeotropically dried 
with benzene (5 × 1 mL), in THF (1.5 mL) at –78 °C. After 2 h, a freshly prepared solution of iodine 
in THF (1.00 M, 170 µL, 0.171 mmol, 3.00 equiv) was added dropwise to the stirred reaction 
mixture. After stirring for 1 h at –78 °C, the reaction was allowed to warm to 0 °C and was stirred 
for an additional 2 h, at which point water (0.5 mL), a saturated aqueous NaHSO3 solution (1 mL), a 
1 M NaOH aqueous solution (until pH>10), and CHCl3 (2 mL) were added sequentially. The layers 
were separated and the aqueous layer was extracted with CHCl3 (3 × 2 mL). The organic layers were 
combined, dried over anhydrous MgSO4, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (silica gel, eluent: gradient: 2:1 → 1:1 → 0:1 
hexanes:EtOAc, 1% Et3N → 90:9:1 CHCl3:MeOH:NH4OH) to afford tertiary amine 208 (10.7 mg, 
73%) as a >9:1 mixture of diastereomers at C4 and as a pale yellow oil. 
 
1H NMR (500 MHz, C6D6, major C4-epimer reported) δ: 3.58 (s, 1H), 2.65 (d, J = 1.7 Hz, 1H), 2.56 
(s, 1H), 1.99 (t, J = 6.7 Hz, 1H), 1.90 (d, J = 4.1 Hz, 1H), 1.85–1.79 (m, 1H), 1.79–1.76 (m, 1H), 
1.77–1.72 (m, 1H), 1.66–1.59 (m, 3H), 1.59–1.52 (m, 2H), 1.34–1.29 (m, 1H), 1.28 (t, J = 3.0 Hz, 
1H), 1.23 (d, J = 2.7 Hz, 1H), 1.21–1.18 (m, 1H), 0.96 (dd, J = 2.1, 4.0 Hz, 1H), 0.71 (d, J = 0.7 Hz, 
1H), 0.68 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, C6D6, major C4-epimer reported) δ: 213.1, 
119.5, 73.8, 70.8, 56.7, 51.2, 46.8, 46.0, 41.0, 39.9, 38.3, 33.3, 26.9, 25.2, 22.4, 15.5. FTIR (thin 
film) cm-1: 2924, 2880, 2007, 1705, 1453. HRMS (ESI) (m/z) calc’d for C16H22N2NaO [M+Na]+: 
281.1624, found 281.1624. TLC (90:9:1 CHCl3:MeOH:NH4OH), Rf : 0.22 (KMnO4).  
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(−)-Lyconadin B (32): 
A solution of NH3 in MeOH (7.00 M, 2 mL) was added to tertiary amine 208 (10.7 mg, 
0.0414 mmol, 1.00 equiv). The resultant solution was heated to 120 °C and stirred for 3 d, at which 
point it was cooled to room temperature and concentrated under reduced pressure. The crude residue 
was then purified by preparatory thin-layer chromatography (silica gel, eluent: 85:13.5:1.5 
CHCl3:MeOH:NH4OH) to afford (–)-lyconadin B (32) (6.1 mg, 57%) as a white solid. 
 
1H NMR (600 MHz, CD3OD) δ: 3.50 (s, 1H), 3.31 (s, 1H), 3.29 (dd, J = 3.2, 12.0 Hz, 1H), 2.86 (d, J 
= 12.3 Hz, 1H), 2.54–2.43 (m, 2H), 2.43–2.32 (m, 2H), 2.27 (d, J = 5.0 Hz, 1H), 2.15–2.11 (m, 1H), 
2.00–1.94 (m, 2H), 1.93 (dd, J = 3.7, 5.7 Hz, 1H), 1.89–1.82 (m, 1H), 1.79–1.72 (m, 1H), 1.70 (d, J 
= 13.5 Hz, 1H), 1.07 (ddd, J = 2.1, 12.1, 13.7 Hz, 1H), 0.95 (t, J = 13.2 Hz, 1H), 0.90 (d, J = 6.5 Hz, 
3H). 13C NMR (126 MHz, CD3OD) δ: 173.2, 135.2, 120.7, 73.0, 63.9, 61.6, 49.5, 48.5, 40.6, 40.4, 
34.3, 33.0, 31.4, 26.1, 24.9, 22.0. FTIR (thin film) cm-1: 3403, 3205, 2946, 2923, 2849, 1672, 1372.  
HRMS (ESI) (m/z) calc’d for C16H23N2O [M+H]+: 259.1805, found 259.1810. [α]D21: –102 (c = 0.5, 
MeOH).144 TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf : 0.33 (KMnO4, UV). 
  
                                                                                                                                                 
144 The specific rotation reported for (–)-lyconadin B (32), which is contaminated with impurities, is [α]D23: –66 
(c = 0.5, MeOH). 
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Table S3. 1H NMR Data Comparison Between Natural and Synthetic (−)-Lyconadin B (32) in 
CD3OD. 
 
 
Isolation Report132b (1H, 600 MHz, 
CD3OD) 
Synthetic (−)-Lyconadin B (32)  
(1H, 600 MHz, CD3OD) 
0.89 (d, J = 6.5 Hz, 3H) 0.90 (d, J = 6.5 Hz, 3H) 
0.94 (t, J = 13.2 Hz, 1H) 0.95 (t, J = 13.2 Hz, 1H 
1.04 (ddd, J = 2.4, 12.6, 12.6 Hz, 1H) 1.07 (ddd, J = 2.1, 12.1, 13.7 Hz, 1H) 
1.68 (d, J = 13.5 Hz, 1H) 1.70 (d, J = 13.5 Hz, 1H) 
1.74 (m, 1H) 1.79–1.72 (m, 1H) 
1.84 (m, 1H) 1.89–1.82 (m, 1H) 
1.89 (s, 1H) 1.93 (dd, J = 3.7, 5.7 Hz, 1H) 
1.95 (m, 2H) 2.00–1.94 (m, 2H) 
2.10 (m, 1H) 2.15–2.11 (m, 1H) 
2.25 (d, J = 4.8 Hz, 1H) 2.27 (d, J = 5.0 Hz, 1H) 
2.37 (m, 2H) 2.43–2.32 (m, 2H) 
2.47 (m, 2H) 2.54–2.43 (m, 2H) 
2.83 (d, J = 12.0 Hz, 1H) 2.86 (d, J = 12.3 Hz, 1H) 
3.25 (m, 1H) 3.29 (dd, J = 3.2, 12.0 Hz, 1H) 
3.26 (d, J = 3.1 Hz, 1H) 3.31 (s, 1H) 
3.45 (s, 1H) 3.50 (s, 1H) 
  
 237 
 
Figure S6. Comparison of 1H NMR Spectra of Natural and Synthetic (−)-Lyconadin B (32) in 
CD3OD. 
 238 
Table S4. 13C NMR Data Comparison Between Natural and Synthetic (−)-Lyconadin B (32) in 
CD3OD. 
 
 
Isolation Report132b (13C, 126 MHz, 
CD3OD) 
Synthetic (−)-Lyconadin B (32)  
(13C, 126 MHz, CD3OD) 
22.1 22.0 
24.0 24.9 
26.2 26.1 
31.5 31.4 
33.4 33.0 
34.6 34.3 
40.9 40.4 
41.2 40.6 
48.2 48.5 
49.9 49.5 
61.9 61.6 
63.6 63.9 
72.5 73.0 
120.7 120.7 
135.8 135.2 
173.3 173.2 
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Figure S7. Comparison of 13C NMR Spectra of Natural and Synthetic (−)-Lyconadin B (32) in 
CD3OD. 
  
 240 
 
(+)-Lyconadin A (31): 
Lyconadin B (32) was heated neat under an atmosphere of air at 160 °C for 25 h. The crude 
residue was then purified by flash column chromatography (silica gel, eluent: gradient: 90:9:1 → 
80:18:2 CHCl3:MeOH:NH4OH) to afford (+)-lyconadin A (31) (1.8 mg, 57%) as a white solid. 
 
1H NMR (600 MHz, CD3OD) δ: 7.39 (d, J = 9.1 Hz, 1H), 6.32 (d, J = 8.8 Hz, 1H), 4.05 (s, 1H), 3.44 
(dd, J = 2.9, 12.6 Hz, 1H), 3.38 (br. s., 1H), 2.79 (d, J = 12.3 Hz, 1H), 2.72 (br. s., 1H), 2.19 (d, J = 
4.4 Hz, 1H), 2.12 (ddd, J = 3.5, 5.3, 13.5 Hz, 1 H), 2.03–1.97 (m, 1H), 1.95 (br. s., 1H), 1.93–1.88 
(m, 1H), 1.83 (dt, J = 6.0, 12.0 Hz, 1H), 1.69 (d, J = 14.1 Hz, 1H), 1.11 (t, J = 12.2 Hz, 1H), 1.01 (t, 
J = 12.5 Hz, 1H), 0.93 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ: 165.4, 149.3, 141.8, 
126.3, 116.6, 72.6, 64.0, 61.7, 50.8, 48.1, 41.0, 40.5, 34.3, 33.8, 26.2, 22.0. FTIR (thin film) cm-1: 
3197, 2922, 2850, 1655, 1611, 1457, 947. HRMS (ESI) (m/z) calc’d for C16H21N2O [M+H]+: 
257.1648, found 257.1660. [α]D22: +37 (c = 0.12, MeOH). TLC (80:18:2 CHCl3:MeOH:NH4OH), Rf 
: 0.33 (KMnO4). 
  
air, neat
160 °C
(57%)
N
Me
H
N
O
H H
H
Lyconadin A (31)
N
Me
H
N
O
H H
H
Lyconadin B (32)
 241 
Table S5. 1H NMR Data Comparison Between Natural and Synthetic (+)-Lyconadin A (31) in 
CD3OD. 
 
 
Isolation Report132a (1H, 600 MHz, 
CD3OD) 
Synthetic (+)-Lyconadin A (31)  
(1H, 600 MHz, CD3OD) 
0.95 (d, J = 6.4 Hz, 3H) 0.93 (d, J = 6.5 Hz, 3H) 
1.05 (t, J = 13.0 Hz, 1H) 1.01 (t, J = 12.5 Hz, 1H) 
1.18 (t, J = 12.1 Hz, 1H) 1.11 (t, J = 12.2 Hz, 1H) 
1.74 (br. d., J = 13.9 Hz, 1H) 1.69 (d, J = 14.1 Hz, 1H) 
1.86 (m, 1H) 1.83 (dt, J = 6.0, 12.0 Hz, 1H) 
1.94 (m, 1H) 1.93–1.88 (m, 1H) 
2.04 (m, 1H) 1.95 (br. s., 1H) 
2.07 (m, 1H) 2.03–1.97 (m, 1H) 
2.14 (ddd, J = 3.9, 5.6, 13.9 Hz, 1H) 2.12 (ddd, J = 3.5, 5.3, 13.5 Hz, 1 H) 
2.25 (br. d., J = 4.4 Hz, 1H) 2.19 (d, J = 4.4 Hz, 1H) 
2.81 (m, 1H) 2.72 (br. s., 1H) 
2.88 (d, J = 13.7 Hz, 1H) 2.79 (d, J = 12.3 Hz, 1H) 
3.54 (d, J = 2.7 Hz, 1H) 3.38 (br. s., 1H) 
3.55 (dd, J = 3.1, 13.7 Hz, 1H) 3.44 (dd, J = 2.9, 12.6 Hz, 1H) 
4.19 (br. s., 1H) 4.05 (s, 1H) 
6.35 (d, J = 8.9 Hz, 1H) 6.32 (d, J = 8.8 Hz, 1H) 
7.42 (d, J = 8.9 Hz, 1H) 7.39 (d, J = 9.1 Hz, 1H) 
 
  
 242 
 
 
Figure S8. Comparison of 1H NMR Spectra of Natural and Synthetic (+)-Lyconadin A (31) in 
CD3OD. 
  
 243 
Table S6. 13C NMR Data Comparison Between Natural and Synthetic (+)-Lyconadin A (31) in 
CD3OD. 
 
 
Isolation Report132a (13C, 126 MHz, 
CD3OD) 
Synthetic (+)-Lyconadin A (31)  
(13C, 126 MHz, CD3OD) 
21.9 22.0 
26.1 26.2 
33.6 33.8 
34.0 34.3 
40.2 40.5 
40.2 41.0 
48.1 48.1 
50.4 50.8 
61.4 61.7 
64.6 64.0 
73.1 72.6 
116.6 116.6 
126.2 126.3 
141.6 141.8 
148.8 149.3 
165.3 165.4 
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Figure S9. Comparison of 13C NMR Spectra of Natural and Synthetic (+)-Lyconadin A (31) in 
CD3OD. 
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Figure S10. X-Ray Crystal Structure of (–)-Lycopecurine (39). 
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X-Ray Crystallography:  A crystal mounted on a diffractometer was collected data at 100 K.  The 
intensities of the reflections were collected by means of a Bruker APEX II DUO CCD diffractometer 
(CuKα radiation, λ=1.54178 Å), and equipped with an Oxford Cryosystems nitrogen flow apparatus.  
The collection method involved 1.0° scans in ω at 30°, 55°, 80° and 115° in 2θ.  Data integration 
down to 0.84 Å resolution was carried out using SAINT V7.46 A (Bruker diffractometer, 2009) with 
reflection spot size optimisation.  Absorption corrections were made with the program SADABS 
(Bruker diffractometer, 2009).  The structure was solved by the direct methods procedure and refined 
by least-squares methods again F2 using SHELXS-97 and SHELXL-97 (Sheldrick, 2008) with OLEX 
2 interface (Dolomanov, et al., 2009).  Non-hydrogen atoms were refined anisotropically, and 
hydrogen atoms were allowed to ride on the respective atoms. Crystal data as well as details of data 
collection and refinement are summarized in Table 1, geometric parameters are shown in Table 2 and 
hydrogen-bond parameters are listed in Table 3. The Ortep plots produced with SHELXL-97 program, 
and the other drawings were produced with Accelrys DS Visualizer 2.0 (Accelrys, 2007). 
 
Table S7. Experimental Details. 
Crystal data 
Chemical formula C16H26BrNO 
Mr 328.29 
Crystal system, space group Orthorhombic, P212121 
Temperature (K) 100 
a, b, c (Å) 9.1763 (3), 9.5392 (3), 17.2775 (7) 
V (Å3) 1512.38 (9) 
Z 4 
Radiation type Cu Kα 
µ (mm-1) 3.63 
Crystal size (mm) 0.16 × 0.14 × 0.12 
 
Data collection 
Diffractometer Bruker D8 goniometer with CCD area detector diffractometer 
Absorption correction Multi-scan  
SADABS 
 Tmin, Tmax 0.594, 0.670 
No. of measured, independent 
and 
 observed [I > 2σ(I)] reflections 
30629, 2677, 2676   
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Rint 0.039 
(sin θ/λ)max (Å-1) 0.595 
 
Refinement 
R[F2 > 2σ (F2)], wR(F2), S 0.016,  0.043,  1.09 
No. of reflections 2677 
No. of parameters 181 
H-atom treatment H atoms treated by a mixture of independent and constrained refinement 
Δρmax, Δρmin (e Å-3) 0.23, -0.30 
Absolute structure Flack H D (1983), Acta Cryst. A39, 876-881 
Absolute structure parameter -0.013 (12) 
 
Computer programs: APEX2 v2009.3.0 (Bruker-AXS, 2009), SAINT 7.46A (Bruker-AXS, 2009), 
SHELXS97 (Sheldrick, 2008), SHELXL97 (Sheldrick, 2008), Bruker SHELXTL (Sheldrick, 2008). 
 
Table S8. Geometric parameters (Å, º). 
C1—N21 1.498 (2) C8—H8B 0.9900 
C1—C2 1.528 (2) C9—C16 1.521 (2) 
C1—H1A 0.9900 C9—C10 1.530 (2) 
C1—H1B 0.9900 C9—H9 1.0000 
C2—C3 1.539 (2) C10—C11 1.520 (2) 
C2—H2A 0.9900 C10—H10A 0.9900 
C2—H2B 0.9900 C10—H10B 0.9900 
C3—C4 1.533 (2) C11—N21 1.5385 (18) 
C3—H3A 0.9900 C11—C12 1.540 (2) 
C3—H3B 0.9900 C12—C13 1.550 (2) 
C4—C11 1.5387 (19) C12—H12 1.0000 
C4—C5 1.5671 (19) C13—C14 1.537 (2) 
C4—C14 1.578 (2) C13—H13A 0.9900 
C5—O1 1.431 (2) C13—H13B 0.9900 
C5—C6 1.557 (2) C14—C15 1.531 (2) 
C5—H5 1.0000 C14—H14 1.0000 
C6—C7 1.555 (2) C15—N21 1.519 (2) 
C6—H6A 0.9900 C15—H15A 0.9900 
C6—H6B 0.9900 C15—H15B 0.9900 
C7—C8 1.523 (2) C16—H16A 0.9800 
C7—C12 1.528 (2) C16—H16B 0.9800 
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C7—H7 1.0000 C16—H16C 0.9800 
C8—C9 1.523 (2) N21—H21 0.88 (2) 
C8—H8A 0.9900 O1—H1 0.80 (2) 
 
N21—C1—C2 109.63 (13) C8—C9—H9 108.0 
N21—C1—H1A 109.7 C10—C9—H9 108.0 
C2—C1—H1A 109.7 C11—C10—C9 114.10 (13) 
N21—C1—H1B 109.7 C11—C10—H10A 108.7 
C2—C1—H1B 109.7 C9—C10—H10A 108.7 
H1A—C1—H1B 108.2 C11—C10—H10B 108.7 
C1—C2—C3 113.07 (13) C9—C10—H10B 108.7 
C1—C2—H2A 109.0 H10A—C10—H10B 107.6 
C3—C2—H2A 109.0 C10—C11—N21 109.62 (12) 
C1—C2—H2B 109.0 C10—C11—C4 122.13 (14) 
C3—C2—H2B 109.0 N21—C11—C4 98.99 (11) 
H2A—C2—H2B 107.8 C10—C11—C12 113.92 (12) 
C4—C3—C2 116.30 (13) N21—C11—C12 109.19 (12) 
C4—C3—H3A 108.2 C4—C11—C12 101.57 (12) 
C2—C3—H3A 108.2 C7—C12—C11 107.39 (12) 
C4—C3—H3B 108.2 C7—C12—C13 109.81 (13) 
C2—C3—H3B 108.2 C11—C12—C13 104.71 (12) 
H3A—C3—H3B 107.4 C7—C12—H12 111.5 
C3—C4—C11 111.28 (13) C11—C12—H12 111.5 
C3—C4—C5 109.82 (12) C13—C12—H12 111.5 
C11—C4—C5 114.36 (12) C14—C13—C12 101.96 (13) 
C3—C4—C14 117.04 (13) C14—C13—H13A 111.4 
C11—C4—C14 92.93 (11) C12—C13—H13A 111.4 
C5—C4—C14 110.68 (13) C14—C13—H13B 111.4 
O1—C5—C6 106.46 (13) C12—C13—H13B 111.4 
O1—C5—C4 112.07 (13) H13A—C13—H13B 109.2 
C6—C5—C4 116.25 (12) C15—C14—C13 103.15 (14) 
O1—C5—H5 107.2 C15—C14—C4 104.07 (12) 
C6—C5—H5 107.2 C13—C14—C4 103.06 (12) 
C4—C5—H5 107.2 C15—C14—H14 115.0 
C7—C6—C5 117.58 (13) C13—C14—H14 115.0 
C7—C6—H6A 107.9 C4—C14—H14 115.0 
C5—C6—H6A 107.9 N21—C15—C14 102.18 (12) 
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C7—C6—H6B 107.9 N21—C15—H15A 111.3 
C5—C6—H6B 107.9 C14—C15—H15A 111.3 
H6A—C6—H6B 107.2 N21—C15—H15B 111.3 
C8—C7—C12 110.82 (13) C14—C15—H15B 111.3 
C8—C7—C6 113.05 (14) H15A—C15—H15B 109.2 
C12—C7—C6 109.78 (13) C9—C16—H16A 109.5 
C8—C7—H7 107.7 C9—C16—H16B 109.5 
C12—C7—H7 107.7 H16A—C16—H16B 109.5 
C6—C7—H7 107.7 C9—C16—H16C 109.5 
C7—C8—C9 111.01 (13) H16A—C16—H16C 109.5 
C7—C8—H8A 109.4 H16B—C16—H16C 109.5 
C9—C8—H8A 109.4 C1—N21—C15 109.19 (12) 
C7—C8—H8B 109.4 C1—N21—C11 112.76 (12) 
C9—C8—H8B 109.4 C15—N21—C11 105.13 (11) 
H8A—C8—H8B 108.0 C1—N21—H21 111.8 (13) 
C16—C9—C8 112.64 (14) C15—N21—H21 108.8 (15) 
C16—C9—C10 109.62 (13) C11—N21—H21 108.9 (13) 
C8—C9—C10 110.55 (13) C5—O1—H1 105.8 (15) 
C16—C9—H9 108.0   
 
N21—C1—C2—C3 40.1 (2) C8—C7—C12—C11 -60.35 (16) 
C1—C2—C3—C4 -35.4 (2) C6—C7—C12—C11 65.24 (16) 
C2—C3—C4—C11 50.1 (2) C8—C7—C12—C13 -173.65 (13) 
C2—C3—C4—C5 177.78 (14) C6—C7—C12—C13 -48.07 (17) 
C2—C3—C4—C14 -55.0 (2) C10—C11—C12—C7 53.76 (16) 
C3—C4—C5—O1 -31.50 (18) N21—C11—C12—C7 176.66 (12) 
C11—C4—C5—O1 94.41 (15) C4—C11—C12—C7 -79.45 (14) 
C14—C4—C5—O1 -162.23 (12) C10—C11—C12—C13 170.46 (13) 
C3—C4—C5—C6 -154.25 (15) N21—C11—C12—C13 -66.64 (15) 
C11—C4—C5—C6 -28.3 (2) C4—C11—C12—C13 37.25 (15) 
C14—C4—C5—C6 75.02 (17) C7—C12—C13—C14 113.42 (14) 
O1—C5—C6—C7 -113.45 (15) C11—C12—C13—C14 -1.61 (16) 
C4—C5—C6—C7 12.2 (2) C12—C13—C14—C15 74.38 (14) 
C5—C6—C7—C8 94.35 (18) C12—C13—C14—C4 -33.71 (15) 
C5—C6—C7—C12 -30.0 (2) C3—C4—C14—C15 63.42 (17) 
C12—C7—C8—C9 62.88 (17) C11—C4—C14—C15 -52.31 (14) 
C6—C7—C8—C9 -60.85 (18) C5—C4—C14—C15 -169.75 (12) 
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C7—C8—C9—C16 -177.37 (14) C3—C4—C14—C13 170.81 (14) 
C7—C8—C9—C10 -54.35 (17) C11—C4—C14—C13 55.08 (13) 
C16—C9—C10—C11 172.64 (14) C5—C4—C14—C13 -62.35 (15) 
C8—C9—C10—C11 47.88 (17) C13—C14—C15—N21 -80.85 (14) 
C9—C10—C11—N21 -171.87 (12) C4—C14—C15—N21 26.48 (15) 
C9—C10—C11—C4 73.32 (18) C2—C1—N21—C15 52.05 (17) 
C9—C10—C11—C12 -49.20 (18) C2—C1—N21—C11 -64.42 (17) 
C3—C4—C11—C10 56.32 (18) C14—C15—N21—C1 -110.75 (14) 
C5—C4—C11—C10 -68.83 (19) C14—C15—N21—C11 10.47 (15) 
C14—C4—C11—C10 176.88 (13) C10—C11—N21—C1 -54.47 (16) 
C3—C4—C11—N21 -63.73 (15) C4—C11—N21—C1 74.43 (14) 
C5—C4—C11—N21 171.13 (13) C12—C11—N21—C1 -179.91 (12) 
C14—C4—C11—N21 56.83 (12) C10—C11—N21—C15 -173.34 (13) 
C3—C4—C11—C12 -175.57 (13) C4—C11—N21—C15 -44.44 (14) 
C5—C4—C11—C12 59.29 (16) C12—C11—N21—C15 61.23 (14) 
C14—C4—C11—C12 -55.01 (12)   
 
Table S9. Hydrogen-Bond Parameters. 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
N21—H21···Br1i 0.88 (2) 2.29 (2) 3.1728 (12) 178.3 (18) 
O1—H1···Br1 0.80 (2) 2.52 (2) 3.3162 (13) 174 (2) 
 
Symmetry code(s):  (i) x, y+1, z. 
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 Figure 1. Perspective views showing 50% probability displacement. 
 
Figure 2. Three-dimensional supramolecular architecture viewed along the a-axis 
direction. 
 
c 
b 
 
 
 
Figure S11. erspective vie s showing 50% probability displacement. 
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Figure 1. Perspective views showing 50% probability displacement. 
 
Figure 2. Three-dimensional supramolecular architecture viewed along the a-axis 
direction. 
 
c 
b 
 
 
Figure S12. Three-dimensional supramolecular architecture viewed along the a-axis direction. 
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Appendix D 
Chapter Five Catalog of 1H and 13C NMR Spectra 
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